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Abstract 
 Schizophrenia is a complex and disabling psychiatric disorder that results in significant 
burden and challenges to those who suffer from it, their families, and to our larger society.  One 
of the most vexing problems facing individuals with schizophrenia today is the co-occurrence of 
substance use disorders (SUDs).  Longitudinal evidence indicates that many individuals with 
schizophrenia and comorbid SUD exhibit severe patterns of substance use over the course of the 
disorder, such that few achieve sustained remission or recovery.  Intrinsic motivation deficits are 
promising potential contributors to substance use severity in this population, and consequently 
might serve as effective treatment targets. There is also evidence to suggest that women show 
less deficit in intrinsic motivation than men.  To date, measurement in this area has been limited, 
and no study has investigated the longitudinal relations between prospective changes in intrinsic 
motivation and changes in substance use severity among individuals with schizophrenia and 
comorbid SUD. This study makes use of baseline, 6-, and 12-month follow-up data from patients 
with schizophrenia and comorbid SUD (n = 535 at baseline; n = 219 at 6-months; n = 150 at 1-
year) selected from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) 
study to: (1) extend validation of a promising new measure of intrinsic motivation developed by 
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Nakagami, Xie, Hoe, and Brekke (2008) for schizophrenia to schizophrenia and comorbid SUD; 
(2) elucidate its longitudinal relations with substance use severity among this population; (3) and 
examine whether such relations vary across genders.  A comprehensive psychometric analysis 
was used to examine the factor structure, reliability, and retest reliability of the instrument in this 
population; and hierarchical linear regression and hierarchical linear modeling were among the 
analytic methods used to examine the cross-sectional and longitudinal relations between intrinsic 
motivation and substance use severity. Psychometric results supported the reliability and retest 
reliability of the intrinsic motivation measure when applied to schizophrenia and comorbid SUD, 
but also revealed a potential shift in the latent factor structure of the instrument. Cross-sectional 
findings revealed a significant negative prediction of intrinsic motivation by alcohol and drug 
use severity after adjusting for demographic and clinical confounds, neurocognition and negative 
symptoms. Longitudinal results with intrinsic motivation strengthened the findings garnered in 
the cross-sectional analyses. Evidence was found suggesting longitudinal intrinsic motivation 
change is a salient incremental predictor of reductions in patient’s alcohol/ drug use severity, 
above and beyond the effects of age, illness chronicity, overall psychopathology, comorbidity 
status, and phase 1 randomization medication effects. Analyses of relations with gender indicated 
little to no cross-sectional associations between intrinsic motivation and substance use severity, 
and gender did not moderate the longitudinal association between intrinsic motivation and 
substance use severity. These findings suggest that changes in intrinsic motivation may be 
uniquely associated with changes in substance use severity in schizophrenia and comorbid SUD.  
Future research will need to replicate these findings, while focusing on intervention efforts that 
seek to target the intrinsic motivation deficits of schizophrenia and comorbid SUD, to help offset 
the severe and destabilizing effects exacted by substance use severity in this population.  
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I. INTRODUCTION  
 
A.  OVERVIEW 
 Schizophrenia is a complex and disabling psychiatric disorder that poses significant 
challenges to those who suffer from it, their families, and to our larger society.  The disorder 
affects about 1% of the population, is considered among the top 10 disease related disabilities in 
the world (Murray & Lopez, 1996), and is characterized by the presence of positive (thought 
disturbance, delusions, hallucinations) and negative symptoms (ahedonia, amotivation, anergia). 
One of the most vexing problems facing people with schizophrenia today is the co-occurrence of 
substance use disorders (SUDs), which affects about 50% of those with the disorder during a 
lifetime (Reiger et al., 1990; Volkow, 2009; see Chapter 2 for a more detailed description of 
SUD pathology in schizophrenia).  Many people with co-occurring SUDs and schizophrenia 
experience severe and persistent patterns of substance use during the course of the disorder, such 
that few are clinically stable, gainfully employed, or adequately housed (Drake, O’Neal, & 
Wallach, 2008).  Since few persons among this population are motivated to reduce their use of 
substances, many persist with their patterns of use for years in the face of significant disability 
(Horsfall, Cleary, Hunt, & Walter, 2009).  Consequently, this comorbidity is associated with less 
favorable long-term outcomes in schizophrenia and represents a major, unsolved challenge for 
the clinical management and outcome of this population (Mueser et al., 1990; Green, Zimmet, 
Strous, & Schildraut, 1999; Green, 2005).  
 Recent evidence indicates that one of the most likely potential contributors to the 
pervasive patterns of substance use severity in persons with comorbid SUD and schizophrenia 
are deficits in intrinsic motivation.  Intrinsic motivation concerns the inherent tendencies that all 
human beings have to seek out novelty and challenges, to extend and exercise capacities, and to 
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explore and to learn (Deci & Ryan, 2007).  When people carry out behaviors in the absence of 
any extrinsic tangible reward (i.e., money or praise), and do not require any external support to 
sustain the behavior, the motivation for engaging in such a process is said to be intrinsic (Deci & 
Ryan, 2007).  Recently, research among persons with dual disorders has begun to point to the 
importance of deficits in intrinsic motivation to substance use severity in schizophrenia (Martino, 
Carroll, Kostas, Perkins, & Rounsaville, 2002; Graber, Moyers, Griffith, Guajardo, & Tonigan, 
2003; Kavanagh et al., 2004a; James et al., 2004; Edwards et al., 2006; Baker, Bucci, Lewin, 
Kay-Lambkin, Constable, & Carr, 2006; Martino, Carroll, Nich, & Rounsaville, 2006; Drapalski, 
Bennett, & Bellack, 2011), with emerging evidence suggesting that women exhibit a greater 
readiness to change their substance use behaviors than men (Drapalski et al., 2011), which may 
lead to greater reductions in substance use severity for women in this population.  However, this 
research has been largely limited by modest sized samples of dual diagnosis participants selected 
from specialty populations (i.e., veterans, first episode psychosis) that has included few women 
and persons with comorbid SUD and schizophrenia.  Consequently, there is a need for studies 
that seek to comprehensively examine intrinsic motivation among larger and more heterogeneous 
samples of persons with comorbid SUD and schizophrenia by investigating its impact on 
substance use severity, and whether such relations vary across genders.  
   For this dissertation, intrinsic motivation is conceptualized in terms of the behaviors 
people carry out because of the positive feelings that are associated with performing actions in 
the absence of extrinsic rewards (Deci & Ryan, 2007).  These actions do not require for such 
persons to rely on external support to be initiated or sustained.  This dissertation utilizes an 
operational definition of intrinsic motivation that is based on the sum of theoretically relevant 
items taken from the Quality of Life Scale (Heinrichs, Hanlon, & Carpenter, 1984), including 
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purpose, curiosity, and motivation.  Using these conceptual and operational definitions, 
Nakagami, Xie, Hoe, and Brekke (2008) developed a promising new instrument for measuring 
intrinsic motivation in schizophrenia.  Psychometric evaluations of the instrument have shown 
that it yields valid assessments of intrinsic motivation and demonstrates moderate levels of 
internal consistency (𝛼 = . 74) among community patients with the disorder (Nakagami et al., 
2008).  Subsequent investigations using this instrument have not only confirmed a long history 
of evidence indicating that persons with schizophrenia possess intrinsic motivation deficits (i.e., 
Barch, 2004), but have also shown that such deficits impede the ability of those with the disorder 
to generate internal drives to sustain behavior changes absent external support or reinforcement 
(Nakagami et al., 2008; Yamada, Lee, Dinh, Barrio, & Brekke, 2010; Nakagami, Xie, Hoe, & 
Brekke, 2010).  Perhaps not surprisingly, evidence from the dual diagnosis field has also shown 
that such deficits can disengage intrinsic motivational processes when persons with comorbid 
SUD and schizophrenia try to generate their internal drives toward reducing substance use 
severity (i.e., Drake et al., 2008; Horsfall et al., 2009).  
 While various instruments have been used to measure intrinsic motivation in the dual 
diagnosis treatment research, such approaches largely focus on the degree to which such persons 
exhibit intrinsic motivation to change substance-specific behaviors (i.e., DiClemente, 2003; 
DiClemente, Nidecker, & Bellack, 2008).  This research does not seek to take any of these more 
widely used substance-specific behavior approaches to the measurement of intrinsic motivation 
(i.e., DiClemente 2003), but rather seeks to extend validation of a more general measure of the 
construct developed by Nakagami and colleagues (2008) in schizophrenia to schizophrenia and 
comorbid SUD. This instrument may not only provide greater accuracy to estimating the base 
rates of intrinsic motivation deficits schizophrenia and comorbid SUD, but may also provide 
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greater insight into the longitudinal relationship between such deficits and substance use severity 
among this population. Further, it is also important to clarify that this research does not seek to 
estimate the relationship between intrinsic motivation and substance use severity via readiness-
to-change measures in the context of a motivational rehabilitation program, but rather seeks to 
examine the prospective naturalistic changes in such relations in schizophrenia and comorbid 
SUD.  Conducing such a study is important as extending validation of a diagnosis-specific 
instrument to schizophrenia and comorbid SUD may serve as a critical component in informing 
whether prospective naturalistic changes in intrinsic motivation can lead to reductions in 
substance use severity among this population.  
 Recently, Nakagami, Xie, Hoe, and Brekke (2010) showed that their intrinsic motivation 
instrument predicted change in functional outcomes in community patients with schizophrenia, 
suggesting that such deficits are important areas to target in intervention research.  While this 
measure has yet to be validated in schizophrenia and comorbid SUD, there is evidence from the 
dual diagnosis treatment research to suggest that such deficits can be improved among this 
population via participation in motivation rehabilitation programs (i.e., which generally, though 
not always, target reductions in SUD pathology), and that improvements in intrinsic motivation 
may be linked with reductions in substance use severity (i.e., Hunt et al., 2013; for review). For 
example, compelling evidence from a motivational intervention study by Graber and colleagues 
(2003) demonstrated that non-treatment seeking (for SUD pathology) persons with co-occurring 
SUDs and schizophrenia can develop and/or build intrinsic motivation for carrying out and 
sustaining behavior changes to reduce their use of substances.  More recently, evidence from a 
motivational intervention study by Drapalski and colleagues (2011) showed that treatment-
seeking (for SUD pathology) women with dual disorders were more intrinsically motivated to 
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change their behaviors associated with SUD pathology than men.  Indeed, these motivational 
rehabilitation studies suggest that persons with schizophrenia and comorbid SUD can reduce 
their substance use severity so long as they make gains in their intrinsic motivation. Compared to 
men, women may exhibit a greater ability to reduce such severities as they make gains in their 
intrinsic motivation. However, little is known about the relationship between changes in intrinsic 
motivation and changes in substance use severity as they naturally occur outside of these 
specialty intervention programs that very few in this population receive.  
The contribution of this dissertation is to investigate the relationship between prospective 
naturalistic changes in intrinsic motivation and substance use severity in a large heterogeneous 
sample of participants with co-occurring SUDs and schizophrenia (n = 535 at baseline; n = 219 
at 6-months; n = 150 at 1-year), after extending validation of the intrinsic motivation instrument 
developed by Nakagami and colleagues (2008) to this population.  This will be accomplished by 
utilizing the QLS-derived measure of intrinsic motivation to examine whether people with 
schizophrenia and comorbid SUD exhibit less severe patterns of SUD pathology as they make 
gains in intrinsic motivation, and whether men and women differ in their patterns of severity as 
they make gains in intrinsic motivation. The present study is conducted within the context of a 
large-scale randomized-controlled trial of medication treatments for persons with schizophrenia 
(i.e., first and second generation antipsychotic medications); however, rather than focus on the 
effects of such treatments on SUD pathology or intrinsic motivation, this research uses its 
longitudinal context to conduct a robust examination of the link between prospective naturalistic 
changes in intrinsic motivation and changes in substance use severity, and then investigates 
whether such relationships vary across genders.  This investigation is important because it seeks 
to test a potentially critical determinant (intrinsic motivation) by which substance use severity 
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can be reduced in comorbid SUD and schizophrenia, and may not only serve to extend treatment 
development efforts aimed at reducing such pathology in the larger dual diagnosis population to 
include a provision targeting the intrinsic motivational deficits of schizophrenia, but may also 
lead to findings that call for gender-specific care.   
 What follows is an overview to the importance of substance use severity in co-occurring 
SUDs and schizophrenia, as well as a summary of the current state of the evidence with regard to 
the factors that contribute to SUD pathology in this population that signal the need for further 
research on the relationship between intrinsic motivation and substance use severity among 
persons with co-occurring SUDs and schizophrenia.  The following section is only intended to 
serve as a brief introduction to the topic, as a greatly expanded review of the research discussed 
herein is provided in Chapter 2.  
 
B.  THE PROBLEM OF SUBSTANCE USE SEVERITY IN SCHIZOPHRENIA 
 Persistent and pervasive patterns of substance use severity are highly problematic 
features of SUD pathology that often plague the lives of those who suffer from co-occurring 
SUDs and schizophrenia.  Many reports have considered U.S. deinstitutionalization policies as a 
key contributor to the emergence of co-occurring SUDs in schizophrenia, which have worsened 
these conditions in terms of the persistent severities of substance use observed among this 
population.  Such efforts had begun in the mid-1960s by shifting the locus of care from state 
hospitals to the community, thereby removing individuals with schizophrenia from the controlled 
conditions that had limited their access to substances of abuse.  Consequently, the post-
deinstitutionalization rates of SUDs among people with schizophrenia grew from 30% in 1970 to 
nearly 50% by 1990 (Westermeyer, 2006), with this effect on comorbidity becoming widely 
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acknowledged as a national public health issue in the mid-1980s (McHugo et al., 2006).  In 
addition, while there was a lack of treatments and services available to accommodate the unique 
needs of this population at this time, such individuals became characterized as “difficult to 
serve” (Pepper, Krishner, & Ryglewicz, 1981; Bachrach, 1982), with their severe patterns of 
substance use being labeled as “treatment resistance” (Osher & Drake, 1996).   Ever since 
deinstitutionalization, the problem of co-occurring SUDs in schizophrenia has proliferated, yet 
since no social policies, treatments, or services have been able to successfully address this issue, 
a large number of affected persons have sustained their substance use for years in despite facing 
significant disability.  Today, such patterns characterize the severity of SUD pathology, and are 
defined within the context of the frequency, duration, consequences, and impairments associated 
with the long-term and recurrent use in schizophrenia and comorbid SUD (Drake et al., 2006).     
    Research on co-occurring SUDs in schizophrenia has shown that affected individuals 
tend to experience prolonged disability stemming from the significant severity that SUD 
pathology exacts on schizophrenia, although some improvements do occur over the long-term 
course of these conditions.  For example, in a 10-year study of 130 people with co-occurring 
SUDs and schizophrenia, Drake and colleagues (2006) found that after at least 3 years of 
experiencing significant substance use severity, 50% of the sample had begun to show signs of 
recovery (as measured by achieving control over both disorders, attaining independent housing, 
or a better quality of life).  While such findings are seemingly optimistic, research conducted 
over the past several decades has indicated that this comorbidity remains present in affected 
persons throughout the lifespan (Westermeyer, 2006), and thus recovery does not mean that 
those who achieve such a status are cured.  Further, this comorbidity has been linked with a host 
of adverse clinical outcomes at relatively low substance use severity thresholds among 
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individuals with schizophrenia (Drake et al., 1990; Ziedonis et al., 2005).  For example, studies 
of persons with co-occurring SUDs and schizophrenia have shown that the use of substances 
significantly contribute to missed general and medication appointments (Owen, Fischer, Booth, 
& Cuffel, 1996; Hipwell, Singh, & Clark, 2000; Coldham, Addington, & Addington, 2002), 
which lead to more positive symptom exacerbations (Pencer & Addington, 2003), more relapses, 
higher rates of emergency service utilization (Curran et al., 2003; Barnes, 2008), and greater 
rates of inpatient hospitalizations (Linszen, Dingemans, & Lenior, 1994; Swofford, Kasckow, 
Scheller-Gilkey, & Inderbitzin, 1996).  
 Research following people with co-occurring SUDs and schizophrenia throughout the 
long-term course of these conditions has documented just how problematic the severity of SUD 
pathology, can be for this population.  Bartles, Drake, and Wallach (1995) followed a cohort of 
people with co-occurring SUDs and schizophrenia for 7-years and found that the prevalence of 
SUD increased by 1% per year.  Notably, at the 7-year follow-up, there was no indication that 
any of the 148 participants had achieved sustained remission (i.e., after meeting criteria for 
alcohol use disorder, none of the criteria are met during a period of 12-months or longer; 
American Psychiatric Association [APA], 2013).  Another study by Lambert and colleagues 
(2005) found that when following a cohort of 643 people for 18-months after their first episode, 
high baseline severities of substance use predicted poorer rates of remission over the study.  
While these data suggest that people with this comorbidity can sustain their use of substances for 
several years in the face of significant severity, other studies suggest that this population may 
adopt abstinence (Drake, McHugo & Noordsy, 1993; Dixon, McNary, & Lehman, 1998; Drake 
et al., 2006).  Drake, McHugo, and Noordsy (1993) followed a cohort of 18 persons with co-
occurring SUDs and schizophrenia for 4-years and found that 11 achieved at least one 6-month 
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remission.  In addition, emerging research indicates that women with co-occurring SUDs and 
schizophrenia use substances less frequently than men (Leung & Chue, 2000), and that such 
women also exhibit less longitudinal severities of use than men (Køster, Lajer, Lindhardt, & 
Rosenbaum, 2008).  As such, the weight of the evidence in this area of research supports 
observations that show co-occurring SUDs in schizophrenia are frequently characterized by 
persistent patterns of severe substance use. These patterns may be less severe for women; and 
when present, such pathology limits remission and recovery rates among this population.  
 Unfortunately, while the evidence is clear that SUD pathology is problematic in 
schizophrenia, previous attempts to understand the factors that may have an impact on substance 
use severity among those with the disorder has produced mixed results.  Diversity in the extant 
research findings has resulted, at least in part, from variability in the measurement instruments 
used to assess the degree of severity associated with a SUD diagnosis in schizophrenia (Dixon, 
1999; Carey, 2002; Ziedonis et al., 2005).  Exposure to trauma has been a salient predictor of 
substance use severity among this population, as such factors tend to worsen SUD pathology in 
schizophrenia, perhaps due to the inherent difficulties such persons have in coping with and 
tolerating emotionally charged situations (Gearon, Bellack, Rachbeisel, & Dixon, 2001; Scheller-
Gilkey, Moynes, Cooper, Kant, & Miller, 2003; Gearon, Kaltman, Brown, & Bellack, 2003).  
Symptoms of psychosis would also seem to be likely contributors to SUD pathology; however, 
investigations of these contributions have yielded mixed results, with a few studies showing 
modest relations between social anhedonia, delusions, hallucinations, and more frequent 
substance use (Gregg, 2012).  Antisocial personality disorder (ASPD) and its childhood 
precursor, conduct disorder, are known predictors of increased substance use severity among this 
population (Mueser, Noordsy, Drake, & Fox, 2003; Mueser et al., 2006). This is perhaps due to 
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the serious challenges stemming from the poor treatment compliance associated with this 
combination of comorbidities.  While gender has shown some potential as a salient predictor of 
SUD pathology, most studies of these relations have also produced mixed results, with some 
reporting significant differences between men and women (Køster et al., 2008; Koskien et al., 
2009a), and others reporting no significant relationships (Brunette & Drake, 1997; Brunette & 
Drake, 1998; Koskien et al., 2009b).  Taken together, such factors are far from accounting for all 
the variance in SUD pathology in co-occurring SUDs in schizophrenia, indicating that there are 
other important factors precluding the remission and recovery from the severe patterns of 
substance use among this population.  
 What follows is an overview of the importance of investigating the relevance of intrinsic 
motivation deficits as a potential contributor to the persistent patterns of substance use severity 
observed in persons with co-occurring SUDs and schizophrenia, and whether such a relationship 
varies across genders among this population. The following section is only intended to serve as a 
brief introduction to the potential relationship between intrinsic motivation deficits and substance 
use severity in schizophrenia, as a greatly expanded review of the research discussed herein is 
provided in Chapter 2.  
  
C. INTRINSIC MOTIVATION AS A CONTRIBUTOR TO SUBSTANCE USE 
SEVERITY IN SCHIZOPHRENIA 
 One of the most promising potential contributors to the persistent patterns of substance 
use severity observed in individuals with schizophrenia is deficits in intrinsic motivation. Studies 
conducted over the past century have supported the conceptualization of schizophrenia as a 
disorder of motivational impairment, with some of the earliest descriptions of the illness 
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emphasizing a disturbance of volition as the fundamental process in its pathology (see Foussias 
& Remington, 2010, for review).  In fact, psychiatrists as early as Emile Krapelin (1919) have 
described schizophrenia as an illness of early and progressive deterioration, attributing deficits in 
core motivational processes in dictating the changes characterizing this decline.  Today’s 
nosology of mental disorders considers the presence of prominent motivational deficits such as 
amotivation and ahedonia to be defining features of the disorder (APA, 2013).  Such deficits are 
characterized by a diminished capacity in taking interest in activities (amotivation), and by an 
inability to experience pleasure from tasks that most people find enjoyable (ahedonia).    
 Over the past decade, evidence has begun to suggest that the intrinsic motivation deficits 
observed in schizophrenia impede the ability of those with the disorder to generate internal 
drives to sustain behavior changes absent external rewards (see Chapter 2, Section C.2 for an 
expanded discussion on intrinsic motivation deficits in schizophrenia).  Regarding individuals 
with co-occurring SUDs and schizophrenia, evidence has also begun to suggest that such deficits 
can disengage persons with these conditions from generating internal drives to achieve 
reductions in substance use severity (see Chapter 2, Section C.3 for an expanded discussion on 
intrinsic motivation deficits in co-occurring SUDs and schizophrenia).  Most of the evidence 
regarding this issue has emerged within the context of investigations of psychosocial approaches 
designed to enhance dual diagnosis clients’ intrinsic motivation to reduce or cease their use of 
substances (see Hunt et al., 2013, for review).  For example, compared to dual diagnosis clients 
without schizophrenia, the weight of the evidence indicates that persons with co-occurring 
schizophrenia and SUDs demonstrate less motivation to change the behaviors associated with 
their use of substances while participating in treatment programs, are more difficult to engage, 
make slower progress, and drop out of such programs at faster rates (see Drake et al, 2008; 
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Horsfall et al., 2009; Hunt et al., 2013, for reviews).  While such patterns may actually implicate 
the problems associated with the intrinsic motivation deficits observed in schizophrenia rather 
than issues with compliance associated with the pathology of the SUD, this question has 
remained largely unexamined in the dual diagnosis treatment research to date.   
 Unfortunately, relatively little research has examined the actual contributions of intrinsic 
motivation deficits to substance use severity in co-occurring SUDs and schizophrenia, even 
within the context of relevant motivational rehabilitative approaches (see Dixon et al., 2009; 
Hunt et al., 2013;  for reviews).  Nonetheless, among the studies that have been conducted 
among this population, a compelling investigation by Graber and colleagues (2003) examined 
the relationships between intrinsic motivation and the substance use behavior of 30 non-
treatment seeking (i.e., for SUD pathology) veterans with schizophrenia and co-occurring SUDs 
participating in a motivational rehabilitative treatment program.  The investigators found that the 
ability to increase intrinsic motivation was stronger among the participants in the experimental 
condition (motivational interviewing), which was a significant predictor of reduced alcohol use 
disorder pathology (Graber et al., 2003).  Subsequent studies of motivational rehabilitative 
programs for people with co-occurring SUDs and schizophrenia have shown that such persons 
can improve their substance use outcomes regardless of the treatment to which they were 
assigned  (Martino et al., 2006; Edwards et al., 2006), perhaps suggesting both groups made 
comparable gains in intrinsic motivation.  Finally, one recent study by Drapalski and colleagues 
(2011) examined gender differences between treatment seeking (i.e., for SUD pathology) and 
treatment non-seeking groups in their readiness to change substance use behaviors upon study 
enrollment.  The investigators found that treatment-seeking women exhibited the highest 
motivation for changing their behaviors associated with substance use upon enrollment 
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compared to all other groups observed.  Taken together, these findings highlight the significance 
of intrinsic motivation deficits to substance use severity in co-occurring SUDs in schizophrenia, 
and the potential for such relationships to vary by gender among this population.  
 
D.  LIMITATIONS OF PREVIOUS RESEARCH  
1. Narrow focus on motivational rehabilitation  
 While studies have investigated the relationship between deficits in intrinsic motivation 
and substance use severity in persons with co-occurring SUDs and schizophrenia, this research 
suffers from several important limitations.  First, to date investigations of intrinsic motivation in 
co-occurring SUDs and schizophrenia have exclusively been conducted within the context of 
motivational rehabilitation programs for the larger dual diagnosis population.  Some of these 
programs have adapted their motivational modalities to accommodate the symptoms of psychosis 
(Martino et al., 2002; Martino et al., 2006), yet not one has modified a treatment protocol to 
account for the intrinsic motivation deficits unique to the pathophysiological processes of 
schizophrenia (see Chapter 2, Section C.2). Nevertheless, a limited number of such motivational 
rehabilitation studies conducted within the larger dual diagnosis population have shown that 
individuals with schizophrenia and comorbid SUD can reduce their substance use severity as 
they make gains in their intrinsic motivation (Graber et al., 2003; Kavanaugh et al., 2004; 
Edwards et al., 2006; Baker et al., 2006).  It should be noted, however, that the positive effect of 
changes in intrinsic motivation in relation to changes in substance use severity has been obtained 
within the context of several limiting conditions.  For example, not only have these studies made 
use of modest sized samples, but such investigations also selected their samples from specialty 
populations that included few women as well as small proportions of persons with co-occurring 
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SUDs and schizophrenia.  Consequently, this narrow focus on examining such effects within the 
context of dual diagnosis motivational programs has raised several important questions about 
how such findings generalize to the larger population of persons with co-occurring SUDs and 
schizophrenia (McHugo et al., 2006).  As such, elucidating the relationship between changes in 
intrinsic motivation and changes in substance use severity as they naturally occur outside of 
these specialty intervention programs that very few people in the population actually receive 
represents an important area of further investigation.  
2. Lack of representativeness  
 Second, the majority of investigations examining the relationship between intrinsic 
motivation and substance use severity have largely lacked samples that are generalizable to the 
larger population of persons with co-occurring SUDs and schizophrenia.  For example, the only 
study to observe relations between intrinsic motivation and substance use severity where 100% 
of the study sample consisted of schizophrenia participants was conducted with a modest number 
of veterans (N = 30) who were mostly male (1 woman participant) (Graber et al., 2003).  Similar 
issues are readily discernable in studies conducted by Kavanaugh et al. (2004) and Edwards et al. 
(2006). Both investigations observed relations between intrinsic motivation and substance use 
severity using specialty samples of dual diagnosis clients, where only about 50% of their modest 
sized (N = 25; N = 47, respectively) samples consisted  of first episode schizophrenia patients. In 
addition, Kavanaugh et al. (2004) recruited their study sample from an inpatient unit, and then 
followed such patients after they were (mostly) discharged to the care of their families.  While 
Kavanaugh et al. (2004) has contributed to the evidence supporting significant relations between 
intrinsic motivation and substance use severity among this population, the findings may be less 
applicable to the vast majority of chronic patients with co-occurring SUDs and schizophrenia 
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who live in the community, have free access to drugs and alcohol, and rely on public rather than 
family support (Drake et al., 2008).  As a consequence of the methodological issues inherent to 
these studies, most of dual diagnosis research that has considered the importance of intrinsic 
motivation to substance use severity may not generalize to the majority of individuals with co-
occurring SUDs and schizophrenia. As such, research on larger and more heterogeneous samples 
of persons with these conditions is needed.   
3. Inattention to confounding effects/extrinsic rewards 
 Third, the studies investigating the relations between intrinsic motivation and substance 
use severity in schizophrenia and comorbid SUD have also been limited by the potential 
confounding influence of extrinsic rewards.  Relevant evidence from studies conducted with 
healthy individuals indicates that extrinsic rewards, such as money and praise, can undermine the 
development of intrinsic motivation unless the information is delivered in a context that supports 
the person’s autonomy (Deci, Ryan, & Koestner, 1999, for review).  A few motivational studies 
delivered extrinsic rewards in the form of remuneration payments to participants at the time that 
such persons received the motivational session targeting improvements in intrinsic motivation to 
reduce their SUD pathology (i.e., James et al., 2006; Martino et al., 2006).  This makes it 
difficult to discern the actual mechanisms underlying the relations between improvements in 
intrinsic motivation and reductions in substance use severity that were documented in these 
investigations.   
4. Limited use of intrinsic motivation measures 
 Finally, studies of the relations between intrinsic motivation and substance use severity in 
co-occurring SUDs and schizophrenia have primarily employed readiness-to-change assessments 
to measure the stage of change associated with the individual’s current level of motivation to 
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improve specific target behaviors, such as reductions in substance use severity.  Such a person’s 
stage of change is based on one of 5 stages of change that coincide with the transtheoretical 
model (TTM) of intentional behavior change (precontemplation, contemplation, preparation, 
action, maintenance) (DiClemente, 2003).  Motivation, according to the TTM perspective, 
requires for individuals to engage in enough cognitive/ experiential activities to move through 
the early stages and to engage in behavioral activities to initiate and sustain the change 
(DiClemente, Nidecker, & Bellack, 2008).  While it can be assumed that targeted behaviors that 
are sustained over the long-term likely result from intrinsic goals, readiness-to-change measures 
do not actually account for whether the motivation for a person’s engagement in change 
processes is intrinsic (i.e., motivated by internal desire to change) or extrinsic (i.e., motivated by 
money or other external factors).  Given the potential for low intrinsic motivation base rates in 
co-occurring SUDs and schizophrenia to impede the recovery of such persons from severe and 
persistent patterns of substance use (see Chapter 2, Section C.1 for an expanded discussion of the 
base rates of intrinsic motivation deficits in schizophrenia), a measure that is more focused on 
intrinsic motivational processes among this population is needed to supplement the assessment.     
 Recently, a promising measure of intrinsic motivation has been developed, tested, and 
validated among individuals with schizophrenia by Nakagami et al. (2008).  Such a measure is 
premised on a conceptualization of intrinsic motivation acknowledging that behaviors are carried 
out because of the positive feelings associated with an action in the absence of any tangible 
reward, or actions that are taken for their own sake that do not require any reinforcement or 
external supports to be initiated or sustained (Deci & Ryan, 2007).  This measure utilizes an 
operational definition of intrinsic motivation that is based on the sum of theoretically pertinent 
items from the Quality of Life Scale (Heinrichs et al., 1984), including purpose, motivation, and 
20 
 
curiosity.  These items show face validity in terms of their focus on cross-situational phenomena 
in life experience such as goals, plans, and in areas of interest/ drive (Nakagami et al., 2010).  
Thus, it stands to reason such items may also characterize the interest/ drive such persons with 
schizophrenia and comorbid SUD manifest in terms of reducing their substance use severity.  
This research uses these operational and conceptual definitions of the construct, yet prior 
schizophrenia research has conceptualized and operationalized intrinsic motivation in various 
ways (i.e., Yodkovik, Sypher-Locke, & Hanewinkel, 2008; Choi & Medalia, 2010).  However, 
not only has Nakagami and colleagues’ (2008) instrument shown reliable assessments of intrinsic 
motivation among persons with schizophrenia living in the community (Nakagami et al., 2008; 
Nakagami et al., 2010; Yamada, Lee, Dinh, Barrio, & Brekke, 2010), but it has also shown valid 
predictions of change in functional outcomes in comparative samples of those with the disorder 
(Nakagami et al., 2010).  Unfortunately, the validity of this measure has yet to be confirmed 
among those with co-occurring SUDs and schizophrenia.  Given the broad applicability of 
employing this measure for predicting changes across a host of functional outcome domains 
among those with the disorder, this study seeks to extend the research in this area by examining 
prospective naturalistic changes in the relationship between intrinsic motivation and substance 
use severity for a large sample of persons with co-occurring SUDs and schizophrenia. This study 
also seeks to examine the degree to which such a relationship varies across genders, after 
extending the validation of this instrument to persons with comorbid schizophrenia and SUD.  
 
E.  STUDY AIMS 
 This study aims to conduct a longitudinal investigation examining the impact of intrinsic 
motivation on substance use severity among persons with schizophrenia and comorbid SUD and 
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its patterns in men and women, after extending validation of a promising new measure of 
intrinsic motivation to this population.  Such analytic aims will be carried out using secondary 
data that were collected as part of the Clinical Antipsychotic Trials of Intervention Effectiveness 
(CATIE) study (Liberman et al., 2005). The CATIE study evaluated a broad array of functional, 
clinical, and substance use outcomes in persons with schizophrenia who were participating in a 
randomized clinical trial of the effectiveness of first and second generation antipsychotic 
medications (i.e., Stroup, McEvoy, & Liberman, 2010).  This research is not focused on 
elucidating the pharmacological treatment effects of the CATIE trial, but rather seeks to make 
use of its longitudinal context to follow the 535 participants who had schizophrenia and 
comorbid SUD at baseline for up to 1-year of treatment.  This was done in order to examine 
naturalistic the prospective relationship between changes in intrinsic motivation and changes in 
substance use severity among the sample, and to then investigate whether such a relationship 
varies across genders.  The CATIE study sought to include adults with schizophrenia who would 
be representative of those seen in typical clinical settings across the U.S. by recruiting “real-
world” patients, including those with comorbid substance use disorders (an exclusion of many 
clinical trials), and thus provides a unique dataset for examining whether improvements in 
intrinsic motivation are related to improvements in substance use severity among this population.  
Using data from the CATIE study, this research aims to: 
 
Aim #1:  Extend the validation of a promising measure of intrinsic motivation to persons with 
schizophrenia and comorbid SUD.  Intrinsic motivation is assessed using an inventive technique 
recently developed by Nakgami, Xie, Hoe, and Brekke (2008), which gauges intrinsic motivation 
by taking the sum of theoretically pertinent intrapsychic deficit items from the Quality of Life 
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Scale (Heinrichs et al., 1984), probing purpose, motivation, and curiosity.  This measure of 
intrinsic motivation has not been previously applied to persons with comorbid SUD and 
schizophrenia.  Thus, this analytic aim will be addressed by subjecting the total pool of 7-items 
from the intrapsychic deficit subscale to an exploratory factor analysis. 
Aim #2:  Examine the cross-sectional relationships between intrinsic motivation, gender, and 
substance use severity.  This analytic aim will be carried out using baseline data (n = 535) to 
employ independent sample t-tests (two-tailed) for examining the bivariate relationships between 
gender and intrinsic motivation and gender and substance use severity. Baseline data will also be 
used to compute correlation matrices and hierarchical linear regression analyses to examine the 
zero-order and unique associations (adjusting for negative symptoms and neurocognition) 
between intrinsic motivation and substance use severity. 
Aim #3:  Investigate the longitudinal contribution of changes in intrinsic motivation to changes 
in substance use severity, and then examine whether gender moderates this relationship. This 
analytic aim will be carried out by employing a series of growth curve models. Unconditional 
models will first be fit to examine whether or not there is variability in the initial status and the 
rates of change in the 1-year trajectories of substance use severity among the sample. Analysis 
will proceed by then expanding unconditional models to conditional models to examine the 
longitudinal contribution of changes in intrinsic motivation to changes in substance use severity. 
Conditional growth curve models will then be expanded to examine the moderating effects of 
gender on these relations.  
 Taken together, the results of these aims will be used to derive implications for future 
intervention development efforts for persons with co-occurring SUDs and schizophrenia.  The 
analytic aims and associated hypotheses proposed above seek to take an important step in 
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establishing empirical support for targeting deficits in intrinsic motivation within specialized dual 
diagnosis treatment programs for persons with co-occurring SUDs and schizophrenia, and in 
identifying the significance of intrinsic motivation deficits as a potential gender-specific 
treatment target among this population.  In observing significant relationships between intrinsic 
motivation deficits and substance use severity, such findings can be directed toward existing 
interventions to enhance their effects on intrinsic motivation deficits in an effort to reduce the 
pervasive patterns of substance use severity among this population.  In the presence of significant 
variability across genders with regard to these relationships, findings from this research can be 
directed toward novel treatments that not only enhance their effects on intrinsic motivation 
deficits but also attend to their unique impact on men and women among this population. 
 
F.  RELEVANCE TO SOCIAL WORK 
 Patterns of severe and persistent substance use are pervasive among persons with co-
occurring SUDs and schizophrenia and are refractory to many of the currently available 
medication and psychosocial treatments for dual disorders (Westermeyer, 2006).  Taking a multi-
systemic social work approach to this social problem emphasizes how the U.S. social policies 
that closed mental hospitals for humanitarian reasons exposed vulnerable individuals with 
schizophrenia to substances in the community. This has resulted in significant SUD pathology 
being observed among those with the disorder.  Such a counterbalance to an overly medical 
perspective is important because it necessarily considers the psychosocial factors that create and 
sustain an environment in which persons with co-occurring SUDs and schizophrenia persist in 
their patterns of severe substance use over the long-term course of these conditions.   Since the 
problem of co-occurring SUDs in schizophrenia largely resulted as an unintended psychosocial 
24 
 
effect of U.S. deinstitutionalization policies (i.e., what failed with respect to hospitals, housing, 
and community-based services)—it stands to reason that a potential solution to this problem may 
be largely a matter of developing psychosocial remedies that lie within the grasp of social work 
investigators to undertake.  Social work investigations are needed that seek to understand the 
factors that contribute to SUD pathology in schizophrenia, to gain insights for developing 
treatments to offset the destabilizing effects of the persistent and severe patterns of substance use 
that continue to plague the lives of those who suffer from these conditions.  Intrinsic motivation 
deficits have been identified as potential contributors to substance use severity in this population, 
and women may exhibit more intrinsic motivation toward changing their behaviors associated 
with substance use than men.  Persons with co-occurring SUDs and schizophrenia comprise a 
vulnerable group of individuals who are in desperate need of better treatments and services to 
improve their quality of life and to lessen the impact of the psychosocial consequences of 
substance use.  Social work has long been concerned with helping vulnerable populations in need 
by applying multi-systemic approaches to psychosocial phenomena, and thus a study proposing 
to examine  the relationship between intrinsic motivation and substance use severity among 
persons with co-occurring SUDs and schizophrenia, and then investigate whether such a 
relationship varies across genders is important and relevant to the field.  
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II. LITERATURE REVIEW 
 
 A study proposing to investigate the impact of intrinsic motivation deficits on outcomes 
of substance use severity and its patterns in men and women among persons with co-occurring 
SUDs and schizophrenia brings together a diverse array of literature from the disciplines of 
social work, addictions, psychiatry, psychology, and public health.  This chapter provides a 
review of this literature within and across these disciplines to denote the importance of substance 
use severity to persons with co-occurring SUDs and schizophrenia and larger society, as well as 
evidence pointing to the construct of intrinsic motivation for understanding the profound degree 
of substance use severity experienced by this population.  The review begins by providing initial 
information regarding the nature and socio-political trends in the disorder, and then examines the 
literature surrounding the patterns of substance use severity within and across genders.  The 
review then proceeds with an examination of the intrinsic motivation construct that highlights its 
potential for understanding the degree of substance use severity persons with schizophrenia and 
comorbid SUD experience. This review does so by first providing a general overview of the 
intrinsic motivation construct. What follows is a critical analysis of the evidence surrounding 
intrinsic motivation deficits in schizophrenia and comorbid SUD and the relationships between 
these deficits and substance use severity among this population and its patterns in men and 
women. Finally, this review concludes by providing a brief discussion of the current issues 
surrounding the measurement of intrinsic motivation in schizophrenia, which underscores the 
importance of a study on the impact of intrinsic motivation on outcomes of substance use 
severity among persons with co-occurring SUDs and schizophrenia and its patterns in men and 
women. 
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A.  OVERVIEW OF CO-OCCURRING SUBSTANCE USE DISORDERS AND 
SCHIZOPHRENIA 
 Schizophrenia is a complex and disabling psychiatric disorder that poses significant 
challenges to those who suffer from it, their families, and to our larger society.  One of the most 
vexing problems among adults with schizophrenia today is the co-occurrence of SUDs, often 
called dual diagnosis or dual disorders.  These individuals are diagnostically complex, clinically 
unstable, difficult to recruit to studies, difficult to engage in treatment, and especially difficult to 
retain in treatment.  Such challenges and motivational issues have led to the exclusion of people 
with schizophrenia and comorbid SUD from controlled research studies and to difficulties with 
completing studies aimed at this population.  Within the U.S. healthcare system, the historical 
separation between mental health and addition systems of care has led to a lack of cooperation 
concerning the treatment of these disorders, and to date, no social policies have specifically 
addressed the unique needs of this population.  As such, people with schizophrenia and comorbid 
SUD are vulnerable to a host of adverse consequences, including high rates of hospitalization, 
relapse, legal problems, homelessness, family difficulties, and serious infectious diseases such as 
HIV and hepatitis C.  Today both schizophrenia and SUDs are conceptualized as biologically-
based disorders of the brain such that symptom relapse and remission are common over the life-
course, and there is no known cure for either condition.  The problem of co-occurring SUDs in 
schizophrenia is now considered a major public health issue due to its destabilizing effects and 
considerable cost to families and societies.  This section will first provide a brief discussion of 
schizophrenia, and will then move into a more focused discussion of co-occurring SUDs among 
those with the disorder and its significance as a major public health issue in both the U.S. and 
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abroad to highlight the relative importance of this problem to both science and society. 
1. Description and Social Significance 
 Burden of disease. Schizophrenia is a chronic and persistent psychiatric disorder that 
affects approximately 1% of the population worldwide, and comparatively equal prevalence rates 
have been observed between genders (American Psychiatric Association [APA], 2013).  Despite 
its relatively low lifetime prevalence rate, schizophrenia is among the top ten leading causes of 
disease-related disability in the world (Murray & Lopez, 1996; World Health Organization 
[WHO], 2001).  Within the U.S. alone, it is estimated that approximately 30.3 billion dollars are 
spent on the treatment and the cost of living for people with schizophrenia annually (Wu et al., 
2005).  In addition to the high direct cost of caring for people with schizophrenia, it is estimated 
that other factors among those with the disorder, such as unemployment and reduced workplace 
productivity, cost the U.S. 23.4 billion dollars annually (Wu et al., 2005), making this condition 
one of the most costly psychiatric disorders in the world (Knapp, Mangalore, & Simon, 2004). 
 These direct care and other societal costs are not the only financial burdens associated 
with schizophrenia.  There are also costs of the disorder that are frequently incurred by families 
or caregivers (Magliano et al., 1998; Clark, Xie, Adarhi-Meija, & Sergupta, 2001).  For example, 
research has documented that up to 83% of the friends and family members of people with 
schizophrenia experience practical, emotional, and financial burdens (Magliano et al., 2002). 
They report time lost from work, unreimbursed medical expenses, limited time for leisure, 
elevated symptoms of psychological distress, and disturbed sleep (Schene, Van Wijngaarden, & 
Koeter, 1998; Angermeyer, Liebelt, & Matschinger, 2001; Ohaeri, 2001; Magliano et al., 2002; 
McDonell, Short, Berry, & Dyck, 2003).  This additional source of economic or caregiver burden 
has also been linked to the high mortality rates observed among those with schizophrenia (Knapp 
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et al., 2004).  For example, long-term follow-up studies of schizophrenia patients post-
psychiatric hospital discharge have shown an approximately two fold increase in all causes of 
mortality compared to the general population (Tsuang & Woolson, 1978;  Allebeck & Wistedt, 
1986; Anderson, Connelly, Johnstone,& Owens, 1991), with suicide as the leading reason for the 
excess mortality (Allebeck, Varla, & Wistedt, 1986; Newman, & Bland, 1991; Brown, 1997). 
Further, about 10% of all people with schizophrenia will eventually have a completed suicide 
(Siris, 2001), and of those who survive, many will experience persistent functional disability 
throughout their lives.  Those who have these severe and enduring needs often require long term 
multi-disciplinary input to help them reach an optimal state of functioning (Huxley & Fonseca, 
2013).  Although this entails a comprehensive approach to treatment including medication, 
psychosocial interventions, and assistance with housing and financial sustenance, many 
individuals with schizophrenia remain significantly disabled despite these efforts, often being 
unable to maintain gainful employment, complete schooling, or marry and have families 
(Andreasen, 1995; Huxley & Fonsca, 2013). 
 Psychopathology. The severe degree of disability that schizophrenia has on individuals 
with the disorder, their families, and broader society stems from its clinical features, which are 
commonly expressed in terms of positive and negative symptom clusters (Davies, 2007).  The 
first symptom cluster present in schizophrenia is positive symptoms. Such symptoms include 
delusions (i.e., erroneous beliefs based upon false perceptions that persist despite indisputable 
evidence to the contrary), hallucinations (i.e., experiencing a perception in the absence of an 
apparent stimulus that has qualities of a real perception), and/or thought disturbance (i.e., 
disorganized thinking and speech). The second symptom cluster consists of negative symptoms. 
These symptoms include alogia (i.e., a general lack of additional, unprompted content seen in 
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normal speech), affective flattening (i.e., reduced range and/or intensity of emotional expression), 
avolition/ amotivation (i.e., general lack of drive, or motivation to pursue meaningful goals), and 
anhedonia (i.e., diminished capacity to experience intrinsic pleasure from activity).  While 
individuals with schizophrenia experience both negative and positive symptoms, negative 
symptoms tend to persist even when positive symptoms are controlled with medication (Tandon, 
Nasrallah, & Keshavan, 2010).  According to the most recent Diagnostic and Statistical Manual 
of Mental Disorders (APA, 2013), the continuous presence of any two signs of positive and/or 
negative symptoms for at least one month, in combination with significant functional impairment 
for the past six months, permits the consideration of a diagnosis of schizophrenia. 
 Nature and course. Although schizophrenia has been studied as a major disease entity for 
the past century, to date, its nature and pathogenesis have continued to remain elusive.  The 
disorder has been shown to be associated with a host of neurobiological deviations (Shenton, 
Dickey, Frumin, & McCarley, 2001; Keshavan, Tandon, Butros, & Nasrallah, 2008), and to have 
a strong genetic component (Sullivan, Kendler, & Neale, 2003; Sullivan, 2008), with gene-
environment interactions contributing to over 80% of the liability for developing the disorder 
(Tandon, Keshavan, & Nasrallah, 2008).  However, despite recent advances that have been made 
in neurobiology and molecular biology, no single gene variation or neurobiological marker has 
been consistently associated with a greater likelihood of developing schizophrenia (Tandon et al., 
2008).  Nevertheless, a host of environmental factors have been linked to a greater likelihood of 
developing the disorder some of which include, cannabis use (Semple, McIntosh, & Lawrie, 
2005; Løberg & Hugdahl, 2009), prenatal infection (influenza) or malnutrition (Meyer, Yee, & 
Feldon, 2007; St Clair et al., 2005), perinatal (fetal hypoxia) problems (Byrne, Agerbo, 
Bennedsen, Eaton, & Mortensen, 2007), and early life stress (Norman & Malla, 1993; Harrison, 
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2004; Allardayce & Boydell, 2006).  While any of these factors may increase a person’s risk for 
developing the disorder, none are sufficient to precipitate symptom onset, and the actual cause of 
schizophrenia is not currently known. 
 For those who develop schizophrenia, the onset of symptoms usually occurs during late 
adolescence or early adulthood, and once present, the disorder often takes on a recurrent pattern 
of acute positive symptom exacerbation that is accompanied by persistent cognitive, social, and 
vocational dysfunction (APA, 2013).  These functional deficits tend to persist even when other 
symptoms are in remission or controlled with medication (Tandon et al., 2010).  As the course of 
the disorder progresses, the acute exacerbations of positive symptoms usually remit, such that 
around 50% of people with schizophrenia meet criteria for recovery (defined as remission of 
positive symptoms, participation in work or school, and increased social functioning [Liberman, 
Kopelowicz, Ventura, & Gutkind, 2002; Liberman & Kopelowicz, 2002]) for periods of time 
during their lives, with such periods increasing in frequency and duration once such persons are 
past middle age (Bellack, 2006).  As many who are in recovery continue to experience negative 
symptoms and functional disability across several domains, even the most optimistic views on 
the course of the disorder do not consider those who have achieved this status as being cured of 
schizophrenia (Bellack, 2006).  Although there are few reliable predictors of symptom remission 
and recovery in schizophrenia (Liberman et al., 2002), persons who have the disorder and live in 
developing countries tend to have better long-term outcomes than those who live in developed 
countries (Harding, 2003).  Further, persons with an earlier age of onset generally have poorer 
outcomes than those who are diagnosed with schizophrenia later in life (APA, 2013; Leung & 
Chue, 2000), though the effect of age at onset is likely related to gender.  For example, men have 
an earlier onset of the disorder, poorer premorbid functioning, lower educational achievement, 
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greater structural brain abnormalities, and more prominent negative symptoms and cognitive 
impairment than women (APA, 2013; Leung & Chue, 2000).  While there are no clear 
differences in family history by gender, women generally display more prominent affective 
symptoms and respond better to medications than men (Leung & Chue, 2000). 
 Contributors to functional disability. The past decade of research evidence has identified 
neurocognition as one of the strongest long-term predictors of recovery in schizophrenia (Green, 
Kern, & Heaton, 2004), with cognitive deficits accounting for much of the functional disability 
that is exacted by the disorder (Keefe, 2010).  These deficits are already present at symptom 
onset across a host of information processing domains, including diverse aspects of attention and 
memory and in the executive functions that are critical for initiating and carrying out higher order 
reasoning and problem solving processes (Addington, Saeedi, & Addington, 2005).  According to 
the current state of the field evidence, up to 75% of people with schizophrenia experience profound 
cognitive deficits (Green, 1996; Tandon et al., 2009), and those with such impairments often have 
difficulties with being able to identify salient environmental cues, which are necessary to avoid 
problematic situations that lead to adverse outcomes (Gearon & Bellack, 1999).  As such, 
perhaps it is not surprising then that these deficits have been linked with the high rates of 
criminal justice system involvement, substance use, homelessness, and joblessness, observed in 
schizophrenia (Cook, & Razzano, 2000; Folsom & Jeste, 2002; Dickerson et al., 2007; Bell, 
Greig, Zito, & Wexler, 2007; Brekke, Hoe, Long, & Green, 2007; Løberg & Hugdahl, 2009; 
Ascher-Svanum, Nyhuis, Faries, Ball, & Kinon, 2010). 
 Relevant estimates indicate that up to 80% of people with schizophrenia are unable to 
work (Bond & Drake, 2008), that about 50% of those with the disorder experience comorbid 
SUDs during their lifetime (Reiger et al., 1990), and that up to 45% of people who are homeless 
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also have schizophrenia (Folsom & Jeste, 2002).  Indeed, all of these factors significantly add to 
the disability that people with schizophrenia experience, and within the past several decades, 
SUDs have come to be seen as the most common and clinically significant comorbidity affecting 
the management and outcome of those with the disorder worldwide (Ziedonis et al., 2005; 
Buckley, Miller, Leher, & Castle, 2009; O’Hare, 2008).  Additionally, homelessness has been 
linked to both criminal activity and to being a victim among those with the disorder (Lam & 
Rosenheck, 1998), and a study of the correlates of victimization among 962 people with 
schizophrenia by Chapple and colleagues (2004) found that over the course of 1 year, about 18% 
(over 1 in 6) reported being the victim of violence (Chapple et al., 2004).  These rates are well 
above the annual rates of violent victimization in the U.S. general population (Hiday, Swanson, 
Swartz, Borum, & Wagner, 1999; Brekke, Prindle, Bae, & Long, 2001), and studies have 
consistently shown that substance use (Hiday et al., 1999; Brekke, Prindle, Bae, & Long , 2001), 
more severe cognitive deficits (Lehman & Linn, 1984; Brekke et al., 2001; Hiday, Swartz, 
Swanson, Borum, & Wagner, 2002), as well as homelessness or criminal behaviors (Lehman & 
Linn, 1984; Honkonen, Henriksson, Kovisto, Stengard, & Salokangas, 2004), are all associated 
with the higher rates of violent victimization observed in schizophrenia.  Further, high 
unemployment rates in schizophrenia make this population vulnerable to low income levels, 
which may lead to poverty and then into illegal behaviors and associations with potentially 
violent situations (Hiday et al., 2002). 
 In summary, schizophrenia is a devastating psychiatric disorder affecting approximately 
1% of the population worldwide during a lifetime.  The onset of the disorder usually occurs early 
in life, and most people who develop schizophrenia experience lasting functional disability even 
when positive symptoms are in remission or controlled with medication.  The co-occurrence of 
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SUDs with schizophrenia has been widely acknowledged as the most common and clinically 
significant comorbidity affecting the management and outcome of those with the disorder 
throughout the world.  Although schizophrenia has been studied as a major disease entity for at 
least the past century, only within the past several decades has attention been paid to those with 
co-occurring schizophrenia and SUDs as a subgroup with unique treatment needs.  Nevertheless, 
this comorbidity portends a particularly severe course of the disorder, and thus investigators have 
recently begun to turn to the pervasive problem of co-occurring SUDs in schizophrenia as a 
salient factor that may explain the profound degree of observed disability in this population. 
 Co-occurring substance use disorders. Co-occurring or dual disorders are broad terms 
used interchangeably in the literature to refer to the simultaneous presentation of one or more 
psychiatric disorder with one or more SUD (Ziedonis et al., 2005; O’Hare, 2008).  Although 
there is no consensus on how to diagnose a SUD in the presence of a psychiatric disorder or vice 
versa (Ziedonis et al., 2005; Buckley, 2006; O’Hare, 2008), definitions of comorbidity often 
(though not always) include people who acquire a SUD subsequent to a psychiatric disorder 
commonly characterized as severe and persistent, such as bipolar disorder, major depressive 
disorder, or schizophrenia (Mueser et al., 2003; Ziedonis et al., 2005).  Within the U.S., the 
reason for this distinction is premised on the rationale that a person’s psychiatric disorder 
determines his/her eligibility for treatment and services.  This eligibility is defined by most states 
on the basis of the primary psychiatric diagnosis, the degree of disability, and the duration of 
illness (New Freedom Commission on Mental Health, 2003).  From this service eligibility 
perspective, a diagnosis of schizophrenia often precedes the SUD diagnosis in persons who 
develop co-occurring disorders, even if the SUD pathology presented first (Drake et al., 2008). 
 Because even infrequent use of relatively minimal quantities of substances can cause 
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clinically relevant symptoms in individuals with schizophrenia, accurately detecting substance- 
related problems among those with the disorder is important (Ziedonis et al., 2005).  This can be 
accomplished by using a series of brief tools to screen for substance-related problems.  These 
tools often include clinician rated scales, self-reports, collateral sources, and biological indicators 
(analysis of blood, breath, urine, or hair), which are evaluated in terms of their sensitivity (i.e., 
ability to detect substance-related problems if present) and their specificity (i.e., the ability to 
accurately identify persons who do not have substance-related problems) (Ziedonis et al., 2005).  
 While many of these tools are suitable for evaluating substance-related problems in the 
general population, some may unreliably estimate such problems in schizophrenia (Safer, 1987; 
De Beaurpaire et al., 2007; Bahorik, Newhill, Queen, & Eack, 2014).  Challenges have included 
a high rate of under-detected substance use despite abundant evidence to suggest otherwise 
(Safer, 1987; De Beaurpaire et al., 2007; Bahorik et al., 2014).  Further, people with 
schizophrenia often lack collaterals that can attest to their substance use, perhaps due to social 
isolation, compliance issues, or estrangement from family members (Ziedonis et al., 2005). 
While biological indicators can reliably confirm the presence of use, accurate detection depends 
on many factors such as the frequency and type of substance used (Ziedonis et al., 2005).  Given 
the potential problems that may arise with any single screening modality tool, the most reliable 
and valid way to assess for substance-related problems in schizophrenia is to gather information 
from many sources, using multiple methods, and to bring those measures into a rule-based 
process for mounting consensus ratings (McHugo et al., 2006).  Finally, a positive screen signals 
a need to determine whether an actual diagnosis of SUD in schizophrenia is present. 
 As mentioned, there is currently no consensus on how to define a SUD in the context of 
schizophrenia (Ziedonis et al., 2005), although to date, most studies conducted within the U.S. 
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have employed DSM-III, DSM-III-R, and DSM-IV diagnoses (Westermeyer, 2006), yet few 
have used the most recent DSM-V criteria.  While there is relatively little variation across these 
different versions of the DSM in their criteria for a diagnosis of schizophrenia, differences in 
SUD diagnoses do occur, especially regarding abuse (i.e., a pattern of substance use that does not 
result in tolerance [when increased amounts of the substance are needed to achieve the desired 
effect] or withdrawal [when blood or tissue concentrations of a substance decline in an individual 
who had maintained prolonged heavy use], but it is manifested by recurrent and significant 
adverse consequences) (APA, 2000), versus dependence (i.e., a pattern of substance use that can 
result in tolerance and/or withdrawal) (APA, 2000), with such distinctions being omitted from 
the most recent DSM-V (APA, 2013). Nevertheless, across all versions of the DSM, SUDs are 
broadly defined within the context of substance-specific pathological behaviors. This signifies 
that that that the person has developed maladaptive patterns of clinically significant substance 
use resulting in physical, psychological, and/or social impairment.  
Such disorders comprise ten substance-specific classes (i.e., alcohol; caffeine; cannabis; 
hallucinogen; inhalant; opioid; sedative, hypnotic, and anxiolytics; stimulant [amphetamine, 
cocaine, and other stimulants], and tobacco), and when any are used (except for caffeine), they 
can produce such an intense activation of the brain reward system that the resulting effects may 
manifest as more frequent and longer periods of using such substances; cravings or stronger 
urges to use such substances; unsuccessful efforts to reduce the use of such substances; failure to 
fulfill role obligations due to the use of such substances; and/or failure to reduce or abstain from 
substance use (APA, 2013; McLellan, Lewis, O’Brian & Kleber, 2000).  
 According to the DSM-V, any two of these substance-specific patterns of pathological 
behaviors occurring within a 12-month period, in combination with significant functional 
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impairment, permits the consideration of a SUD diagnosis (APA, 2013).The DSM-V describes 
several levels of SUD remission, useful for determining lifetime (i.e., the person met diagnostic 
criteria for SUD at some point during their lifetime) and current (i.e., the person currently meets 
diagnostic criteria for a SUD) prevalence, and the severity of the disorder.  In early remission, 
persons meet no criteria for a SUD for at least three months, but for less than12-month except 
that such persons can experience cravings or urges to use substances.  In sustained remission, no 
criteria for an SUD are met at any time for 12-months, but such persons may have cravings or 
urges to use substances. In a controlled environment, refers to persons who are in a setting where 
the use of substances is restricted.  Lastly, the DSM-V has specifiers to denote the severity of the 
SUD diagnosis (i.e., mild = 2-3 symptoms; moderate = 4-5 symptoms; severe > 6 symptoms).  In 
the context of a schizophrenia diagnosis, distinguishing between current and lifetime diagnoses is 
not necessarily clinically meaningful, as even the minimal use of substances infrequently (i.e. 
low substance use severity) can result in symptom exacerbation and adverse consequences (i.e., 
hospitalization) (Drake et al., 2006).  
 Substance use prevalence.  Research indicates that large numbers of people with 
schizophrenia use drugs or alcohol, and as a result, many of these individuals develop co- 
occurring SUDs during their lifetime (Gregg, 2012).  Estimates of prevalence vary between 
settings and across geographical location (McLellan & Druley, 1977; Chouljian et al., 1995; 
Cuffel, 1996; Bell, Greig, Gill, Whelahan, & Bryson, 2002), but the majority of studies have 
found that SUDs are more prevalent among people with schizophrenia than in the general 
population (Reiger et al., 1990; Westermeyer, 2006; Volkow, 2009).  The largest U.S. population 
prevalence study, the Epidemiologic Catchment Area study (Reiger et al., 1990), involved 
comprehensive assessments of both psychiatric and SUDs via structured interviews with 20, 291 
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randomly selected people from the general population and institutional settings (psychiatric 
hospitals, nursing homes, jails and/or prisons).  The data revealed that that 27% of those with 
schizophrenia experienced a drug use disorder in comparison to 6% of the general population, 
and 34% experienced an alcohol use disorder in comparison to 13% of the general population.  
Overall, 47% of people with schizophrenia were found to have experienced a SUD during their 
lifetime (Reiger et al., 1990).  Similar lifetime comorbidity rates (45%) were reported in the 
National Comorbidity Survey for people with non-affective psychosis (Kessler et al., 1997). 
 Clinical studies have shown significant variations (~20% to 70%) in the prevalence  of 
SUDs in schizophrenia from one sample to the next (McLellan & Druley, 1977; Chouljian et al., 
1995; Cuffel, 1996; Bell et al., 2002), which generally result from sample differences between 
treatment settings and across geographic locations (Mueser et al., 2003).  For example, alcohol is 
the most commonly used substance followed by cannabis, and cocaine among people with 
schizophrenia and co-occurring SUDs in the U.S. and the United Kingdom, but studies that have 
been conducted in the U.K. generally report lower rates of use than those that have been 
conducted in the United States (Volkow, 2009; Gregg, 2012).  Further, a review of relevant 
treatments and services estimated that 38% to 50% of people with schizophrenia and co- 
occurring SUDs received primary inpatient services, 20% to 37% received primary mental health 
services, and 6% to 15% received primary addiction services (Carra & Johnson, 2008).  Given 
these differences, it is not surprising that variations in the prevalence of SUDs in schizophrenia 
have been observed across the treatment settings where such persons receive services.  However, 
regardless of the type of treatment setting or amount of services received, many studies have 
reported variations in the prevalence of co-occurring SUDs and schizophrenia across Australian, 
European, Canadian, and South American samples (Soyka et al., 1993; Jablensky et al., 2000; 
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Korkeila et al., 2005; Margolese, Malchy, Negrete, Tempier, & Gill, 2004; Rossi Menezes, & 
Ratto, 2004).  Such evidence suggests that this comorbidity may depend on environmental and 
cultural changes including alcohol and drug availability in social environments (Gregg, 2012), 
which supports the commonly held view that people with schizophrenia and co-occurring SUDs 
use substances that are readily available and accessible in the community in which they live 
(Mueser et al., 2003; Gregg, 2012). 
The types of substances used by people with schizophrenia and co-occurring SUDs vary 
widely.  As mentioned, alcohol tends to be the most commonly used substance, followed by 
cannabis, and cocaine within the United States (Volkow, 2009).  Corresponding estimates of 
lifetime prevalence have revealed that between 43% and 65% of people with schizophrenia have 
co-occurring alcohol use disorders, 51% have cannabis use disorders, and 23% have cocaine use 
disorders (Volkow, 2009).  Further, multiple drug and alcohol use is common, and many people 
with co-occurring schizophrenia and SUDs are diagnosed with more than one substance-related 
disorder (Gregg, 2012).  One recent investigation of 122 outpatients with schizophrenia found 
that 70% of the study sample met DSM diagnostic criteria for both alcohol and drug use disorder 
diagnoses (Sheller-Gilkey et al., 2003).  Other substances used by people with schizophrenia and 
co-occurring SUDs include hallucinogens, hypnotics, opiates, and prescription medications, 
though the patterns of use tend to vary widely across studies (Roncero et al., 2011). 
 Risk of substance use.  Approximately 8.5% of the U.S. population aged 12 or older met 
criteria for a SUD in 2012 (Hughes, Muhuri, Sathe, & Spagnola, 2012), with biological features 
such as heredity and the reinforcing properties of substances of abuse in relation to neurological 
mechanisms being important determinants of addiction (Donovan et al., 2012).  Clinical and 
social aspects of addiction, such as the expectancies of drug effect, social networks, dysphoria, 
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poverty, and unemployment are also critical (Drake et al., 2002).  Regarding schizophrenia, the 
substance-related problems that contribute to a SUD diagnosis necessarily are biopsychosocial 
phenomena, with multiple contributing risk factors (Drake, Wallach, Alverson, & Mueser, 2002). 
 People with schizophrenia are more likely to be diagnosed with a SUD than the general 
population, and as a result, many studies have sought to gain a better understanding of the 
correlates that contribute to the increased risk of substance-related problems in this population. 
To date, a number of demographic correlates of SUDs have been documented for people with 
schizophrenia. While there is some variation in terms of the type of SUD (i.e., cannabis or 
alcohol use disorder), there is also some consistency in terms of the correlates that have been 
identified among those with the disorder (Mueser et al., 2003; Koskien et al., 2009a; Koskien et 
al., 2009b).  Like people in the general population with SUDs, people with schizophrenia who 
develop co-occurring SUDs are more likely to be male (Koskien et al., 2009b; Roncero et al., 
2011; Mueser et al., 2003; Gregg et al., 2007). They tend to be younger (with the exception of 
those with alcohol use disorders) Koskien et al., 2009a; Koskien et al., 2009b), less educated 
(Dixon, Haas, Weiden, Sweeny, & Frances, 1991), and are more likely to have a family history 
of substance use problems (Mueser, Bennet, & Kushner, 1995; Menezes et al., 1996; Cantwell, 
2003; Barnes, Mutsatsa, Hutton, Watt, & Joyce, 2006; Kavanagh et al., 2004b).  People with 
schizophrenia who develop co-occurring SUDs also experience many of the known social and 
psychological risk factors for substance-related problems in the general population, such as 
poverty, living in high-risk neighborhoods, having deviant peer groups, and unemployment 
(Drake et al., 2002). 
 Although relatively few studies have examined the relationship between SUD pathology 
and psychiatric history, there is some evidence to suggest that substance-related problems are 
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associated with an earlier onset of schizophrenia (Kovasznay, Fleischer, & Tanenberg-Karant, 
1997), and with an earlier age at first hospitalization (Salyers & Mueser, 2001).  Further, this 
comorbidity has also been associated with better premorbid social functioning (defined as the 
quantity and quality of society relationships attained prior to symptom onset) as well as superior 
cognitive functioning (defined as the cognitive functioning level a person with schizophrenia 
achieved before symptom onset) (Salyers & Mueser, 2001; Løberg, & Hugdahl, 2009).  People 
who are more socially active and have greater cognitive capacities have resources to procure 
substances through their environments and social networks, and thus are at an increased risk to 
develop a SUD (Salyers & Mueser, 2001; Løberg, & Hugdahl, 2009).  However, it is important 
to mention that these correlates are not always reliable, and certainly some people with poor 
premorbid cognitive function and poor premorbid social function go on to develop schizophrenia 
and co-occurring SUDs (Mueser et al., 2003).  
 The only reliable clinical correlate of SUD comorbidity in schizophrenia is antisocial 
personality disorder (ASPD), and its childhood precursor, conduct disorder (Kavanagh et al., 
2004; Mueser et al., 2003).  A host of studies have shown that individuals with schizophrenia 
and ASPD are more likely to have a co-occurring SUD than individuals without ASPD (Caton, 
Shrout, Eagle, Opler, & Felix, 1994; Mueser et al., 2000).  Among people who develop these 
conditions, ASPD has been associated with a more severe course of SUD, including an earlier 
age of onset and larger quantities of use (Mueser et al., 2003).  Further, a recent study uncovered 
a late-onset subtype of ASPD in persons with schizophrenia.  These persons tended to have the 
most severe SUD pathology, the most homelessness and criminal justice system involvement 
(Mueser et al., 2006).  Due to the their vulnerability to numerous adverse consequences, people 
with co-occurring schizophrenia, ASPD, and SUDs represent a high-need subgroup that require 
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intensive monitoring and treatment in order to optimize outcomes. 
 Models of comorbidity.  There are a host of risk factors that place individuals with 
schizophrenia at much greater risk for SUD than the general population. However, despite more 
than twenty years of research there is still no consensus on the aetiology of the increased rates of 
SUD among people with schizophrenia.  In the absence of confirmatory scientific evidence to 
explain such phenomena, Kushner and Mueser (1993) have put forward four types of models: (1) 
secondary psychosis models (i.e., substance use causes psychosis), (2) secondary substance use 
models (i.e., substance use is a consequence of psychosis), (3) common origin models (i.e., 
substance us and psychosis share a common origin), and (4) bidirectional models (i.e., substance 
use and psychosis are bidirectional; interacting and maintaining each other). While Gregg, 
Barrowclough, & Haddock (2007) revealed that the support for these models is modest, they do 
provide some useful clues into the etiopathogenic relationship between these conditions. 
 Secondary psychosis models are premised on the idea that substance use causes the onset 
of schizophrenia.  While many of the substances people with schizophrenia use are known to use 
have acute psychotic effects (alcohol, cannabis, hallucinogens, and stimulants [D’Souza et al., 
2004; Gregg et al., 2007]), and studies have shown that some of these substances (alcohol and 
amphetamines [Roncero et al., 2011, Gregg, 2012]) worsen symptoms, there is little evidence to 
suggest that such substances actually cause the onset of the disorder (Gregg et al., 2007; Gregg, 
2012).  However, a number of large-scale prospective longitudinal cohort studies have shown 
that cannabis users are more likely to develop schizophrenia than non-cannabis users 
(Andreasson, Allebeck, Engstrom, & Rydlberg, 1987; van Os et al., 2002; Arseneault et al., 
2002; Weiser, Knobler, Noy, & Kaplan, 2002; Zammit, Allebeck, Andreasson, Lundberg, & 
Lewis, 2002; Ferdinand et al., 2005; Henquet et al., 2005; Fergusson, Horwood, & Ridder, 2005; 
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Foti, Kotov, Guey, & Bromet, 2010).  Nevertheless, many people who use cannabis do not go on 
to develop schizophrenia (Gregg, 2012), which signals a need for future research to investigate 
the reasons for why some people may be more vulnerable to its (cannabis) effects than others. 
 Secondary substance use models posit that schizophrenia leads to substance use. The 
most widely-documented of these is the self-medication hypothesis (Khantzian, 1985, 1997), 
which suggests that substance use is an attempt to self-medicate symptoms such as depression, 
anxiety, and hallucinations (Gregg et al., 2007).  There is some data to suggest that people with 
schizophrenia use substances to help them cope with problems or decrease the symptoms of the 
disorder (i.e., [Addington & Duchak, 1997; Gearon, Bellack, Rachbeisel, & Dixon, 2001; 
Goswami, Mattoo, Basu, & Singh, 2004; Spencer, Castle, & Michie, 2002; Gregg, Haddock & 
Barrowclough, 2009]), with the majority of this evidence being obtained from self-report studies 
(Gregg et al., 2007).  Such studies have indicated that people with schizophrenia reportedly 
prefer drugs such as cocaine, cannabis, amphetamine, and hallucinogens (Liberman et al., 1987; 
Van Kammen & Baronow, 1988; Dixon et al., 1991; Green et al., 1999, 2005), and that these 
substances may be used to alleviate insomnia, psychomotor disturbances, anxiety, social deficits, 
feelings of loss of vitality, dysphoria, or hopelessness—all of which have been associated with 
SUD among individuals with the disorder (Sommers, 1985; Dixon et al., 1991; Addington & 
Duchak, 1997; Fowler, Carr, Carter, & Lewin, 1998; Scheller-Gilkey et al., 2003).  However, it 
is important to note that investigations of the self-medication hypothesis have been largely 
mixed, and thus this hypothesis remains unsupported by the available empirical evidence (see 
Gregg et al., 2007, for review).  
 Common origin models of substance use and schizophrenia have been proposed 
emphasizing biological, individual, and societal factors.  Although most of these factors have 
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already been addressed in the previous section on risk factors a few points are highlighted here. 
While there is evidence to suggest that genetic factors uniquely contribute to schizophrenia and 
to SUD (Gottesman & Shields, 1976; Tsuang, Bar, Harley & Lyons, 2001), the extent to which 
the two disorders share a common genetic vulnerability is not currently known (Gregg et al., 
2007).  However, some authors have suggested the possible role of reward circuitry dysfunction 
and dopamine opioid neurotransmission systems (Chambers, Krystal, & Self, 2001; Volkow, 
2009).  It has been suggested that this relationship implies a common underlying vulnerability 
for both disorders in which the pathology of the cannabinoid system in schizophrenia is 
associated with both increased rates of cannabis use and increased rates of schizophrenia 
(Volkow, 2009).  Nevertheless, further research is needed to determine the relevant underlying 
neuropathological processes before confirmatory conclusions can be made. 
 Bidirectional models are premised on the idea that schizophrenia and SUD trigger and 
maintain each other.  For example, substance use may serve as a stressor precipitating the onset 
of schizophrenia in vulnerable persons and then such problems are subsequently maintained by 
continued use (Mueser, Drake, & Wallach, 1998).  Consequently, bidirectional models tend to 
involve multiple risk factors (Mueser et al., 2003), as delineated in the previous section. For 
example, trauma precedes the onset of substance use in some people with schizophrenia, but also 
put some people at increased risk of subsequent substance- related problems, re-traumatization, 
and relapse of positive symptomatology (Gregg, 2012).  Although there is significant literature to 
support that certain situations and experiences trigger SUD pathology and maintain substance use 
problems in people with schizophrenia (Gregg et al., 2009), there has not yet been a direct 
empirical test of this model (Gregg, 2012). 
 While the four types of models help clarify our understanding of the increased rates of 
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SUDs among persons with schizophrenia, it is clear that no single model can adequately explain 
this problem in its entirety.  As a result of the risk conferred by substance use, people with co- 
occurring SUDs and schizophrenia are vulnerable to a host of adverse consequences. 
 Consequences of substance use. For people with schizophrenia, the consequences of SUD 
pathology diverge from what is seen in the general population in several important ways.  Rather 
than facing job loss, marital problems, and driving violations, people with schizophrenia have 
difficulties managing entitlement funds, participating in treatment and rehabilitation, maintaining 
stable housing, and avoiding victimization (Drake et al., 2002).  As a product of these substance-
related challenges, people with schizophrenia are at greater risk than the general population for 
suffering illness and injury caused by risky behaviors like unprotected sex and needle sharing 
(Gearon & Bellack, 1999), and serious infectious diseases like HIV and hepatitis C (Cournos, 
McKinnon, & Sullivan,  2005).  People with co-occurring SUDs and schizophrenia also present a 
host of challenges to the clinical management and long-term outcome of their conditions that 
diverge from what is seen in the larger dual diagnosis population.  For instance, after inpatient 
treatment, individuals with co-occurring SUDs and schizophrenia are less likely to present for 
outpatient follow-up (Olfson, Marcus, & Doshi, 2010), and compared to dual diagnosis clients 
without schizophrenia, this population is less motivated to change their substance use, are more 
difficult to engage in treatment, display slower progress, and drop out of long-term programs 
more easily (Horsfall et al., 2009).  As a product of these challenges, people with co-occurring 
SUDs and schizophrenia are also at greater risk than the larger dual diagnosis population for 
incurring a host of adverse outcomes that are uniquely associated with these conditions.  
 Further, there is also evidence to suggest that people with schizophrenia and co-occurring 
SUDs have poorer long-term outcomes than their counter-parts with schizophrenia without SUDs 
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(Menezes et al., 1996; Margolese, Malchy, Negrete, Tempier, & Gill, 2004).  For example, in an 
18-month longitudinal study of 100 outpatients with schizophrenia, those who had co-occurring 
SUDs showed a deteriorating functional status over time whereas those with schizophrenia only 
tended to remain functionally stable (Chouljian et al., 1995).  Such outcomes largely result from 
treatment non-compliance among persons with schizophrenia and co-occurring SUDs (Owen et 
al., 1996; Cuffel, 1996; Hipwell et al., 2000; Coldham et al., 2002), such that both medication 
and general appointment attendance are poorer, leading to more positive symptoms (Pencer & 
Addington, 2003), more relapses, higher rates of emergency services use (Barnes, 2008; Curran 
et al., 2003), and greater rates of inpatient hospitalization (Linszen et al., 1994; Swofford et al., 
1996; Schmidt, Hesse, & Lykke,  2011).  Studies have also shown that, compared to individuals 
with schizophrenia only, those with co-occurring SUDs and schizophrenia have an elevated risk 
of suicide (Suokas et al., 2010), and are otherwise at risk of experiencing higher rates of mortality 
(mean age at time of death SZ/ SUD = 50; mean age at the time of death SZ = 62) (Schmidt et al., 
2011).  
 Since even the infrequent use of substances in small amounts can have a significant 
adverse impact on these clinical outcomes (Drake, Osher, & Wallach, 1989; Mueser, Drake, & 
Wallach, 1998; Gonzales, Bradizza, Vincent, Stasiewicz, & Paas, 2007), people with co-
occurring SUDs and schizophrenia are less likely than other substances users to develop the 
physiological stigmata of addiction (Drake et al., 1990), and thus the consequences of SUD 
pathology are largely psychosocial (i.e., the psychological and social impact of SUD pathology is 
generally more severe than the biological impact of SUD pathology) in this population (Drake et 
al., 2002).  Substance use appears to produce greater psychological morbidity by undermining 
specific psychological functions in schizophrenia, thereby reducing an affected person’s ability 
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to cope with chronic or recurrent manifestations of the disorder (Westermeyer, 2006).  Further, 
several studies have documented reduced attention and memory function among persons with co-
occurring schizophrenia and SUDs (Sevy, Kay, & Opler; 1990; Oepen, Levy, & Saemann, 1993; 
Tracy, Josiassen, & Bellack, 1995), demonstrating an interruption of specific cognitive and 
psychological processes.  Chronic cocaine use largely produced these deficits in combination 
with impaired nonverbal problem solving and abstracting ability in one study (O’Malley, 
Adamse, & Heaton, 1992).  Research has also suggested that cocaine users with co-occurring 
schizophrenia and SUDs may be at risk to more severe forms of tardive dyskinesia (Brady, 
Anton, & Ballenger, 1990), and there is also evidence to suggest that chronic cannabis use may 
increase the risk of tardive dyskinesia in this population (Zaretsky, Rector, & Seeman, 1993). 
 Aside from the clinical manifestations of substance use, this population suffers from a 
host of adverse social consequences. For example, people with schizophrenia and co-occurring 
SUDs are more prone to violent victimization than their counterparts without SUDs (Scheller-
Gilkey et al., 2003; Gearon et al., 2003; Compton, Furman, & Kaslow 2004; Swartz et al., 2006). 
Such individuals are more likely to be exposed to people who may take advantage of them both 
financially and sexually (Goodman et al., 2001).  This is particularly true for women with these 
conditions, who are more prone to have experienced childhood sexual and physical abuse 
(Gearon & Bellack, 1999; Alexander, 1996), and who are more vulnerable to subsequent violent 
victimization in adulthood (Gearon et al., 2003).  Relevant research has also reported findings to 
suggest that childhood abuse in African Americans with schizophrenia may increase the risk of 
co-occurring SUDs for this subgroup (Compton et al., 2004).  
Compared to their counter-parts with schizophrenia and without SUDs, people with co-
occurring SUDs and schizophrenia are vulnerable to a range of other substance-related adverse 
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outcomes including increased rates of suicidal ideation (Bartels, Drake, & McHugo, 1992), more 
severe aggression and violence (Cuffel, Shumway, Chouljian, & MacDonald, 1994; Fulwiler, 
Grossman, Forbes, & Ruthazer, 1997), as well as increased criminal activity and incarceration 
(Abram & Teplin, 1991; Abram, Teplin, & McClelland,2003).  These consequences lead to 
greater degrees of interpersonal conflict and stress, which contribute to increased rates of family 
conflict and contentious interactions with service providers (Kashner et al., 1991; Salyers & 
Mueser, 2001; Barrowclough, Ward, Wearden, & Gregg, 2005).  Such behaviors coupled with 
the pervasive patterns of substance use observed among this population result in a host of 
negative consequences such that people with co-occurring SUDs and schizophrenia are more 
prone to social exclusion (Todd et al., 2004), housing instability, and homelessness (Drake et 
al.,1991; Caton et al., 1994).  Despite these severe consequences, studies have shown people 
with schizophrenia and co-occurring SUDs have little incentive to change their substance-related 
behaviors, with one study showing that up to 77% of their sample manifested low motivations to 
cease their use of substances (Ziedonis & Trudaeu, 1997). 
 Longitudinal severity of substance use. There is overwhelming evidence to suggest that 
alcohol and other drug use can lead to a host of negative consequences for people who suffer 
from co-occurring schizophrenia and SUDs.  The strong associations between the presence of a 
comorbid substance use disorder and adverse outcomes in schizophrenia has led to increased 
pessimism with regard to the course and severity (i.e., the patterns, frequency, duration, 
impairment, and consequences of substance use) of substance use problems in this population 
(Drake et al., 2006).  This pessimistic outlook has been in part confirmed by Bartles, Drake, and 
Wallach (1995) in a 7-year study of 148 persons with schizophrenia and co-occurring SUDs.  At 
the 7-year follow-up, results revealed that the lifetime prevalence of alcohol use disorders 
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increased by 1% per year (7% overall).  This study, which began in the 1980s, did not show any 
propensity for remission of alcohol use severity for these participants with schizophrenia (Bartles 
et al., 1995).  Another study by Wade and colleagues (2006) found that when following 103 
persons for 15-months after their first episode of schizophrenia, high severities of substance use 
was associated with an increased risk of inpatient admission, relapse and shorter time to relapse.  
 While these data suggest that persons with such conditions can sustain their use for years 
in the face of significant disability (Drake et al., 1996), there is also data to suggest that this 
population may adopt abstinence (Drake & Wallach, 1993; Dixon et al., 1998; Drake et al., 
2006).  For example, one 4-year study of 18 persons with co-occurring schizophrenia and SUDs 
by Drake, McHugo, and Noordsy (1993) found that 11 had at least one six-month remission at 4-
year follow-up, and of the three who failed to achieve any remission, all were cannabis users.  Of 
the 11 who had achieved one 6-month remission, the average duration of the remission was 26.5 
months (SD = 13.5).  Overall, this study suggested a high rate of sustained remission, lasting up 
to a few years on average once the remission was sustained for six-months or longer (Drake et 
al., 1993).  
 In general, alcohol use disorders have been associated with higher remission rates, and 
thus less substance use severity, than other SUDs (i.e., cocaine use disorders or cannabis use 
disorders) that co-occur with schizophrenia (Westermeyer, 2006).  For example, one study 
reported sustained remission rates of up to 90% in a sample of persons with schizophrenia and 
co-occurring alcohol use disorders (Bell et al., 2002).  This study by Bell and colleagues (2002) 
confirmed the earlier findings by Drake and colleagues (1993), whereby those with co-occurring 
alcohol use disorders and schizophrenia achieved higher remission rates than those with cannabis 
use disorders.  Evidence also suggests high cocaine use severity and poor remission from cocaine 
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use disorders.  For example, the study by Bell and colleagues (2002) found that the rate of one-
month remission was 58% (n = 37) for persons with schizophrenia and cocaine use disorders 
compared to 90% (n = 35) for persons with schizophrenia and alcohol use disorders.  Further, the 
results of a longitudinal study of 100 persons with schizophrenia and co- occurring SUDs 
showed cocaine users significantly increased the quantity and frequency of their use, whereas 
other substance users maintained stable patterns (Chouljian et al., 1995).   
 Recovery from substance use. As an attempt to conceptualize severity, course, and 
outcome, the concept of recovery has emerged as a central theme in the mental health and 
behavioral addiction treatment literature (Drake et al., 2006).  Although the concept has been 
defined in numerous ways in the fields of both mental health and addictions, most definitions 
include some notion that people need to feel hopeful of a future that contains the essentials for 
working, learning, and participating fully in the community (Vaillant, 1995; New Freedom 
Commission Report on Mental Health, 2003; Jacobson, 2004), with achieving sustained 
remission being particularly important in the field of addictions (Drake et al., 2006).  In the 
general population, people with SUDs achieve recovery, and they consistently cite psychosocial 
factors such as hope, new beliefs, relationships, and activities, as key to their recoveries 
(Vaillant, 1995). 
 Recovery from substance-related problems among persons with schizophrenia and SUDs 
involves similar changes. In an ethnographic study of the longitudinal course of persons with co- 
occurring schizophrenia and SUDs, Alverson, Alverson, and Drake (2000) identified four factors 
that were strongly correlated with such persons’ efforts to achieve sustained abstinence.  These 
factors included (1) habitual engagement in an enjoyable activity; (2) decent, stable housing; (3) 
a caring relationship with someone who accepts mental illness and does not abuses substances; 
50 
 
and (4) a positive, valued relationship with a mental health professional.  Quantitative survey 
research generally supports the ethnographic work of Alverson and colleagues (2000) (i.e., 
Bebout et al., 1997; Sengupta, Drake, & McHugo, 1998; Trumbetta et al., 1999), and a recent 10- 
year recovery outcome study of 130 people with co-occurring schizophrenia and SUDs showed 
that many were able to achieve control over (63%) both disorders, to live independently (57%), 
to achieve competitive employment (40%), and to attain what they perceived as a (58%) better 
quality of life (Drake et al., 2006).  Most notably, the results of this study documented severe and 
prolonged disability during years 1 to 3, and then steady improvement from years 3 to 10.  At the 
3-year follow-up, the majority were still at sub-threshold recovery levels, which suggests that 
recovery from substance-related problems in this population improves and progresses over many 
years, not just during the early phase of integrated dual diagnosis treatment (Drake et al., 2006). 
 In summary, substance-related problems and co-occurring SUDs are common and 
problematic for persons with schizophrenia.  These conditions are more prevalent in persons with 
schizophrenia than in the general population of adults, although these estimates may vary by 
treatment setting and geographic location.  Taken together, the various manifestations of 
substance-related problems in schizophrenia suggest that biological vulnerability reacts with 
psychosocial vulnerability, to produce extraordinarily negative outcomes for this population. 
Already disadvantaged by the stigma of having a serious mental illness these individuals are 
drawn to use substances that are accessible and available to them in the communities in which 
they live.  As substance-related problems increase in severity, such persons often cannot manage 
the few resources society affords them, and as a result they may become victims of abuse, 
socially isolated, unemployed, or homeless.  While these consequences may represent the failures 
of the social welfare, addiction, and mental health service delivery systems in the U.S., emerging 
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evidence suggests that many people with co-occurring schizophrenia and SUDs meet broad 
definitions for recovery, and achieve what they perceive as a good quality of life. 
2. Socio-Political Trends in Co-Occurring Substance Use Disorders and Schizophrenia 
 The co-occurrence of SUDs with schizophrenia is associated with a number of negative 
consequences that make this comorbidity a major public health issue in both the U.S. and abroad. 
As such, any investigation that attempts to improve our understanding of those who suffer from 
these conditions must be grounded not only in the scientific evidence-base, but also in the socio- 
political context that drives society’s response to this comorbidity and its treatment.  Within the 
U.S., the co-occurrence of SUDs with schizophrenia is not only an issue of psychiatric diagnosis 
but a sociological phenomenon reflecting our broader society’s extrusion of people with 
schizophrenia from protected living arrangements that limit access to substances of abuse.  Such 
an assertion is generally supported by published reports indicating that comorbid SUDs occurred 
infrequently in schizophrenia prior to 1960.  Before then, such persons were treated in state 
hospitals, where their use of substances was largely restricted–suggesting that the problem of 
comorbid SUDs in schizophrenia proliferated as the result of the deinstitutionalization policies 
for those with severe mental illness in the United States.  By the 1980s the co-occurrence of 
SUDs with schizophrenia had become widely acknowledged as a major public health issue, but 
available treatments were delivered in different settings.  This disconnect in services, coupled 
with the need for both addiction and mental health treatment for persons who would have notable 
difficulty negotiating two separate systems of care, led to the subsequent development of 
integrated treatment strategies.  To date, these efforts have not been widely implemented across 
the U.S., and no social policies specifically address the unique needs of this population. Such 
factors have led to an unfortunate lack of responsibility and cooperation within addiction and 
52 
 
mental health systems of care regarding the treatment of persons with co-occurring SUDs and 
schizophrenia.  These unfortunate outcomes largely stem from the fact that addiction and mental 
health services emerged via separate historical movements, with the treatment of addictive 
disorders being both shunned and alternatively embraced by mental health providers. This 
section briefly reviews the progression of socio-political trends that drive society’s response to 
the treatment of persons with co-occurring SUDs and schizophrenia, via the lens of the historical 
separation of mental health and addiction services in the United States.  As such, the purpose of 
this review is to provide an overview of the relevant social policies and current federal initiatives 
attempting to address the treatment and services available to those who suffer from this 
comorbidity, in order to delineate the significance of a study of substance use severity in co- 
occurring SUDs and schizophrenia to current social policy. 
 Over the centuries, the treatment of addictive disorders has been alternatively embraced 
and shunned by the U.S. health care system in general, and by the providers of mental services in 
particular (Osher & Drake, 1996).  Addictive disorders were first treated in medical settings in 
the nineteenth century, after Benjamin Rush advocated for a disease-based theory of addiction 
and Samuel Woodward successfully argued for their treatment in the asylum (Baumohl & Jaffe, 
1995).  Such asylums were the byproduct of the moral treatment movement of mental illness, 
where the absence of effective treatments led to a palliative social welfare response to disorders 
like schizophrenia via institutional reform (Morrissey & Goldman, 1986).  Dorothea Dix, a social 
worker who was attracted to the cause of the “insane poor” in the 1840s, was the key lobbyist for 
the construction of moral public asylums in the United States (Dix, 1975).  While this movement 
was premised on the idea that mental illnesses could be cured by treating afflicted persons with 
dignity and respect, such principles became expendable by the mid-1850s under the pressures of 
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increasing rates of mental illness due to immigration to the U.S., poverty, and industrialization 
(Trattner, 1999).  Absent federal support, state legislatures had to respond to these pressures, and 
initially did so by expanding asylum capacity or by erecting larger facilities (Morrissey & 
Goldman, 1986).  Such asylums became filled with chronic patients that overcrowded these 
facilities and under-minded any attempts at therapeutic practice.  Under these circumstances, 
psychiatrists could not produce medical “cures” for patients with addictions or schizophrenia, 
and such disorders soon became associated with incurability (Deutsch, 1949).  These challenges 
coupled with the mounting costs that became associated with such institutions eroded public 
support and asylums began to vanish across the United States (Trattner, 1999).  Such events 
occurred at the turn of twentieth century, just as a budding mental hygiene movement posited 
that inexpensive, community-based care could treat acute schizophrenia, as well as engage 
patients in early stages of addiction and arrest the development of addictive conditions. 
 The pessimism associated with the asylums gave way to a new found optimism for the 
mental hygiene movement, a national wave of reform leading to community-based care for 
persons with schizophrenia and addictive disorders.  At the turn of the twentieth century, society 
was outraged by exposés of the conditions in asylums, which included a personal account by 
Clifford Beers (Dain, 1980).  Beers, who had recovered from schizophrenia himself, documented 
his experiences within the deteriorating conditions of the asylum in 1908, and then went on to 
found the National Committee for Mental Hygiene in 1909 (Morrissey & Goldman,  1986).  
Since the National Committee for Mental Hygiene was premised on principles of early 
prevention and detection of mental illness, the mental hygienists could do little for the treatment 
of chronic schizophrenia or alcoholism (the dominant substance-related disorder) (Morrissey 
&Goldman, 1986).  However, this reform spawned the development of new mental health 
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agencies such as psychiatric dispensaries and child guidance clinics, and had a large impact on 
educating the public on the potential causes and early diagnosis of mental illnesses (Trattner, 
1999).  All of these factors suggest that the mental hygiene movement not only exposed the 
ineffective asylum treatments, but also provided support for community-based services. 
Additionally, while largely focused on mental health, this movement also carried with it the trend 
of medically treating addictive disorders, and extended such practice to include prevention 
(Osher & Drake, 1996). 
 During the 1930s, Alcoholics Anonymous (AA) provided a mechanism for transferring 
the treatment of alcohol-related problems from institutions to the community (Osher & Drake, 
1996). Narcotics Anonymous (NA) similarly facilitated non-institutional treatment for persons 
with drug addictions. However, these “non-medical” approaches diverted addictions treatment 
away from psychiatry and established parallel systems of care.  Further, the health care system 
largely shunned the treatment of addictive disorders for at least the next twenty years, and it was 
not until new theories posited biologic underpinnings to addictions that the traditional system 
reluctantly reconsidered its role in providing treatment.  Most notably, in 1960 E.M. Jellinek 
posited a model that was substantiated by science and justified the re-medicalization of addictive 
disorders. It should be noted that Mary Richmond, a social worker most commonly credited for 
her work with the Charity Organization Society, actually posited a model of alcoholism nearly a 
half-century earlier in Social Diagnosis (1917, 1944).  Richmond specifically documented that 
“inebriety is a disease”, and went on to provide a description of this “disability” that mirrored 
Jellinek’s model, yet her model of alcoholism was largely ignored for decades until it could be 
substantiated by science (Straussner, 2008).  
 Between 1930 and 1960, the federal response to mental health and addictive disorders 
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reinforced the separation of these systems. Via the Mental Health Act of 1946, the National 
Institute of Mental Health (NIMH) was charged with the responsibility for developing mental 
health, alcohol and drug initiatives, and policy (Osher & Drake, 1996).  However, the NIMH 
remained silent on the issue of addictive disorders until their re-medicalization in the 1960s, and 
then the institute had begun to actively advocate for more community-based alcohol treatment 
clinics. When Congress subsequently enacted the Narcotic Addict Rehabilitation Act in 1966, 
NIMH was authorized to make grants to establish community-based drug treatment programs and 
had begun to support the development of numerous therapeutic communities.  A few years later, 
decriminalization laws were passed such that interventions for persons with drug addictions were 
diverted from the criminal justice system to the health sector (Osher & Drake, 1996).  While 
these socio-political trends in the treatment of addictions show that such disorders were widely 
acknowledged as medically-based problems by the 1960s, affected persons had still received 
their treatment in settings separate from those with mental disorders. 
 Unlike people with primary substance-related disorders, a considerable proportion of 
people with schizophrenia continued to receive treatment for the disorder in institutional settings 
up through the mid-1960s.  However, by the mid-1960s, the emergence of aftercare clinics, acute 
inpatient facilities, phenothiazines, and brief psychosocial modalities, had established 
considerable advocacy support for community mental health care (Morrissey & Goldman, 1986).  
Further, via the promise of early intervention, and especially with the discovery of new drug 
therapies, public advocacy groups championed that the long-term disability of schizophrenia 
could be offset, which would render the need for institutional treatment obsolete (Lyons, 1984).  
Such advocacy support combined with the results of several federal studies that were conducted 
during the late-1950s on the needs of the mentally ill, promoted a strong case for a community 
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care (Morrissey & Goldman, 1986).  As a result, in 1963 Congress passed the Community 
Mental Health Centers Act to allow states to deinstitutionalize persons with schizophrenia by 
providing federal funding to build an elaborate system of community mental health treatment 
centers (Rochefort, 1984). 
 Although the resulting effect of the Community Mental Health Centers Act cut the state 
hospital census by two-thirds (~6,000) by 1970 (Rochefort, 1984), this shift in the locus of care 
did little to solve the problem of chronic mental illness (Morrissey & Goldman, 1986).  By the 
1970s it became clear that many with schizophrenia were in need of services well beyond what 
the meagerly funded community centers could provide (Grob, 1994).  Consequently, existing 
state hospitals continued to provide back up for these untried community programs, which were 
able, in turn, to focus on less disabled persons (Rochefort, 1984).  Nevertheless, state hospitals 
continued to be used as last ditch efforts for treatment refractory patients while a growing 
recognition that socioeconomic factors are critical to community well-being stimulated a host of 
social policies to help sustain mentally ill people in the community (Rochefort, 1984).  Most 
notably, in the 1960s and early 1970s Social Security amendments were made to Medicaid and 
Supplemental Security Income to provide cash and in-kind benefits to people with schizophrenia 
living in the community (Frank, Goldman, & Hogan, 2003).  Unfortunately, and despite these 
efforts, the community offered very little to no material supports or protection, which inevitably 
raised this population’s vulnerability to an array of adverse consequences (Drake et al., 2002).  
 Consequently, by the mid-1970s recently deinstitutionalized schizophrenia patients 
accounted for nearly 30% of the urban homeless population (Bassuk, 1985).  Related to the 
vulnerabilities conferred by being homeless (Kogel, Burnam, & Farr, 1988), a new subgroup of 
“difficult to serve” patients emerged (Pepper et al., 1981; Bachrach, 1982), and substance abuse 
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was associated with their “treatment resistance” (Osher & Drake, 1996).  Public concerns about 
this subgroup and about the treatment of addictive disorders led to the 1975 amendment of the 
Community Mental Health Center Act, which expanded the scope of community treatment to 
include drug and alcohol services (Drake & Osher, 1996).  However, such provisions did little to 
assuage the stark increase in the post-deinstitutionalization rates of SUDs among people with 
schizophrenia, which grew from 30% in 1970 to nearly 50% by 1990 (Westermeyer, 2006).  
Further, as a result of greater access to addiction treatment, the costs of providing community 
addiction and mental health care soared, and the states quickly began to experience declining 
support (Baumohl & Jaffe, 1995).  Consequently, the community mental health infrastructure 
soon proved to be grossly inadequate for fulfilling the needs of this newly identified population 
of persons with co-occurring SUDs and schizophrenia. 
 Although funding for the community mental health centers was insufficient from the 
start, the enactment of the Omnibus Budget Reconciliation Act in the 1980s and the repeal of the 
Mental Health Systems Act depleted what meager funds remained (Rochefort, 1984).  As a 
result, states could no longer sustain these programs, and the community centers began to vanish 
across the United States.  With the dissolution of these centers came the advent of the 1987 
Alcohol, Drug Abuse, and Mental Health Administration Reorganization Act (Osher & Drake, 
1996), which formed the Alcohol, Drug Abuse, and Mental Health Administration (ADAMHA).   
While this policy sought to improve community outcomes in people with addictive and mental 
health disorders, it did so by firming the separation of these systems (Osher & Drake, 1996).  The 
Act introduced a state-managed block grant mechanism such that federal alcohol, drug, and 
mental health grants were joined into a single block grant, allowing for the states to develop 
separate and corresponding structures for alcohol, drug, and mental health services.  Then, 
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between 1970 and 1990, a notable shift had been reported with regard to the delivery of 
addiction services via settings separate from mental health services (Schnibble & Mandervile, 
1993).  During this time, such systems had become more exclusive via seeking to provide 
treatment and services within the context of narrowly defined populations (Osher & Drake, 
1996).  As such, the results of a series of federally funded studies beginning in 1985 showed 
people with co-occurring disorders had worse outcomes than those with one disorder, and that 
such findings were due to numerous administrative barriers, resistances, and gaps between the 
addiction and mental health service delivery systems (Minkoff & Drake, 1991).  Consequently, 
during a time of waning resources, and when addiction and mental health services were both in 
high demand, persons with co-occurring SUDs and schizophrenia often did not receive any 
treatment for their conditions. 
 In yet another federal reorganization in 1992, ADAMHA was split into a services agency 
– the Substance Abuse and Mental Health Services Administration (SAMHSA), which had been 
officially authorized to oversee strategies to serve persons with co-occurring disorders (Osher & 
Drake, 1996).  This reorganization occurred just as new approaches began to underscore the 
importance of integrated strategies for persons co-occurring disorders (Ziedonis, 2004).  Such a 
model is premised on the idea that the treatment system bears the burden of ensuring that the 
client’s needs are met by linking addiction and mental health approaches in a coherent fashion 
within the same setting (Mueser et al., 2003).  Basic elements include an assertive engagement 
style, close monitoring, comprehensive care, supportive living, step-wise treatment, and a long- 
term perspective (Mueser et al., 2003).  Despite all of the optimism surrounding integrated 
treatment models, diverse licensing agreements between addiction and mental health service 
delivery systems largely precluded any opportunity to co-mingle funds (Ridgley & Dixon, 1995), 
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which created a mismatch of these structures to clinical need (Osher & Drake, 1996).  As such, 
many agencies struggled with making integrated services available for persons with co-occurring 
disorders, and had to resort to providing sequential treatment (stabilized in one system and then 
referred to the other), or treatment in parallel (treatment in separate systems, absent stabilization) 
systems with little coordination (Minkoff & Drake, 1991).  Consequently, the mismatch of these 
structures to clinical need promoted an inappropriate use of services and raised the level of 
suffering in persons with co-occurring SUDs and schizophrenia (Bachrach, 1982). 
 Ever since deinstitutionalization, the problem of co-occurring SUDs in schizophrenia has 
proliferated, and many of the social policies that were enacted during this time largely worked 
against this population.  As the complex needs of this population had both exposed the separation 
of mental health and addiction services, they also signaled a convergence of treatment principles 
and a plan for service integration. Such integrated systems had begun (as available) to be applied 
to this population as early as the 1980s, with the hope that such models of service delivery would 
improve the treatment and long-term recovery outcomes for those with co- occurring disorders. 
At the same time, a powerful consumer movement had begun to grow such that the traditional 
perspective on the course of schizophrenia and the associated assumptions about the potential of 
those with the disorder to live a productive and satisfying life were challenged (Bellack, 2006). 
These consumer voices were backed by evidence from a series of long-term outcome studies, 
demonstrating that the course of schizophrenia is variable across and within individuals and that 
many people with the disorder who meet strict diagnostic criteria can achieve good outcomes 
(Bellack, 2006). These 2 forces—new data and consumer voices— contributed to a political 
change that has recently begun to have an impact on public attitudes, patterns of service delivery, 
and the relationships between providers and consumers.  
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 A central focus in this recent political change is the concept of recovery. Although 
definitions of the recovery concept have varied over the past decade, most include some notion 
that people with schizophrenia need to feel hopeful of a future that contains the essentials for 
living, working, learning, and participating fully in the community (New Freedom Commission 
Report on Mental Health, 2003).  Notably, recovery has a different set of meanings in the field of 
addictions (Vaillant, 1995).  These definitions also variously address processes and outcome, 
subjective and objective status, but a consistent feature of recovery in the field of addictions is 
sustained abstinence (Drake et al., 2006).  For people with schizophrenia and co-occurring 
SUDs, achieving sustained abstinence and/or active remission from substance use is critical, with 
one recent study observing 10-year recovery rates of over 50% such that participants had 
achieved what they perceived as a better quality of life, and over 60% were actively attaining 
remissions from substance use (Drake et al., 2006).  While these findings are hopeful, it is 
noteworthy to mention that the total 130 participants of this study do not represent the large 
majority of persons with co-occurring SUDs and schizophrenia who would have challenges 
negotiating comparable integrated treatment outside of the context of a structured research 
program. 
 Recent attention on the recovery outcomes of persons with co-occurring disorders has 
stemmed in part from the findings of federally funded studies on the systems of service delivery 
in the United States.  Most notably, findings of the 2003 President’s New Freedom Commission 
on Mental Health recently concluded that the most significant barrier precluding persons with co- 
occurring disorders from being able to accomplish a productive and fulfilling life is poor service 
integration (Executive Order No. 13263).  Such results spurred a flurry of initiatives sponsored 
by SAMHSA, including a National Co-Occurring Center for Excellence that provides cross-
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training on-site to support state and community-based program efforts to better address the 
problem of co-occurring disorders (Ziedonis, 2004).  Regardless of these efforts, challenges have 
persisted with regard to launching system-level integrated services that seek to bridge federal and 
state agencies, modify reimbursement, and establish networks of integrated programs (Ziedonis, 
2004).  The resulting effects have produced a fragmented service delivery system, with addiction 
and mental services being largely unaccountable to the consumer (Ziedonis et al., 2005). 
Consequently, poor service-level integration has been identified as the largest current problem in 
addressing the problem of co-occurring SUDs in schizophrenia today (Ziedonis, 2004).  
 Consistent with the recovery model, the New Freedom Commission report stated, 
“consumers, along with service providers, will actively participate in designing and developing 
the systems of care in which they are involved….consumers and their families will play a larger 
role in managing the funding for their services” (New Freedom Commission Report on Mental 
Health, 2003, p. 8).  However, programmatic challenges to implementing integrated treatment 
modalities within addiction and mental health settings largely preclude the likelihood of such 
partnerships at the clinical level.  First, co-occurring disorders are conceptualized differently in 
mental health versus addiction treatment settings, with clinical staff having different perspectives 
on treatment, in part because of the different presentations encountered in each setting (Ziedonis, 
2004).  Second, it is often the case that no single entity or agency takes responsibility for case 
management services and service coordination.  Third, there is a need for greater availability of 
improved communication between treatment providers, and enhanced access to a wide range of 
medical, psychiatric, and addiction services (Ziedonis et al., 2005).  With no social policies or 
regulatory agencies mandating improved service coordination, the existing settings cannot 
support collaborative design and treatment development efforts for people with co-occurring 
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SUDs and schizophrenia at the clinical level.  
 As a consequence of these systemic and clinical barriers to integrated treatment, current 
federal initiatives and social policies have had a limited impact on improving the outcomes of 
substance use severity and recovery for persons with co-occurring SUDs and schizophrenia. 
Unfortunately, such efforts will continue to have a limited impact on improving the clinical 
management and outcome of people with co-occurring SUDs and schizophrenia until the issues 
undergirding a unified framework are effectively addressed.  While very recent efforts to 
improve service quality have achieved great importance and permeated health care generally 
with the passage of the Affordable Care Act of 2010, such concepts do not appear to have 
penetrated very far into improving the quality of service integration for persons with co-
occurring mental health and substance use disorders (Pincus, Spaeth-Rublee, & Watkins, 2011). 
In fact, rather disturbing results from a recent study by the Institute of Medicine revealed that, 
despite gains that have been made in the quality of care in general medical/surgical sector, the 
quality of care for Americans with mental health and substance use problems remains as poor 
today as it was several years ago (Institute of Medicine, 2006).  The contentious history between 
mental health versus addiction service delivery systems in the U.S. has undoubtedly had a 
negative impact on launching and subsequently delivering requisite integrated approaches 
designed to improve outcomes of substance use severity and maximize recovery among people 
with co-occurring SUDs and schizophrenia (Ziedonis et al., 2005).  As such, this investigation 
has the potential to make important contributions to highlight these limitations in current policies 
by building an evidence-base that supports a potentially important determinant of disability in 
schizophrenia (intrinsic motivation), and by deriving practice implications for addressing this 
determinant to facilitate the recovery of persons with co-occurring SUDs and schizophrenia by 
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improving substance use severity outcomes in this population. 
 
B.  ROLE OF GENDER IN THE PATTERNS OF SUBSTANCE USE SEVERITY IN 
MEN AND WOMEN WITH SCHIZOPHRENIA 
 Over the past century, gender differences in schizophrenia have been consistently 
reported in the research literature (Krapelin, 1909, 1919; Kretschmer, 1921; Leung & Chue, 
2000; Goldstein & Lewine, 2000); with the weight of the evidence largely indicating that women 
experience a better longitudinal course and outcome in the disorder than men (Angermeyer, 
Kuhn, & Goldstein, 1990; Leung & Chue, 2000).  The areas of outcome in which women with 
schizophrenia have been found to exhibit a better prognosis than men include education 
(Goldstein & Link, 1988), vocational functioning (Angermeyer, Kuhn, & Goldstein, 1990; 
McGlashan & Bardenstein, 1990;  Salokangas & Stengard, 1990; Andia et al., 1995), social 
functioning (Wattie & Kedward, 1985; Mueser, Bellack, Morrision, & Wixted, 1990; Andia et 
al., 1995; Murray & Van Os, 1998), fewer and shorter hospitalizations (Angermeyer et al., 1990; 
Eaton et al., 1995), lower suicide rates (Test, Burke, & Wallisch, 1990; Heila et al., 1997), and 
less frequent use of alcohol and illicit drugs (McGlashan & Bardenstein, 1990; Test et al., 1990; 
Cuffel & Chase, 1994).   
 While differences between the genders have long been studied in schizophrenia research, 
only recently has attention begun to be paid to variations in the severity of substance use in co-
occurring SUDs and schizophrenia. Thus, the consistently better outcomes observed among 
women with the disorder would seem to suggest the potential for women with co-occurring 
SUDs and schizophrenia to exhibit less severe patterns of substance use severity than men with 
these conditions.  However, the weight of the limited evidence suggest mixed results, with some 
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studies showing that women exhibit less severe SUD pathology than men, and others showing no 
significant relations with regard to the severity of substance use between the genders.  As such, 
not only is a study that proposes to examine differences in the longitudinal patterns of SUD 
pathology in schizophrenia greatly needed, but the results of such a study may lead to important 
implications for gender-specific interventions, which could inform the treatment and recovery of 
this population in a unique way. This section reviews the limited gender-specific literature in co-
occurring SUDs and schizophrenia, to substantiate a hypothesis that tests whether women 
demonstrate better outcomes of substance use severity than men among this population. 
 During the course of the disorder, people with co-occurring SUDs and schizophrenia 
experience recurrent patterns of substance use severity, which pertains to the frequency, duration, 
and impairments (symptom and functional) associated with long-term use (Drake et al., 2006). 
Regarding these indicators, prior investigations have shown that women with co-occurring SUDs 
tend to use fewer substances less frequently and in smaller amounts than men (Drake, et al., 
1989; Mueser et al., 1990; Test et al., 1990; Køster et al., 2008).  Consequently, these women 
tend to exhibit less impairment as a result of their substance use over the course of the disorder 
than men (Køster et al., 2008; Roncero et al., 2011).  For example, Køster, Lajer, Lindhardt, and 
Rosenbaum (2008) followed 62 patients with co-occurring schizophrenia and SUDs for 2-years 
from symptom onset.  Upon enrollment, more men used alcohol and cannabis in significantly 
greater quantities compared to women, and these men persisted in using these substances in 
significantly greater frequencies (3 times the rate of women) and quantities over the follow-up 
than women (Køster et al., 2008).  However, despite these differences, both genders exhibited 
marked improvements on indicators of severity (i.e., drug consumption and abuse) during the 2-
year follow-up (Køster et al., 2008). Results showed that the overall sample improved in terms of 
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their substance use severity over the follow-up, with women exhibiting greater propensities 
toward remission than men, which supports a hypothesis that seeks to test whether women 
exhibit faster gains in substance use severity improvement than men among this population.   
 Other studies (mostly cross-sectional) that have examined the severities of substance use 
in relation to gender among persons with co-occurring SUDs and schizophrenia report similar 
findings (Koskien et at., 2009a; Brunette & Drake, 1998), with some variability being observed 
depending on whether the primary substance of abuse is alcohol or cannabis. For example, 
Koskien and colleagues (2009a) conducted a meta-analysis on the rates of cannabis use disorders 
in schizophrenia, and reported significantly higher severities among men for all studies (3 of 28, 
studies) comparing cannabis use in relation to gender. For a sample of homeless men (n = 42) 
and women (n = 66) with co-occurring SUDs and schizophrenia, Brunette and Drake (1998) 
found that men had significantly greater cannabis severity than women; the only exception to 
similar severities being observed between the genders.  For a sample of outpatients with co- 
occurring SUDs and schizophrenia, Brunette and Drake (1997) reported similar results such that 
men were found to abuse cannabis for longer periods of time than women prior to enrollment 
(Brunette & Drake, 1997).  However, results revealed no significant differences between the 
genders with regard to the severities of alcohol, cannabis, or poly-drug use, as indicated by 
comparable frequencies and durations of use (Brunette & Drake, 1997).  Taken together, the 
results of these studies suggest a high potential for comparable severities of alcohol use to be 
observed between the genders with men having greater severities of cannabis use than women.  
 Such mixed findings observed among these mostly cross-sectional studies of gender 
differences in the severities of substance use among persons with co-occurring SUDs and 
schizophrenia signal a need for further longitudinal research to examine these effects.  The 
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proposed study seeks to take an important step in advancing field knowledge by identifying 
whether there is significant variability in the longitudinal patterns of substance use severity 
between men and women with co-occurring SUDs and schizophrenia, and potentially deriving 
gender-based treatment implications from such findings, which may lead to optimal long-term 
recovery outcomes of substance use severity among this population. 
 
C.  INTRINSIC MOTIVATION AND SUBSTANCE USE SEVERITY IN 
SCHIZOPHRENIA  
 Intrinsic motivation concerns the inherent tendencies that all human beings have to seek 
out novelty and challenges, to extend and exercise capacities, and to explore and to learn.  For 
this dissertation study, intrinsic motivation is conceptualized in terms of behaviors people carry 
out because of the positive feelings that are associated with performing an action in the absence 
of extrinsic rewards. These actions do not require for such persons to rely on external support or 
reinforcement to be initiated or sustained. This research uses an operational definition of intrinsic 
motivation based on the sum of QLS-derived items; purpose, curiosity, and motivation. Reports 
using these conceptual and operational definitions of the construct have shown persons with 
schizophrenia possess intrinsic motivation deficits that impede their ability to generate internal 
drives to sustain behavior changes absent external support. Evidence from the dual diagnosis 
literature suggests that such deficits can disengage intrinsic motivational processes when persons 
with co-occurring SUDs and schizophrenia try to generate their internal drives toward achieving 
reductions in substance use severity.  Although various motivational rehabilitative programs are 
available to the larger dual diagnosis population, such interventions may not address the deficits 
in intrinsic motivation that are potentially unique to schizophrenia.  Consequently, this research 
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seeks to extend validation of Nakagami and colleague’s (2008) measure of intrinsic motivation 
deficits for schizophrenia to schizophrenia and comorbid SUD. This approach is taken because 
methodological limitations inherent to the dual diagnosis treatment research call for extending 
validation of an intrinsic motivation measure that can provide further research into the relevance 
of intrinsic motivation deficits to substance use severity among this population.   This section 
first provides an introduction to the construct of intrinsic motivation by broadly describing its 
relevance to behavior change processes, and then provides an overview of the application of 
intrinsic motivation to schizophrenia and comorbid schizophrenia and SUD.  Relevant literature 
on the measurement of intrinsic motivation in schizophrenia is then reviewed.  Lastly, research 
supporting the validity of using the intrinsic motivation measure developed by Nakagami and 
colleagues (2008) to predict prospective naturalistic changes in substance use severity among 
persons with co-occurring SUD and schizophrenia is provided.     
1. Overview and Relevance of Intrinsic Motivation 
 The study of intrinsic motivation has been a broad area of adaptive behavior change 
investigation for several decades.  Much of the early research on intrinsic motivation stemmed 
from the behavioral neuroscience literature, which focused on the concept of homeostatic drives 
or the idea that organisms may be driven to maintain a stable internal state in regard to variables 
such as thirst, hunger, or other injective behaviors (see Berridge, 2004, for review).  Beginning 
with Hull’s (1943) theory of drives, intrinsically motivated behaviors were posited as those that 
emerged from psychological needs (and their derivatives) to restore system balance.  Such a 
view on intrinsic motivation focused on the fact that a deficit or error signal in these systems 
(i.e., lack of water, hunger, low blood glucose) triggers behaviors designed to return the system 
to a set point or stable state (see Berridge, 2004, for a discussion of alternative points of view). 
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While views of motivation and intrinsic motivation that rely on homeostatic mechanisms have 
powerful explanatory force in many domains, subsequent social psychological researchers had 
argued that other types of mechanisms that do not rely on explicit deficit signals are needed to 
explain the full range of intrinsically motivated behaviors seen in animals and humans.  Such a 
focus gave rise to the appetitive approach to motivation, which posited that animals and human 
beings may be intrinsically motivated to seek stimuli that are reinforcing in some sense, even if 
these stimuli do not serve to remediate some internal deficit state (Berridge, 2004).  Compared to 
homeostatic views, the appetitive motivational system was seemingly more appealing, as it could 
explain domains in which intrinsic behaviors may be removed from basic needs and potentially 
emerge from abstract concepts such as tendencies, desires, or interpersonal needs.  
 Subsequent focus on appetitive motivation systems in experimental animal research led 
to the contemporary conceptualization of intrinsic motivation, as it was discovered that many 
organisms engage in exploratory, playful, and curiosity-driven behaviors even in the absence of 
reinforcement or reward (White, 1959).  Over the years, a unique set of inherent tendencies have 
come to be seen as the mechanisms potentially underlying intrinsically motivated outcome 
behaviors in humans (Deci et al., 1999, for review).  Such tendencies include (1) the tendency to 
seek out novelty and challenges, or curiosity tendencies; (2) the tendency to extend and exercise 
capacities, or purpose tendencies; and (3) the tendency to explore and to learn, or performance 
tendencies (Ryan & Deci, 2000; Deci et al., 1999).  According to Ryan and Deci (2000), human 
beings can use intrinsic motivation to change their behaviors by catalyzing any of these inherent 
tendencies when they are engaged in an activity that satisfies their needs for being autonomous, 
self-determined, or competent.  Such a process is described in more detail in Figure 1, and has 
become widely acknowledged as the way in which human beings carry out a range of activities 
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to change their behaviors in the absence of reinforcement or reward (Deci & Ryan, 2007).  This 
model can be used to understand the processes that go awry in schizophrenia when deficits in 
intrinsic motivation impede the ability of those with the disorder to generate internal drives to 
sustain behavior changes absent external rewards, and are discussed in further detail in Section 
C.2.  Aspects of this model can also be used to understand how such processes become even 
more disengaged when persons with co-occurring SUDs and schizophrenia try to generate 
internal drives toward achieving and actually sustaining reductions in substance use severity, and 
are discussed in further detail in Section C.3.  
 
Figure 1. Processes by which a person's needs direct the inherent tendencies of human behavior toward 
intrinsically motivated outcome behaviors 
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 Psychological processes underlying intrinsic motivation. One important area of work 
concerning the significance of intrinsic motivation to adaptive behavior change has stemmed 
from studies of curiosity tendencies of human behavior.  Early work by Berlyne (1960) on the 
curiosity tendencies of human behavior documented their growth promoting properties, and the 
developmental characteristics such tendencies provide for facilitating novelty seeking behaviors.  
Specifically, such properties have been found to promote cognitive, social, and physical growth 
among both children and adults (Deci et al., 1999; LaGuardia, Ryan, Couchman, & Ryan, 2000). 
Other studies have shown that the degree to which such curiosity tendencies become catalyzed 
toward intrinsically motivated outcome behaviors varies as a function of the degree to which 
people perceive that the activity they are engaged in satisfies their needs for feeling competent, 
autonomous, or self-determined (Deci et al., 1999; Deci et al., 1981).  Such findings not only 
signal the importance of these curious tendencies to behavior change processes by highlighting 
their growth promoting effects, but also suggest that when people are engaged in an activity that 
supports their needs for feeling competent, autonomous, or self-determined, then such a person’s 
curious tendencies may become catalyzed toward intrinsically motivated outcomes.  
 Research on the purpose tendencies of intrinsic motivation has also focused on how need 
satisfaction is a critical component to catalyzing these tendencies toward intrinsically motivated 
outcomes.  Many investigations have found consistent correlations between service providers 
who supported their patient’s autonomous decision making and their patient’s intrinsically 
motivated behaviors that resulted in more healthy lifestyles (see Deci & Ryan, 2007, for review). 
For example, such studies have focused on how a person’s need for feeling autonomous and self-
determined was critical to catalyzing such tendencies toward facilitating intrinsically motivated 
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outcomes in smoking cessation (Williams et al., 2006), depression reduction (Zuroff et al., 
2007), and exercise/health promotion (Fortier, Sweet, O’Sullivan, & Williams, 2007; William, 
Grow, Freedman, Ryan, & Deci, 1996) intervention programs.  Taken together, these findings 
suggest that whether any particular intervention can catalyze these purpose tendencies toward 
adaptive behavior change varies as a function of the person’s level of interest in the intervention 
itself, and if such an intervention promotes autonomous decision making.  
 Finally, the performance tendencies of human behavior are another important area of 
work concerning the significance of intrinsic motivation to adaptive behavior change (Deci et al., 
1989; Baard, Deci & Ryan, 2004).  For example, studies on the performance tendencies of 
intrinsic motivation have focused on how autonomous decision making in a learning 
environment is a critical component to catalyzing these tendencies toward intrinsically motivated 
outcome behaviors  among high school students (Chirkov & Ryan, 2001), medical students 
(Williams & Deci, 1998), and law students (Sheldon & Krieger, 2007).  For example, Sheldon 
and Krieger (2007) found that mentors promoting autonomous decision making in law schools 
had an important influence on catalyzing performance tendencies among their students toward 
intrinsically motivated outcomes, which manifested as higher grade point averages and bar 
passages rates.  Such findings suggest that not only do people have inherent tendencies to 
explore and to learn, but that one’s perception of his/her autonomous academic performance is 
critical to promoting intrinsically motivated outcome behaviors in learning environments.  
 Social contextual variables, extrinsic rewards, and intrinsic motivation. In addition to 
studying the ways in which people can build intrinsic motivation to facilitate behavior change, 
researchers have also examined a host of factors that can undermine its expression, including the 
presence of extrinsic rewards.  Extrinsic motivation is the motivation to do something because a 
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tangible reward will occur (Deci & Ryan, 2007). The clearest examples of extrinsically 
motivated behaviors are those performed to obtain a tangible reward or to avoid a punishment.  
Further, results of a meta-analysis of over 100 studies revealed that extrinsic rewards decreased 
intrinsic motivation across a range of activities, ages, rewards, and reward contingencies (Deci et 
al., 1999).  In other words, when people were given extrinsic rewards such as money for doing 
an intrinsically interesting activity, their intrinsic motivation for the activity tended to become 
undermined.  That is, the presence of the reward led them to lose their intrinsic interest in the 
activity. There were, however, limiting conditions to these findings.  For example, such results 
largely indicated the rewards that were not dependent on activities conducted to achieve some 
standard or goal tended not to undermine intrinsic motivation, perhaps because they were not 
perceived as controlling one’s behavior (Deci et al., 1999).  In fact, subsequent research has 
shown that the provision of choice increases intrinsic motivation, despite the presence of 
extrinsic rewards (Zuckerman, Porac, Lathin, Smith & Deci, 1978).  For example, Ryan, Mims, 
and Kostner (1983) found that when extrinsic rewards were delivered in an environment that 
supported participants’ autonomy, intrinsically motivated outcomes persisted.  However, Ryan 
(1982) found that when extrinsic rewards were delivered in a controlling context, participants’ 
propensity toward intrinsically motivated outcome behaviors decreased.  Taken together, such 
findings suggest that the presence of extrinsic rewards may undermine intrinsic motivation; 
however, this potential is greatly reduced when one’s needs for competence, self-determination, 
or autonomy are satisfied within the social context of the activity or by the target activity itself.  
 In summary, intrinsic motivation is a unique social psychological construct that holds 
particular relevance to adaptive behavior change. The components of the construct include the 
tendency to seek out novelty and challenges (i.e., curiosity tendencies), the tendency to extend 
73 
 
and exercise capacities (i.e., purpose tendencies), and the tendency to explore and to learn (i.e., 
performance tendencies) (Ryan & Deci, 2000; Deci et al., 1999). When individuals are 
intrinsically motivated to pursue a goal, they engage in targeted behaviors because of the interest, 
enjoyment, and satisfaction derived from their engagement in the activity, rather than due to 
external rewards. Thus, intrinsically motivated behaviors are repeated without external rewards 
or constraints and, therefore, more likely to be maintained.  This is particularly relevant to 
developing treatments for co-occurring SUDs and schizophrenia, as such persons demonstrate 
deficits in increasing intrinsic motivation to change the behaviors associated with their patters of 
substance use to achieve remission or recovery.  As suggested by the literature pursued in this 
section, research in social psychology has progressed over the past several decades pointing to 
the significance of the construct of intrinsic motivation and its relevance as a key motivational 
component in behavior change processes, signaling the potential promise of the construct for 
understanding recovery from substance use severity in schizophrenia.  What follows is a review 
of the research examining the presence of intrinsic motivation deficits in schizophrenia.  Such a 
discussion focuses on how the motivational processes that go awry in schizophrenia impair the 
ability of those with the disorder to generate internal drives to sustain behavior changes absent 
external rewards, and provides a basis for understanding how such processes can become even 
more disengaged when persons with co-occurring SUDs and schizophrenia try to generate 
internal drives toward achieving reductions in substance use severity.  
2. Intrinsic Motivation Deficits in Schizophrenia 
 Research over the past century has supported the conceptualization of schizophrenia as a 
disorder of motivational impairment, with the earliest descriptions of the disorder emphasizing a 
disturbance of volition (avolition/ amotivation) as the underlying process in its pathology (see 
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Foussias & Remington, 2010, for review).  Today’s nosology of mental disorders considers the 
presence of motivational deficits such as amotivation and ahedonia to be among the defining 
features of schizophrenia (APA, 2013).  Such deficits are characterized by a diminished capacity 
to take interest in activities (amotivation), and an inability to experience pleasure from activities 
that most people find enjoyable (ahedonia).  There is no consensus on how to define intrinsic 
motivation deficits in the context of schizophrenia (Foussias & Remington, 2010). Therefore, 
this dissertation study conceptualizes the construct in terms of the behaviors people carry out 
because of the positive feelings associated with performing an action in the absence of extrinsic 
rewards, and operationally defines the construct based on the sum of pertinent intrapsychic 
deficit items of the Quality of Life Scale, including purpose, curiosity, and motivation.  Since 
such an approach is premised on the idea that intrinsically motivated outcomes arise from 
behaviors that people with schizophrenia engage in for their own sake or for the satisfaction they 
get from working towards a goal, perhaps it is not surprising that other studies utilizing such an 
approach have begun to turn to negative symptoms such as amotivation and anhedonia in 
schizophrenia to potentially explain the marked difficulties those with the disorder have in 
developing intrinsically motivated outcome behaviors (Harvey & Strassnig, 2012).  
 Psychopathology impairing intrinsic motivational processes.  Work by Gard, Kring, 
Gard, Horan, and Green (2007) has provided some clues into these relations by showing that 
anhedonia in schizophrenia is linked to deficits in the hedonic experience of anticipatory 
pleasure (enjoyment related to the anticipation of future activities), which impairs intrinsic 
motivational processes, and leads to decrements in goal-directed behaviors among those with the 
disorder.  However, individuals with schizophrenia tend to have intact pleasure responses 
(consummatory anhedonia) when exposed to present stimuli (Berenbaum & Oltmanns, 1992; 
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Kring, Kerr, Smith, & Neale, 1993; Kring & Neale, 1996; Burbridge & Barch, 2007; Heerey & 
Gold, 2007; Der-Avakian & Markou, 2011).  Previous work by Heerey and Gold (2007) has 
provided some insight into this issue by comparing the ratings of pleasure and arousal from 
control and schizophrenia participants.  Results of their investigation showed that participants 
with schizophrenia tended to experience a reduced capacity to anticipate that future goal pursuits 
will be pleasurable (anticipatory anhedonia), in addition to lacking an ability to translate their 
subjective experiences into action, which consequently led to a decrease in the initiation of goal-
directed behaviors (amotivation) (Heerey & Gold, 2007).  Taken together, such results suggest 
that the interrelationship between ahedonia (i.e., anticipatory anhedonia) and amotivation in 
schizophrenia may contribute to the intrinsic motivational deficits observed in the disorder. Such 
deficits could preclude persons with schizophrenia from achieving intrinsically motivated 
outcomes including the ability to achieve remission and recovery from substance use.  
 Social contextual variables, extrinsic rewards, and intrinsic motivation in schizophrenia.  
In addition to studying the ways in which amotivation and ahedonia are linked to the nature and 
causes of intrinsic motivational deficits in schizophrenia, relevant work has considered the 
impact social contextual variables may have on its expression. For example, recent work by 
Silverstein (2010) has highlighted the challenges of engaging highly symptomatic individuals 
with schizophrenia into treatment who have low base rates of a desired behavior.  He has 
suggested that by using tangible rewards with this subset of patients, it may be possible to 
change the value such patients attach to a behavior.  Specifically, tokens, money, and other 
rewards may increase task value sufficiently to enhance the performance of desired behaviors 
(Silverstein, 2010).  Silverstein (2010) further argues that if this activation of extrinsic 
motivation is done properly (i.e., in an environment that promotes autonomy or self-
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competence), it may turn out to be a first step in promoting the internalization of task goals that 
is sometimes necessary for the development of intrinsic motivation (Deci & Ryan, 2007).  In 
addition, Nakagami and colleagues (2010) have provided causal data to suggest that when both 
intrinsic motivation and daily functioning are low among individuals with schizophrenia, initial 
functional improvement might be required to trigger increased levels of intrinsic motivation.  
Such a finding expands upon Silverstein’s (2010) notions to suggest that extrinsic properties 
could be used to stimulate initial behavior change as well as functional improvement and thereby 
trigger higher levels of intrinsic motivation in schizophrenia, contrary to the previous description 
of the intrinsic/extrinsic relationship in healthy individuals.    
 However, there are data to suggest that positive behavior changes initiated through the 
use of monetary compensation during activities is not sustained in schizophrenia after rewards 
are withdrawn (Dickerson, Tenhula, & Green-Paden, 2005).  The degree to which extrinsic 
rewards generalize to everyday task performance is also limited. In addition, further research is 
needed to support the argument by Silverstein (2010), suggesting that low base rates of intrinsic 
motivation among highly symptomatic persons with schizophrenia is a justification for 
employing extrinsic rewards to promote behavior change.  While there is evidence to suggest 
that the most impaired inpatients with schizophrenia exhibit improvements when exposed to 
cognitive remediation that includes manipulations of both extrinsic (Silverstein, 2010), and 
intrinsic motivation (Medalia, Revheim, & Casey, 2002), the comparative advantages of these 
manipulations for subsamples of community patients with schizophrenia, which comprise the 
vast majority of those who are affected by the disorder today, requires further investigation.  
Taken together, the weight of the limited evidence supports the use of extrinsic goals to 
potentially enhance the low base rates of intrinsic motivation among individuals with 
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schizophrenia, yet further research is needed to more fully understand the clinical circumstances 
in which extrinsic and intrinsic goals are best used.  
 Physiological processes underlying intrinsic motivation in schizophrenia. Over the past 
decade, the physiological processes involved in motivation have become a focus of investigation 
in schizophrenia research (Barch, 2004), and behavioral neuroscientists have begun to gain a 
better understanding of how abnormalities in the dopamine system can lower drive- and goal-
directed behaviors via animal experiments (Berridge & Kringelbach, 2008).  Recent work by 
Barch and Dowd (2010) identified four operative components to motivation in schizophrenia, 
and then reviewed the physiological processes that have been linked to each component.  The 
one component that appears to be intact in schizophrenia, which is hedonics or liking a received 
reward, seems to be mediated by activation of the opioid and gamma butyric acid-ergic systems 
in the nucleus accumbens shell and its projections to the ventral pallidum, as well as in the 
orbitiofrontal cortex (Pecina, Smith, & Berridge, 2006; Burgdorf & Panksepp, 2006; Smith & 
Berridge, 2007).  The other three components, which include wanting, assessing value, and goal-
directed action, may be mediated by the mid-brain dopamine system, orbitofrontal cortex and 
anterior cingulate cortex, and dorsolateral prefrontal cortex, respectively (Barch & Dowd, 2010). 
Further, another report by Silverstein (2010) considered a functional disconnectivity between the 
dorsolateral preforontal cortex and the subcortical mesolimbic dopamine system in accounting 
for the marked difficulties people with schizophrenia display in wanting and valuing what they 
like.  Taken together, an important implication of these findings is that the dopaminergic system 
may be a physiological mechanism underlying regulatory function of intrinsic motivational 
processes among persons with schizophrenia.  
 Recent investigations have also examined the physiological processes underlying 
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intrinsic motivation in schizophrenia by questioning if cognition is a rate-limiting factor for 
change (Nakagami et al., 2010).  Indeed, cognitive deficits have long been thought to reflect 
disruption in the pathophysiological processes involved in schizophrenia (Green et al., 2004), 
and as such could potentially represent a physiologically-based rate-limiting factor (Nakagami et 
al., 2010).  Notably, however, Nakagami and colleagues (2010), in their longitudinal study of 
130 outpatients with schizophrenia and schizoaffective disorder, found that baseline cognition 
did not predict change in intrinsic motivation over a 12-month period.  Further, longitudinal 
changes in cognition were not associated with longitudinal changes in intrinsic motivation 
(Nakagami et al., 2010).  Nevertheless, an important implication of these findings is that the 
study participants who had high and low baseline cognitive function increased their intrinsic 
motivation, regardless of whether they had improved in their cognition over the 1-year study.  
Another noteworthy implication of the study conducted by Nakagami et al. (2010) is that the 
physiological mechanisms that mediate aspects of cognition that they measured did not appear to 
be a rate-limiting factor for change in intrinsic motivation.  Perhaps the most important 
implications of the naturalistic longitudinal study conducted by Nakagami et al. (2010) were the 
findings that intrinsic motivation is in fact dynamic over time in schizophrenia; and that study 
participants’ social disability improved as they made gains in intrinsic motivation.  Taken 
together, such findings suggest that while persons with schizophrenia do have deficits in intrinsic 
motivational processes, intrinsic motivation is malleable among those with the disorder, and thus 
can be improved.    
 In another study of 57 outpatients with schizophrenia, Choi and Medalia (2010) used the 
Intrinsic Motivation Inventory for Schizophrenia Research (IMI-SR), a self-report measure for 
assessing intrinsic motivation, and reported on changes in intrinsic motivation in relation to a 4-
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week cognitive training program.  Results supported the dynamic nature of intrinsic motivation 
in schizophrenia, although the change in intrinsic motivation was significant only in a subgroup 
that received a motivationally enhanced version of the training task (Choi & Medalia, 2010). 
Such results elaborate on those previously reported by Nakagami and colleagues (2010), by 
showing that changes in intrinsic motivation can be detected relative to participation in a learning 
program and that such changes are sensitive to the motivational properties of the context in 
which the learning tasks are embedded (Choi & Medalia, 2010). Taken together, these two 
studies provide strong preliminary support for the malleability of intrinsic motivation in 
schizophrenia and give a basis for future studies to replicate and extend the findings by varying 
the social context and sample characteristics, and investigating the validity of methods of 
assessing intrinsic motivation.  
 In summary, the weight of the limited evidence in this area of research suggests that 
persons with schizophrenia have significant deficits in intrinsic motivation, which likely stem 
from symptoms such as ahedonia and amotivation as well as other pathophysiological processes 
affecting dopaminergic systems in the disorder. However, while recent investigations have begun 
to take interest in examining intrinsic motivational processes in schizophrenia, many of these 
studies have been limited in scope, with only one longitudinal investigation focusing on the 
relationships between social disability, cognition, and intrinsic motivation among this 
population. Furthermore, not one of the aforementioned studies have been conducted in a sample 
of individuals with schizophrenia and comorbid SUD.  Unfortunately, while intrinsic motivation 
deficits are clearly present in schizophrenia, the way in which such deficits impair behavioral 
change processes in the disorder by interfering with the development of intrinsically motivated 
goals has not been clearly established.  Nevertheless, since intrinsic motivation deficits in 
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schizophrenia have been shown to impair the ability of those with the disorder to generate 
internal drives for sustaining behavior changes in the absence of receiving extrinsic rewards 
(Nakagami et al., 2008; Yamada et al., 2010; Nakagami et al., 2010), it seems likely that 
individuals with co-occurring SUDs and schizophrenia would be prone to experience 
considerable challenges with developing internal drives to change their addictive behaviors and 
reduce their substance use severity. What follows is a review of the limited evidence examining 
the significance of deficits in intrinsic motivation to substance use severity among persons with 
schizophrenia and co-occurring SUDs, as well as investigations that have studied differences 
between the genders with regard to this relationship.   
3. Intrinsic Motivation as a Contributor to Substance Use Severity in Schizophrenia  
 While considerable research supports the relevance of the construct of intrinsic 
motivation to behavior change processes and evidence within schizophrenia research has 
documented intrinsic motivation deficits in the disorder, not one of these studies has included 
persons with co-occurring SUDs and schizophrenia in their study sample.  Despite the apparent 
lack of available evidence on such persons within schizophrenia research, evidence has begun to 
emerge within the dual diagnosis treatment literature suggesting that the pervasive patterns of 
substance use observed among those with co-occurring SUDs and schizophrenia may be linked 
to deficits in intrinsic motivation among this population.  However, dual diagnosis programs are 
often premised on the assumption that people with co-occurring conditions have intact intrinsic 
motivational processes, which many not be the case for those with comorbid schizophrenia and 
SUD. Thus, examining the relevant literature in this area may provide insight into the reason for 
which persons with comorbid schizophrenia and SUD are often unsuccessful with reducing the 
severity of use in treatment.  Within the dual diagnosis treatment research, various instruments 
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have been used to measure intrinsic motivation, with the majority of approaches focusing on the 
degree to which persons with co-occurring conditions are intrinsically motivated to change 
substance-specific behaviors (see DiClemente, 2003; DiClemente et al., 2008). However, few, if 
any studies have used more general measures of the construct to gauge the intrinsic motivation 
deficits that are potentially unique to comorbid schizophrenia and SUD.  While this dissertation 
does not seek to take any of the more widely employed substance-specific behavior approaches 
to the measurement of intrinsic motivation reviewed in this section (this dissertation takes a 
general approach to the measurement of intrinsic motivation, which is discussed in greater detail 
in Section C.4), it is still important to review the evidence that has emerged within the context of 
dual diagnosis motivational programs.  This evidence not only signals the importance of intrinsic 
motivation deficits to SUD pathology among this population, but also signals the potential for 
the relationship between intrinsic motivation and substance use severity to vary across genders.    
 Such evidence suggesting that intrinsic motivation deficits may impede persons with 
schizophrenia and comorbid SUD from their ability to recover from severe substance use has 
largely stemmed from studies of psychosocial approaches designed to enhance dual diagnosis 
clients’ motivation to change their substance use behaviors (see Hunt et al., 2013, for review).  
The weight of the evidence indicates that, compared to dual diagnosis clients without 
schizophrenia, individuals with co-occurring SUDs and schizophrenia are less motivated to 
change the behaviors associated with their substance use while participating in such programs, 
are more difficult to engage, make slower progress, and drop out of such programs at faster rates 
(Drake et al., 2008; Horsfall et al., 2009).  While such patterns may be in part due to problems 
stemming from the intrinsic motivation deficits of schizophrenia rather than treatment 
compliance issues stemming from the pathology of the SUD, this question has remained largely 
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unexamined within the dual diagnosis research to date.  As such, there is a current need for 
investigations that seek to understand how these intrinsic motivational processes are actually 
linked among this population, as well as further research on the contributions of intrinsic 
motivation to substance use severity in co-occurring SUDs in schizophrenia.  
 Relatively little research has examined the actual contributions of intrinsic motivation to 
substance use severity in co-occurring SUDs and schizophrenia (Hunt et al., 2013, for review). In 
one of the few studies to examine the relationship between intrinsic motivation and substance use 
severity, Graber and colleagues (2003) observed such relations in 30 non-treatment seeking 
veterans with co-occurring alcohol use disorders and schizophrenia in an outpatient motivational 
rehabilitative program.  They found participants’ ability to increase intrinsic motivation was 
stronger among those in the experimental condition (motivational interviewing), and that such a 
modality significantly predicted decreased drinking days and increased rates of abstinence over 
the 24-week follow-up. Another study by James and colleagues (2004) examined substance use 
behavior outcomes in 63 treatment seeking dual diagnosis outpatients (63% schizophrenia) in a 
motivational rehabilitative program.  Similar to Graber and colleagues (2003), they also found 
that the ability to increase intrinsic motivation was stronger among those in the experimental 
condition (motivational enhancement), and that building intrinsic motivation via such a modality 
significantly predicted improved alcohol and drug dependence severity at the 3-month follow-up 
(James et al., 2003).  A study by Kavanagh and colleagues (2004a) also observed the relations 
between intrinsic motivation and substance use outcomes in a sample of 25 first episode patients 
with dual disorders (48% schizophrenia) in a motivational rehabilitative program.  Here too, 
these investigators found that the ability to increase intrinsic motivation was stronger among 
those in the experimental condition (start over and survive), and that the gains in intrinsic 
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motivation that were made through participating in such a modality significantly predicted less 
substance use at the 12-month follow-up. Subsequent motivational rehabilitation studies of dual 
diagnosis clients have revealed that participants reduced their use of substances, regardless of the 
modality to which they were assigned (Martino et al., 2006; Edwards et al., 2006; Baker et al., 
2006), perhaps because both groups developed similar improvements in intrinsic motivation over 
the follow-up periods. Such studies of persons with dual disorders in motivational rehabilitative 
programs provide evidence of the relationship between intrinsic motivation and substance use 
severity in this population.   It should be noted, however, such positive effects of changes in 
intrinsic motivation on changes in substance use severity have been obtained within the context 
of studies employing modest sized samples of dual diagnosis participants selected from specialty 
populations that have included few women and individuals with co-occurring SUDs and 
schizophrenia.   
 In fact, the study by Graber and colleagues (2003) only included 1 woman in their modest 
sized sample of 37 non-treatment seeking veterans with co-occurring alcohol use disorders and 
schizophrenia.  Such a small proportion of women studied by these investigators highlights the 
potential for this subgroup to be underrepresented within the relevant research in this area and 
thus signals a need for further study.  In the only investigation to examine gender differences in 
the relationship between intrinsic motivation and outcomes of substance use severity among 
persons with dual disorders, Drapalski and colleagues (2011) examined such relations in samples 
of treatment non-seeking (N = 175) and treatment seeking (N = 134) men and women with dual 
disorders. Specifically, the investigators of this cross-sectional study sought to examine gender 
differences in the patterns and consequences of substance use, treatment-seeking patterns, and 
participants’ motivation to change for the two samples of study participants. The investigators 
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found that, in both groups, men and women exhibited more similar patterns and severities of 
substance use than differences (retrospectively rated). However, the findings also showed that 
treatment-seeking women demonstrated greater readiness to change their substance use patterns 
and severities than men among this population. Such a finding may be indicative of higher levels 
of intrinsic motivation being present among these women, which could potentially lead to greater 
longitudinal improvements of substance use severity being observed among women than men in 
this population.   
 As can be seen by this review of the literature examining the relationship between 
intrinsic motivation deficits and SUD pathology in co-occurring SUDs and schizophrenia, and 
the potential for this relationship to vary across the genders, some evidence exists to suggest that 
such deficits may be important contributors to the severe and persistent patterns of substance use 
severity observed in this population.  Specifically, people with schizophrenia do exhibit deficits 
in intrinsic motivational processes, which considerably impair the ability of those with the 
disorder to generate internal drives to sustain behavior changes absent external rewards. With 
regard to persons with co-occurring SUDs and schizophrenia, such deficits may disengage 
intrinsic motivational processes when persons with these conditions try to generate internal 
drives to achieve reductions in substance use severity.  Consequently, deficits in intrinsic 
motivational processes among persons with co-occurring SUDs in schizophrenia appear to be an 
important contributor to the severe and persistent patterns of substance use severity observed 
among this population.  
4. Limitations of the Research on Intrinsic Motivation and Substance Use Severity in 
Schizophrenia 
 Confirmatory evidence has yet to be established regarding the significance of deficits in 
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motivational processes to substance use severity in schizophrenia, as work in this area has 
suffered from several important limitations that are readily discernable from this review of the 
literature.  In particular, to date investigations of intrinsic motivation in co-occurring SUDs and 
schizophrenia have largely been conducted within the context of motivational rehabilitation 
programs for the larger population of dual diagnosis clients.  While some of these programs have 
adapted their modalities to accommodate the symptoms of psychosis (Martino et al., 2002; 
Martino et al., 2006), not one has modified their treatment protocol to account for the intrinsic 
motivation deficits of schizophrenia (see Section C.2).  In addition, not only have these studies 
made use of modest sized samples, but such investigations have also selected their samples from 
specialty populations that have included few women as well as small proportions of persons with 
co-occurring SUDs and schizophrenia.  This narrow focus on examining such effects within the 
context of dual diagnosis motivational programs has raised several important questions about 
how such findings generalize to the larger population of persons with co-occurring SUDs and 
schizophrenia who are not participating in motivational interviewing programs that are generally 
not widely available (McHugo et al., 2006).  As such, elucidating the prospective longitudinal 
significance of such deficits in motivational processes to SUD pathology in this population 
represents an important area of further investigation.  
 In terms of whether the findings of motivational rehabilitation studies showing reductions 
in patient’s substance use severity reviewed in Section C.2 generalize to the larger population of 
those with schizophrenia and comorbid SUD, a few areas of concern should be mentioned. The 
only study that observed the relationship between intrinsic motivation and substance use severity 
where 100% of the study sample consisted of persons with schizophrenia was conducted with a 
modest number of veterans (N = 30) who were mostly male (1 woman participant) (Graber et al., 
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2003).  Further, the investigations conducted by Kavanaugh et al. (2004a) and Edwards et al. 
(2006) also observed such effects using specialty samples of dual diagnosis clients, where only 
about 50% of their modest sized (N = 25; N = 47, respectively) samples consisted of persons in 
their first episode of schizophrenia.  In addition, Kavanaugh et al. (2004a) recruited their sample 
from an inpatient unit, and subsequently followed such patients after they were (mostly) 
discharged to the care of a family member.  Further, the positive effect of the experimental 
condition on developing intrinsic motivation to change the behaviors that were associated with 
participants’ substance use severity could not be explained beyond positive interaction with such 
family members (Kavanaugh et al., 2004a).  While Kavanaugh et al. (2004a) has contributed to 
the evidence supporting significant relations between motivation and substance use severity 
among this population, the findings may be less applicable to the majority of chronic patients 
with co-occurring SUDs and schizophrenia who live in the community, have free access to drugs 
and alcohol, and rely on public rather than family support (Drake et al., 2008).  As a 
consequence of the methodological limitations and issues inherent to these studies, most of the 
dual diagnosis research that has considered the importance of intrinsic motivation to substance 
use severity may not generalize to the vast majority of individuals with co-occurring SUDs and 
schizophrenia, and thus research on larger and more heterogeneous samples of persons with 
these conditions is needed.   
 In the context of the limitations discussed, the findings of such studies may be limited by 
the potential confounding influence of extrinsic rewards on intrinsically motivated substance use 
outcomes. Some of the motivational rehabilitation studies reviewed in Section C.3 delivered 
extrinsic rewards (i.e., participant remuneration payments) to participants at the same time that 
such persons received the motivational session targeting improvements in intrinsic motivation to 
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reduce their SUD pathology (i.e.,  James et al., 2006; Martino et al., 2006). While many of the 
approaches that have been adapted to co-occurring disorders to date do foster environments such 
that the persons’ choice and responsibility are valued (see Hunt et al., 2013), without assessing 
change in intrinsic motivation after removing the extrinsic reward, it is difficult to discern the 
actual motivation underlying improvements in substance use severity. As such, these studies 
highlight the potential for extrinsic rewards, such as participant payments, to confound the 
relationship between changes in intrinsic motivation and changes in substance use severity 
among persons with co-occurring SUDs and schizophrenia.  Clearly future investigations are 
needed that can account for these important potential confounding effects and directly examine 
the contributions of intrinsic motivation deficits to substance use severity among this population.  
 Another important limitation to the studies reviewed above is the limited use of intrinsic 
motivation measures.  Each investigation used readiness-to-change assessments to measure the 
stage of change associated with the person’s current level of motivation to improve their target 
outcome behavior (i.e., reduction in use, cessation of use, or improvements in the severity of 
use). Although not all of these studies consistently employed the same readiness-to-change 
assessment, such measures generally base the person’s stage of change on one of the 5 stages of 
change that coincide with the TTM of intentional behavior change (i.e., precontemplation, 
contemplation, preparation, action, maintenance) (DiClemente, 2003). Motivation, according to 
the TTM perspective, requires for individuals to engage in enough cognitive and experimental 
activities to move through early stages and to engage in behavioral activities to initiate and 
sustain the change (DiClemente et al., 2008).  However, because persons with co-occurring 
SUDs and schizophrenia are disadvantaged in cognitive areas, assessing motivation and its role 
in behavior change is more challenging than assessing persons who abuse substances without 
88 
 
schizophrenia (DiClemente et al., 2008).  For example, schizophrenia research clearly indicates 
that the cognitive impairments individuals with schizophrenia (without SUD) possess make it 
difficult for them to benefit from rehabilitation programs (Silverstein, Schenkel, Valone, & 
Nuernberger, 1998; Bellack, Gold, & Buchanan, 1999), and it would stand to reason that these 
same deficits interfere with the ability of those with co-occurring SUDs and schizophrenia to 
benefit from such programs.  Perhaps not surprisingly, there have been questions as to whether 
the same cognitive impairments (perception, attention, memory, and reasoning deficits) and the 
psychotic symptoms that accompany schizophrenia impact the way in which these persons go 
about changing their substance use behavior (DiClemente et al., 2008).  Further, investigators 
have speculated that negative symptoms could make readiness-to-change measures difficult to 
use in schizophrenia because such individuals may be unable to exert the thought and effort 
required to validly complete the assessments (Carey, Maisto, Carey, & Purnine, 2001).  Since 
negative symptoms such as anhedonia and amotivation have been implicated in deficits in 
intrinsic motivational processes among persons with schizophrenia, the utility of these measures 
among this population remains questionable.  Finally, although it is probably safe to assume that 
the targeted behaviors participants’ sustained over the long-term in the studies reviewed above 
likely resulted from intrinsic goals, readiness-to-change measures do not actually account for 
whether the motivation for a person’s engagement in change processes is intrinsic (motivated for 
the desire to change) or extrinsic (motivated for money or external factors).  Given the potential 
for low intrinsic motivation base rates in co-occurring SUDs and schizophrenia to impede the 
recovery of such persons from severe patterns of substance use, a measure that is more focused 
on the deficits specific to the intrinsic motivational processes of this population is needed to 
supplement the assessment.     
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            In summary, there is evidence to suggest that deficits in intrinsic motivation may be 
related to substance use severity among persons with co-occurring SUDs and schizophrenia.  
However, a review of the investigations that have been conducted in this area of research signal 
several important limitations, including (1) narrow focus on motivational rehabilitation, (2) lack 
of samples that represent the larger population of individuals with co-occurring SUDs and 
schizophrenia, (3) inattention to the potential confounding influence of extrinsic rewards, (4) 
limited use of intrinsic motivation measures.  Such limitations highlight the need for further 
investigations that seek to comprehensively examine intrinsic motivation in larger and more 
heterogeneous samples of persons with co-occurring SUDs and schizophrenia by investigating 
its impact on outcomes of substance use severity among this population.  What follows is a brief 
overview of the measures currently used to assess intrinsic motivation deficits in persons with 
schizophrenia, which offers insight into how difficulties experienced in the measurement of this 
construct have contributed to the limited investigation of the relevance of intrinsic motivation to 
substance use severity among persons with co-occurring SUDs and schizophrenia.  
5. Intrinsic Motivation Measurement in Schizophrenia 
 Intrinsic motivation has been a widely studied construct in behavioral neuroscience and 
social psychology for the past several decades, and recently has been recognized as a potential 
key construct for understanding the pervasive patterns of substance use severity among persons 
with co-occurring SUDs and schizophrenia.  Unfortunately, many of the assessments used in 
dual diagnosis research do not provide direct measures the construct of intrinsic motivation, and 
only recently have investigators begun to develop ways of measuring intrinsic motivation deficits 
in schizophrenia.  This section presents a brief overview of intrinsic motivation measurement as 
applied to schizophrenia, which both identifies the few existing measurement techniques for 
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persons with schizophrenia and points to the potential for using a cross-situational measure of 
intrinsic motivation that has been validated among those with the disorder to persons with co-
occurring SUDs and schizophrenia.  This intrinsic motivation measure may provide a promising 
supplement to the readiness-to-change assessments used in dual diagnosis treatment.  
 To date, the majority of the measures attempting to assess intrinsic motivation in 
schizophrenia have made use of self-report measurement strategies.  For example, Barch, 
Yodkovik, Sypher-Locke, and Hanewinkel (2008) recently examined the integrity of intrinsic 
motivation among persons with schizophrenia using a reliable and valid self-report measure of 
intrinsic motivation for healthy individuals, the Motivational Trait Questionnaire (MTQ; 
Heggestad & Kanfer, 2000; Kanfer & Ackerman, 2000; Hinsz & Jundt, 2005).  Prior to Barch 
and colleagues’ (2008) application of the MTQ to schizophrenia, it was used to assess the 
intrinsic motivation of business professionals for carrying out competitive mastery goals in the 
workplace.  Since up to 80% of individuals with schizophrenia are unable to work (Bond & 
Drake, 2008), it is unclear whether this measure can capture the motivational processes by which 
people with schizophrenia adapt and change their behaviors.  Consequently, the MTQ may not 
capture the aspects of intrinsic motivation relevant to understanding intrinsic motivation in 
schizophrenia.  In addition, even if the MTQ can assess motivation for (putatively) pleasurable 
tasks, such activities are limited in scope to learning and work-related behavior dimensions of 
intrinsic motivation (performance), and do not account for the curiosity and purpose dimensions 
of the construct.  Within the context of these considerations, such researchers found that work 
statements from the MTQ tapped aspects of intrinsic motivation relevant to work function in the 
disorder—personal mastery self-reports in the disorder were related to work behavior, with 
higher personal mastery being associated with being gainfully employed (Barch et al., 2008).  
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Although the MTQ is limited in its scope and application to persons with schizophrenia, the 
constructs tapped by this measure assess at least one relevant domain of intrinsic motivation.
 Another self-report, the Intrinsic Motivation Inventory for Schizophrenia Research (IMI-
SR) was designed to gauge the central motivational structures as pertinent to cognitive task 
engagement, skill acquisition, treatment compliance, and remediation outcome (Choi & Medalia, 
2010).  The instrument was developed from the original IMI (Ryan, 1982), comprising 6-
subscales and 54 total items that gauge subjective experiences of interest/enjoyment, effort, 
value/usefulness, pressure/tension, relatedness, and perceived choice ( “I enjoy doing this very 
much,” I think I am pretty good at this activity”) (Choi et al., 2009).  Although the original scale 
has been tailored for a wide range of tasks in nonpsychiatric samples (college students, athletes, 
etc.), this was the first psychometric adaptation to a neuropsychiatric population.  Results 
revealed a final 21-item questionnaire with 3 domains relevant to motivation for treatment 
(interest/ enjoyment, perceived choice, value/ usefulness).  Additionally, the IMI-SR possessed 
good internal consistency (α = .92) and test-retest reliability (interclass correlation coefficient = 
.77).  Although the IMI-SR seems to be a viable measure for assessing intrinsic motivation 
among persons with schizophrenia, its utility is limited to studies of cognitive remediation or 
social disability among those with the disorder, and its cross-situational applicability has yet to 
be determined.  Unfortunately, here too, the IMI-SR appears to be primarily focused on one to 
two (performance and purpose) dimensions of intrinsic motivation, yielding little information 
about the curiosity dimensions of the construct.   
  Recently, Nakagami and colleagues (2008) developed a promising new instrument to 
gauge intrinsic motivation deficits in schizophrenia. This measure is premised on a conceptual 
definition of intrinsic motivation that accounts for the behaviors that people that carry out 
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because of the positive feelings associated with performing actions in the absence of extrinsic 
rewards (Deci & Ryan, 2007).  Such a measure operationalizes the intrinsic motivation construct 
by taking the sum of theoretically pertinent intrapsychic deficit items (i.e., purpose, motivation, 
and curiosity) from the clinician-rated Quality of Life Scale (QLS; Heinrichs et al., 1984). Since 
this measure is not dependent on (predetermined) treatment specific goals or targeted outcomes 
(Nakagami et al., 2008), it is particularly ideal for observing naturalistic prospective changes in 
the relationship between intrinsic motivation and substance use severity among persons with 
comorbid SUD and schizophrenia in this dissertation.  Psychometric evaluations of this intrinsic 
motivation instrument have shown that it demonstrates (𝛼 = . 74) moderate levels of internal 
consistency in community patients with schizophrenia (Nakagami et al., 2008).  Subsequent 
investigations employing this instrument have not only confirmed a long history of evidence 
indicating that persons with schizophrenia possess deficits in intrinsic motivation (i.e., Barch, 
2004), but have also shown that such deficits impede the ability of those with the disorder to 
generate internal drives to sustain behavior changes absent external support (Nakagami et al., 
2008; Yamada et al., 2010; Nakagami 2010).  In addition, evidence from the dual diagnosis field 
has shown that such deficits can disengage intrinsic motivational processes when persons with 
comorbid SUD and schizophrenia try to generate their internal drives toward reducing substance 
use severity (i.e., Drake et al., 2008; Horsfall et al., 2009).  Unfortunately, to date, no studies 
have extended validation of this measure to persons with schizophrenia and comorbid SUD or 
sought to apply it for examining the relationship between prospective naturalistic changes in 
intrinsic motivation and changes in substance use severity among this population. Consequently, 
extending validation of this instrument may not only provide greater accuracy to estimating the 
base rates of intrinsic motivation deficits that are potentially unique to comorbid SUD and 
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schizophrenia, but may also provide greater insight into the relationship between intrinsic 
motivation deficits and substance use severity among this population.   
6. Evidence to the Validity of the Intrinsic Motivation Measure Developed by Nakagami 
and Colleagues (2008) in Schizophrenia  
 While the previous section highlighted the few measures that have been used to estimate 
deficits in intrinsic motivation among persons with schizophrenia, not one of these instruments 
has been validated in schizophrenia and comorbid SUD.  This section puts forth evidence to the 
validity of the instrument developed by Nakagami and colleagues (2008) to assess intrinsic 
motivation deficits in schizophrenia, and then advances the reasons for which such an instrument 
is appropriate to utilize for predicting change in substance use severity among persons with 
schizophrenia and comorbid SUD.  
 Two recent investigations by Nakagami and colleagues (2008, 2010) support the validity 
of using this intrinsic motivation instrument among community patients with schizophrenia, as 
well as using the instrument to predict prospective naturalistic changes in functioning in this 
population.  This instrument is premised on a conceptual definition of intrinsic motivation 
acknowledging that behaviors are carried out because of the positive feelings that are associated 
with an action in the absence of any tangible reward (Deci & Ryan, 2007), and an operational 
definition of intrinsic motivation that is based on the sum of theoretically relevant items (i.e., 
purpose, motivation and curiosity) from the QLS (Heinrichs et al., 1984). These conceptual and 
operational definitions of the construct are consistent with the deficits in intrinsic motivation that 
are potentially unique to persons with schizophrenia, which tend to impede the ability of such 
persons to carry out their goals and plans, particularly in the areas of interest and drive across 
various life domains, including social and occupational role functioning (Nakagami et al., 2010).  
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These life domains are also profoundly and negatively affected by the pervasive patterns of 
substance use among persons with comorbid SUD and schizophrenia (Drake et al., 2008).  Since 
this dissertation examines whether prospective naturalistic changes in the intrinsic motivation 
deficits unique to schizophrenia predict changes in substance use severity, rather than whether 
the readiness such persons have to change their substance use behaviors predict changes in 
substance use severity, it is relevant to extend validation of the instrument developed by 
Nakagami and colleagues (2008) to this sample of schizophrenia and comorbid SUD patients.  
 As mentioned previously, prior psychometric evaluations of the intrinsic motivation 
measure developed by Nakagami and colleagues (2008) showed that the instrument demonstrates 
moderate levels of internal consistency (α = .74) among community patients with schizophrenia. 
These investigators then used this instrument to estimate intrinsic motivation in a cross-sectional 
examination, which provided the first data on the relationships between neurocognition and 
intrinsic motivation, and between intrinsic motivation and psychosocial functioning in a sample 
of community patients with schizophrenia.  Results revealed that both of these associations 
reflected a large effect size (Pearson r > .5, using Cohen’s [1998] criterion), such that intrinsic 
motivation had a strong and positive association with both neurocognition and psychosocial 
functioning.  Since the results of this cross-sectional study suggest that relations exit among 
these variables, but cannot provide an indication of how such variables are related or change over 
time, Nakagami and colleagues (2010) subsequently sought to examine the prospective 
relationships among intrinsic motivation, neurocognition, and psychosocial functioning in 
schizophrenia.  Results showed that intrinsic motivation is dynamic over time in community 
patients with schizophrenia, and also showed that prospective changes in intrinsic motivation 
were a salient predictor of changes in psychosocial functioning (functional disability) among 
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community patients with schizophrenia over the 1-year study.  Such studies show that the 
intrinsic motivation instrument developed by Nakagami and colleagues (2008) provides valid 
estimates of intrinsic motivation deficits in schizophrenia, and is a valid longitudinal predictor of 
change in functional disability as well as other theoretically relevant outcomes among this 
population.  Given this evidence in addition to the broad cross-situational applicability of this 
instrument, this measure is likely to be valid in schizophrenia and comorbid SUD may provide 
greater accuracy in estimating the base rates of such deficits among those with these conditions, 
and could provide greater insight into whether prospective changes in intrinsic motivation 
(improvement) predict changes in substance use severity (reduction) among this population.  
This dissertation study seeks to confirm previous evidence regarding the psychometric properties 
of this measure in sample of persons with comorbid SUD and schizophrenia, followed by 
conducting a longitudinal study of the relationship between prospective changes in intrinsic 
motivation to substance use severity among this population.  
   
D.  PROPOSED STUDY AND HYPOTHESES 
 This study proposes to conduct a longitudinal investigation of the relationship between 
prospective naturalistic changes in intrinsic motivation and changes in substance use severity 
among persons with co-occurring SUDs and schizophrenia (n = 535 at baseline; n = 219 at 6-
months; n = 150 at 1-year), and then seeks to examine whether this relationship varies across 
genders.  Such an examination will be carried out by using secondary data that was collected as 
part of the CATIE study (Liberman et al., 2005), and begins with extending the validation of a 
promising new measure of intrinsic motivation to this population. 
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1. Study Context 
 This research is embedded within the context of the CATIE study, a multi-site multi- 
phase randomized controlled trial comparing the effectiveness of first and second generation 
antipsychotic medications (as measured by the discontinuation of an assigned study treatment at 
any time, for any reason)  among persons with schizophrenia (Liberman et al., 2005).  The 
rationale, design, and methods of the CATIE trial have been extensively described in prior 
reports (Stroup et al., 2003; Swartz et al., 2003; Rosenheck, Doyle, Leslie, & Fontana, 2003; 
Davis, Koch, Davis, & LaVange, 2003). Thus, this section briefly discusses the way in which the 
study sample for this research was recruited, enrolled, and selected for the purpose of conducting 
a secondary analysis of the CATIE data.  Data were collected for the CATIE study from January 
2001 to December 2004, with 1894 potential participants being screened for the trial from 57 
clinical sites across the United States (Liberman et al., 2005).  As CATIE sought to recruit a 
sample that would broadly represent those with schizophrenia that are seen across various 
clinical settings, few exclusion criteria were employed.  These efforts resulted in a total of 1493 
persons with schizophrenia being initially randomly assigned to different study medications at 
Phase 1, which is shown in further detail in Figure 2, and treated for up to 18-months (Liberman 
et al., 2005).  This trial was designed such that those who discontinued the medication to which 
they were assigned in Phase 1 for any reason moved to the next phase to receive a new treatment 
(i.e., Phase 2, followed by Phase 3). The focus on this study is on Phase 1, which contains the 
largest sample size and least amount of attrition. While such participants were being followed on 
these treatments, a broad array of assessments were administered at baseline, 6-, 12-, and 18-
month follow-up periods to capture meaningful information with regard to their cognitive and 
functional status; symptoms and quality of life; service utilization and use of substances.   
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Figure 2. Treatment Phase 1 of the CATIE Trial 
 
 The present study reports data on 535 persons with co-occurring SUDs and schizophrenia 
who enrolled in the CATIE study at baseline, subsequently underwent Phase 1 randomization, 
and were followed for up to 1-year of treatment.  Of the 535 individuals with co-occurring SUD 
and schizophrenia who enrolled in CATIE at baseline, 219 were available at the 6-month follow-
up, and 150 were available at the 1-year follow-up. Using cross-sectional and longitudinal data 
collected on these individuals during their participation in CATIE, this study seeks to investigate 
the impact of intrinsic motivation on substance use severity in schizophrenia and its patterns in 
men and women. While most of the research that has been conducted in this area has examined 
such effects among this population within the context of a motivational rehabilitation program, 
this study investigates the impact of naturalistic prospective changes in intrinsic motivation on 
substance use severity in a sample of persons with schizophrenia and comorbid SUD, who were 
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not seeking treatment for substance use or substance use severity.  In this regard, this research 
makes use of the longitudinal context of the CATIE study to first conduct a robust examination 
of the link between changes in intrinsic motivation and changes in substance use severity, and to 
then examine whether such a relationship varies across genders. The selections that were used to 
derive the sample for carrying out the aims, hypotheses, and analytic techniques for conducting 
this secondary analysis of the CATIE data is presented in Figure 3.     
 
 
Figure 3. Selection of participants with co-occurring SUDs and schizophrenia from the CATIE 
study to derive the sample for the present investigation 
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2. Aims and Hypotheses 
 Using data from the CATIE trial, this research aims to examine the longitudinal impact of 
intrinsic motivation on substance use severity outcomes among persons with co-occurring SUDs 
and schizophrenia and its patterns in men and women, after extending validation of a promising 
measure of intrinsic motivation to this population. The specific aims and associated hypotheses 
include: 
Aim #1: Validate the factor structure of the intrinsic motivation measure.  Intrinsic motivation is 
conceptualized in this research as behavior change processes that are carried out because of the 
positive feelings associated with an action in the absence of any tangible reward, or actions that 
are taken for their own sake that do not require any external supports or reinforcement to be 
initiated or sustained.  Recently, Nakagami, Xie, Hoe, and Brekke (2008) used a novel cross-
situational method to validate the construct in community patients with schizophrenia (Nakagami 
et al., 2008; Yamada, Dinh, Barrio, & Brekke, 2010; Nakagami et al., 2010), which gauges 
intrinsic motivation by summing theoretically pertinent intrapsychic deficit items from the 
Quality of Life Scale (Heinrichs et al., 1984), probing purpose, motivation, and curiosity.  This 
measure of intrinsic motivation has not yet been applied to comorbid SUD and schizophrenia.  
As such, this analytic aim will be addressed by subjecting the total pool of 7-items from the 
intrapsychic deficit subscale to an exploratory factor analysis.  It is expected that the results of 
this analysis will show that the 3-items of purpose, motivation, and curiosity load together on 
one factor and form a distinct factor apart from the other 4-items of the intrapsychic deficit 
subscale.  This intrinsic motivation measure is also expected to yield estimates considered to be 
indicative of a minimally adequate internally consistent scale (α ≥ .70), and demonstrate at least 
minimally sufficient levels of retest reliability across study assessment periods (r  ≥ .40) 
100 
 
(Nunnelly, 1978), when applied to this sample of individuals with schizophrenia and comorbid 
SUD. 
Hypotheses include: 
H1a: The 3-items of purpose, motivation, and curiosity (intrinsic motivation) form 
a distinct and coherent factor apart from the other 4-items of the intrapsychic 
deficit subscale. 
H1b: The 3-item intrinsic motivation measure demonstrates acceptable levels of 
internal consistency (α  ≥  .70) when applied to persons with schizophrenia who 
have comorbid SUDs.  
H1c: The 3-item measure of intrinsic motivation demonstrates at least minimally 
sufficient levels of retest reliability (r  ≥ .40) across study assessment periods. 
Aim #2: Examine the cross-sectional relationships between intrinsic motivation, gender, and 
substance use severity.  Baseline data (n = 535) will be used to compute correlation matrices and 
hierarchical linear regression analyses will examine the zero-order and unique associations 
(adjusting for negative symptoms and neurocognition) between intrinsic motivation and 
substance use severity.  Baseline data will also be used to compute independent sample t-tests 
(two-tailed) for examining the bivariate relationships between gender and intrinsic motivation 
and gender and substance use severity.  
Hypotheses include: 
H2a: Intrinsic motivation is significantly, negatively correlated with substance use 
severity at baseline. 
H2b: Intrinsic motivation is significantly, negatively correlated with substance use 
severity at baseline, after adjusting for the potentially confounding effects of 
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neurocognition and negative symptoms.  
H2c: Men demonstrate significantly greater degrees of substance use severity compared to 
women at baseline. 
H2d: Men exhibit significantly greater deficits in intrinsic motivation compared to women 
at baseline. 
 
Aim #3:  Examine the impact of intrinsic motivation on the1-year outcomes of substance use 
severity, and then investigate the impact of gender on the longitudinal association between 
intrinsic motivation and substance use severity.  This analytic aim will be carried out using a series 
of individual growth curve models.  Unconditional models will first be fit to test whether or not 
there is variability in the initial status and the rates of change in the 1-year trajectories of substance 
use severity among participants. Analysis will proceed by expanding these unconditional models 
to conditional growth curve models to examine the longitudinal contribution of changes in 
intrinsic motivation to changes in substance use severity over the 1-year study.  Conditional 
models will then be expanded to investigate the moderating effects of gender on these relations 
such that an interaction between intrinsic motivation and gender predicts the initial level and the 
rates of change in the 1-year trajectories of substance use severity among participants.  All growth 
curve models will control for relevant demographic and clinical confounders. 
Hypotheses include: 
H3a: Participants exhibit, on average, significant improvement in substance use severity 
over the 1-year study period. 
H3b: Improvement in intrinsic motivation is associated with significant reductions in 
substance use severity over the 1-year study period. 
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H3c: Women demonstrate a stronger association between improvement in intrinsic 
motivation and greater reductions in substance use severity than men over the 1-year 
study period. 
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III. METHOD 
 
 This research makes use of a secondary analysis of data that were collected as part of the 
CATIE trial. To carry out the aims and hypotheses proposed in this dissertation study, a unique 
dataset is created to answer several cross-sectional and longitudinal research questions regarding 
the significance of intrinsic motivation deficits to substance use severity in a large heterogeneous 
sample (n = 535 at baseline; n = 219 at 6-months; n = 150 at 1-year) of persons with comorbid 
SUD and schizophrenia.  Such a dataset will first be used to examine the psychometric properties 
of a promising new measure of intrinsic motivation that has yet to be validated among persons 
with comorbid SUD and schizophrenia.  This data set will then be used to conduct rigorous, 
cross-sectional, and longitudinal examinations of the relationship between deficits in intrinsic 
motivation and substance use severity among participants with comorbid SUD and schizophrenia.  
Finally, this dataset will be used to conduct cross-sectional and longitudinal examinations of the 
moderating impact of gender on the relationships between intrinsic motivation and substance use 
severity.  The contents of this chapter provide a detailed description of the participants, design, 
and measures that were used as part of the CATIE trial that not only help address such questions, 
but also comprise the proposed analytic methods for carrying out the aims of this research.  
 
A. PREVIOUS WORK SUPPORTING THE RATIONALE FOR THE PROPOSED 
DISSERTATION STUDY  
 My previous work supports various decisional aspects, as well as the rationale for a study 
proposing to examine the impact of intrinsic motivation on substance use severity and its patterns 
across genders in adults with schizophrenia and comorbid SUD.  Since I previously found that a 
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considerable proportion (44%) of CATIE participants did not accurately self-report their drug 
use compared to biological assays (Bahorik et al., 2013), the clinician-rated alcohol use scale and 
drug use scale will be used to measure current substance use severity status and change (as a 
scaled variable) in substance use severity for this dissertation.  Of note, the most consistent 
predictor of under-reported drug use in the aforementioned study was cognitive impairment, 
which I thought may help explain the puzzling results of studies demonstrating improved 
cognitive function in schizophrenia patients using drugs, or at least those who self-report using 
drugs (see Yücel et al., 2010). Perhaps not surprisingly, when biological assays were used to 
confirm drug use status in a subsequent investigation, few cognitive differences emerged 
between CATIE participants using and not-using drugs (Bahorik et al., 2014).  Since such results 
largely suggested that substance misusing schizophrenia patients (SMS) do not exhibit superior 
cognition compared to their non-substance misusing counterparts, I then sought to determine the 
degree to which substance use severity impacts cognition in an SMS sample (selected with at 
least moderate levels of alcohol or cannabis severity).  This study revealed that moderate levels 
of alcohol severity were associated with worse emotion processing than high levels of alcohol 
severity, and no significant associations were observed with regard to moderate or high levels of 
cannabis severity (Bahorik et al., 2014).  Despite the fact that such findings showed few 
differences between SMS patients with high or moderate levels of alcohol or cannabis severity, 
the deficits observed are known to create difficulties when such patients try to form social 
relationships, negotiate out of dangerous situations, and build intrinsic motivation to reduce the 
severity of substance use (Drake et al., 2008).  Furthermore, in another investigation, I found 
noteworthy differences in the patterns of alcohol and cannabis between men and women with 
schizophrenia (i.e., Bahorik, Newhill & Eack, 2013). The outcomes of this study suggest the 
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potential for the mentioned difficulties to vary across genders among this population.  All of 
these factors may have an impact on the severe and pervasive substance use patterns observed in 
schizophrenia; therefore studies are needed that build from this work by investigating the role 
factors other than cognition may have in precluding this population from achieving abstinence 
and recovery.  The study proposed in this dissertation seeks to build from my previous work by 
examining relations between prospective changes in intrinsic motivation to changes in substance 
use severity and the degree to which such a relationship varies across genders in a larger and 
more heterogeneous sample of participants with comorbid SUD and schizophrenia.  
 
B.  STUDY DESIGN AND PARTICIPANTS 
 This research is conducted within the context of the CATIE study (Liberman et al., 
2005), which evaluated various functional, clinical, and substance use outcomes among persons 
with chronic and recurrent forms of schizophrenia participating in a clinical trial comparing the 
effectiveness of first and second generation antipsychotic medications (Stroup et al., 2003; 
Liberman et al., 2005; Stroup et al., 2010).  This study made use of a longitudinal, randomized-
controlled design where participants were randomly assigned to antipsychotic treatment under 
double-blind conditions, and followed for up to 18-months.  Patients were recruited from 57 
settings across the U.S., including 16 university clinics, 10 state mental health agencies, 7 
Veterans Affairs medical centers, 6 private nonprofit agencies, 4 private-practice sites, and 14 
mixed-system sites to participate in the CATIE study (Stroup et al., 2003; Stroup et al., 2010).  
Individuals were eligible for enrollment if they had a diagnosis of schizophrenia, as confirmed 
by the Structured Clinical Interview (SCID; First, Spitzer, Gibbon, & Williams, 1996) for DSM-
IV disorders, and were between the ages of 18 and 65 (Liberman et al., 2005).  Persons older 
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than 65 were excluded from the CATIE study to avoid potential confounds in physical and 
cognitive decline that can occur in aging patients with schizophrenia (Stroup et al., 2010).  
Persons in their first episode of schizophrenia (i.e., those who first began antipsychotic drug 
treatment for psychosis within the previous 12-months and had psychotic symptoms for less than 
3 years) were also excluded, in order to avoid the potential bias of high antipsychotic medication 
responsiveness that occurs in these patients at relatively low dosages. Persons with refractory 
illness were excluded (i.e., resistant to treatment), because their severe illness was thought to 
preclude the detection of treatment effectiveness. Women who were pregnant or breastfeeding; 
those who had known contraindications to study medications assignments; and/or those with 
acutely unstable medical conditions were also excluded.  No further exclusion criteria were 
employed as part of the CATIE study to make the results generalizable to the broad group of 
persons with chronic and recurrent forms of schizophrenia for whom a change in medications was 
appropriate due to incomplete symptom remission or adverse effects (Stroup et al., 2003; Stroup 
et al., 2010).  Finally, this research selected CATIE study participants who met DSM-IV criteria 
for a co-occurring SUD and schizophrenia, as confirmed by the SCID to carry out the aims, 
hypotheses, and methods proposed herein. As indicated in Figure 2 (see Section 2.D.1), such 
selection procedures resulted in a 535 participants with co-occurring disorders at baseline, 219 at 
6-months, and 150 at 1-year who comprised the baseline and follow-up samples for this research.  
 
C.  MEASUREMENTS 
 To achieve the aims of this research and examine the longitudinal impact of intrinsic 
motivation on substance use severity and its patterns in men and women, a combination of self- 
report and clinician-rated instruments were used to assess intrinsic motivation (independent 
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variable), substance use severity (dependent variable), and gender (moderator variable).  The 
moderator variable in Aim 3, gender, was recorded as part of a demographic questionnaire that 
was administered during the screening procedures of the CATIE study.  The instruments used to 
assess these variables included the Drug Use Scale; the Alcohol Use Scale; and the Quality of Life 
Scale (intrinsic motivation).  A summary of the measures employed for assessing the relationship 
between the independent (intrinsic motivation) and dependent variables (alcohol use severity and 
drug use severity, respectively) as part of the research conducted herein as well as the variables 
that may potentially confound this relationship (negative symptoms and neurocognition)  are 
provided in Table 1.  The psychometric properties and use of these measures among individuals 
with co-occurring SUDs and schizophrenia are discussed in further detail in the following 
sections.  
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Table 1. Study Variables and Measurement Sources 
Variable Source (Items) Calculation 
Substance Use Severity AUSa  (1 item) 
DUSc  (1 item) 
NAb 
Total Psychopathology PANSSd total (30 items) Sum of items  
P1 – P7; N1 – N7; G1 
– G16  
Negative 
Symptomatology 
PANSS negative (7 items) Sum of items  
N1 – N7  
Total Neurocognitive 
Functione  
Reasoning: based on the 64 card version of the 
WCST (perseverative error [reverse scored] 
and categories completed) and WAIS-R 
Mazes (2 items) 
Working Memory: based on visuospatial 
computerized tests of memory and the LNS 
test (2 items) 
Processing Speed: based on the Grooved 
Pegboard (dominant hand), the WAIS-R 
Digit-span test; and COWAT/category 
instances test scores (3 items) 
Vigilance: based on d´ averages from the CPT 
(3 items)  
Verbal Memory: based on scores from the 
HVLT (3 items)  
Mean of scaled items 
1– 13 
Intrinsic Motivation QLSf intrapsychic deficit subscale items of  
    purpose, motivation, and curiosity (3 items)  
Sum of items 14, 15, 
16 
Gender  Demographic questionnaire (1item)  Male = 1, Female = 2 
a AUS = Alcohol Use Scale (Drake, Mueser, & McHugo, 1996).  
b AUS/DUS scores were computed by research project clinicians during the CATIE trial; final 
scores are available for use in this research.  
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c DUS = Drug Use Scale (Drake et al., 1996).  
d PANSS = Positive and Negative Symptom Scale (Kay, Fiszbein, & Opler, 1987).  
e Total Neurocognitive Function = overall neurocognition composite. (WCST = Wisconsin Card 
Sorting Test [Heaton Chelune, Taley, Kay, & Kurtiss, 1993]; WAIS-R Mazes = Wechsler 
Intelligence Scale Mazes [Wechsler, 1991]; LNS = Letter Number Sequencing Test [Gold, 
Carpenter, Randolph, Goldberg, & Weinberger, 1997]; WAIS-R Digit-span test = Wechsler Adult 
Intelligence Scale-Revised, Digit Span Test [Wechsler, 1981]; COWAT = Controlled Oral Word 
Association Test [Benton & Hamscher, 1978]; CPT = Continuous Performance Test [Cornblatt et 
al., 1988]; HVLT = Hopkins Verbal Learning Test [Brandt, 1991]). 
f QLS = Quality of Life Scale (Heinrichs et al., 1984).  
 
1. Independent Variable: Intrinsic Motivation 
  Intrinsic motivation is conceptualized in this research as behavior change processes that 
are carried out because of the positive feelings associated with an action in the absence of any 
tangible reward, or actions that are taken for their own sake that do not require any external 
supports or reinforcement to be initiated or sustained (Deci & Ryan, 2007).  To examine the 
cross-sectional (Aim #2) and longitudinal (Aim #3) relationship between intrinsic motivation and 
substance use severity and its patterns in men and women, an approach will be used to measure 
intrinsic motivation that was recently developed by Nakagami and colleagues (2008).  Such a 
technique utilizes an operational definition of intrinsic motivation that is based on the sum of 
theoretically relevant intrapsychic deficit items from the Quality of Life Scale (QLS; Heinrichs 
et al., 1984), including purpose, motivation, and curiosity. The selection of these three items 
show face validity in terms of their focus on cross-situational phenomena in life experience such 
as goals, plans, and in areas of interest and drive (see Table 2). 
 The QLS was originally developed to assess deficit syndrome in schizophrenia (i.e., the 
presence of high negative symptoms and an absence of dysphoria), but is now widely used as a 
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proxy measure of major role functioning in clinical outcome studies in schizophrenia research 
(Swartz, 2010).  The instrument is a structured interview-based, clinician-rated measure that 
gathers information on the patient’s symptoms and functioning for the preceding 4-weeks in the 
areas of work (4-items), interpersonal relationships (8-items), community functioning (2-items), 
and intrapsychic deficits (7-items) (Heinrichs et al., 1984). The QLS consists of 21-items 
covering the previous mentioned domains, each of which is rated on a 7-point scale (0 to 6) and 
then summed, with lower scores reflecting more severe impairment of the function in question. 
The model on which the QLS is based had conceptualized the intrapsychic domain as being at 
the core of the deficit syndrome in schizophrenia.  In this regard, these 7-items are intended to 
elicit clinical judgments in the dimensions of cognition, conation, and affectivity such that the 
patient’s sense of purpose, motivation, curiosity, ability to experience pleasure, and emotional 
interactions are assessed.  Given this context, recent studies have put forth theoretically driven 
and empirically supported evidence showing that particular aspects of these intrapsychic deficits 
lie at the core of another feature of schizophrenia—deficits in intrinsic motivation (Nakagami et 
al., 2008).    
 Such investigations have assessed deficits in intrinsic motivation among community 
samples of patients with schizophrenia by using the sum of 3-items (purpose, curiosity, and 
motivation) from the intrapsychic deficit subscale of the QLS (Nakagami et al., 2008; Yamada et 
al., 2010; Nakagami et al., 2010).  Recent psychometric evaluations of this inventive technique 
indicate that the 3-items of purpose, curiosity, and motivation load together on one factor, and 
that the measure demonstrates acceptable levels of internal consistency (α = .74) in community 
schizophrenia patients without comorbid SUD (Nakagami et al., 2008; Yamada et al., 2010).  
Further, this measure of intrinsic motivation has previously shown good discriminant construct 
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validity by demonstrating little overlap with the negative symptom items of the Brief Psychiatric 
Rating Scale (BPRS; range of r = .12 to .19) (Nakagami et al., 2008).  Taken together, such 
findings suggest that the intrinsic motivation construct assessed by this measure is a construct 
unique from negative symptoms, that such a construct is premised on a theoretically driven and 
empirically supported factor structure, and is predictive of theoretically relevant outcomes in 
community patients with schizophrenia.  However, despite the potential of using this measure for 
assessing intrinsic motivation deficits in schizophrenia, it has not yet been examined among a 
sample of persons with co-occurring SUDs and schizophrenia.  
 
Table 2. Pertinent Intrapsychic Deficit items from the Quality of Life Scale that comprise the 
proposed Measure of Intrinsic Motivation 
Item Suggested Probes Rating Anchors 
   
Sense of Purpose:  
 
To rate the degree to 
which the person posits 
realistic, integrated 
goals for his/her life.  
What makes life worth living for you? 
 
Do you think much about the future? 
 
Have you set any goals for yourself? 
 
What plans do you have for your life 
over the next year?  
0 
 
1 
     
 
 
No plans or plans are 
bizarre, delusional or 
grossly unrealistic.  
  2 
     
3 
Has plans, but they are 
vague, not 
integrated, with the 
person’s life.  
 
  4 
 
5 
 
Realistic plans for 
next year or so but 
little integration into 
long-range life plan.  
 
  6 Realistic plans, 
short/long range. 
 
Degree of Motivation:  
 
To rate the extent to 
How motivated have you been?  
 
Have you had much enthusiasm, 
0 
 
1 
Lack of motivation 
significantly interferes 
with basic routine.  
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which the person is 
unable to initiate or 
sustain goal directed 
activity due to 
inadequate drive.  
energy, and drive?  
 
Have you tended to get into a rut?  
Have you tended to put things off?  
 
 
    
 
 
  2 
 
3 
 
 
Able to meet basic 
maintenance demands 
of life, but lacks 
motivation to make 
accomplishments.  
 
  4 
 
5 
 
     
 
 
Able to meet routine 
demands of life, but 
lack of motivation 
results under-
achievement in some 
areas.  
  6  
Curiosity:  
 
To rate the degree to 
which the person is 
interested in his/her 
surroundings and 
questions those things 
he/she doesn’t 
understand.  
How often have you seen or heard 
about something that you wanted to 
know more about or understand 
better?  
 
What sorts of things? 
 
How curious about things have you 
been?  
0 
 
1 
 
 
    
 
    
 
Very little curiosity or 
interest in new topics 
or events.  
 
  2 
    
3 
 
Some sporadic 
curiosity, but not 
pursued in thought or 
action. 
 
  4 
 
5 
    
 
 
Some curiosity and 
time spent thinking 
about topics or 
interest and some 
actual effort to learn 
about them.  
 
  6 Curiosity about a 
number of topics and 
effort to learn more 
about some of them.  
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Note.  The QLS consists of 21-items, each of which is clinician rated on a 7-point scale. Lower 
scores reflect more severe impairment of the function in question.  
 
 
2. Dependent Variable: Substance Use Severity 
Substance use severity is conceptualized in this research as pervasive patterns of drug 
and/or alcohol use that can profoundly and negatively impact symptom and functional outcomes. 
To examine the relationships among intrinsic motivation, gender, and substance use severity 
(Aim #2 and #3), these indicators of substance use severity are assessed using the clinician-rated 
Alcohol Use Scale and the Drug Use Scale (AUS, DUS; Drake et al., 1990; Mueser et al., 1995; 
Drake, Mueser, & McHugo, 1996; Mueser et al., 2003). The AUS and DUS are parallel 5-point 
(1-item) behaviorally anchored scales, where each rating anchor corresponds with DSM criteria 
for substance abuse/ dependence (see Table 3), and higher scores indicate greater degrees of 
substance use severity (Mueser et al., 2003). For example, a rating of 1 corresponds to no use 
(i.e., abstinence); a rating of 2 parallels substance use without evidence of abuse or dependence 
(i.e., use of drug or alcohol, but no evidence of persistent or recurrent problems in psychosocial 
domains of functioning stemming from such use); a rating of 3 corresponds to meeting criteria 
for abuse, but not dependence (i.e., use resulting in problems with social relationships, role 
functioning, and/or legal problems); a rating of 4 indicates that the patient meets criteria for 
dependence (i.e., either non-physiological or psychological); and a rating of 5 suggests that in 
addition to meeting criteria for dependence, the patient’s use has been so severe that it has 
resulted in institutionalization (i.e., repeated hospitalizations, emergency room visits, or time 
spent incarcerated). Clinicians complete the AUS and DUS during brief (15 to 45 minutes) face-
to-face interviews with patients by rating the worst period of drug (DUS) and/ or alcohol (AUS) 
severity over the past 6-months (Mueser et al., 2003).  During the process of rating the AUS and 
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DUS, clinicians assess the functional impact (or lack thereof) drug and/or alcohol use has across 
patients’ social (i.e., family problems, housing instability, social isolation, difficulty budgeting 
funds, and legal status), physical (i.e., hygiene problems, change in physical appearance, health 
problems, and injuries), and psychiatric (i.e., treatment non-adherence, suicidal thoughts, 
cognitive impairment, symptom relapses, sudden mood shifts, and appearance of new symptoms) 
domains of functioning.  If the patient is in an institution, then the reporting period for drug 
(DUS) and/ or alcohol (AUS) severity for the time period considered is that (time) preceding 
institutionalization. Following the patient interview, clinicians then garner information about the 
patient’s drug and/or alcohol use from collateral contacts, group home staff, and family members 
(if available and per the patient’s consent). While patient responses (i.e., self-report) provide the 
basis of the 1-5 rating on the AUS and DUS, clinicians consider any existing records (i.e., 
medical release, psychiatric hospitalization records) and available collateral information in the 
final rating for the 6-month reporting period (Mueser et al., 2003).   
The AUS and DUS have been widely used among persons with co-occurring SUDs and 
schizophrenia for several decades (Drake et al., 1990), and have accumulated a considerable 
amount of psychometric validation (Carey, Cocco, & Simons, 1996). Drake and colleagues 
found excellent sensitivity (95%) and specificity (100 %) for ratings of alcohol use for the 
previous 12-months among outpatients with schizophrenia, compared with diagnoses of alcohol 
abuse or dependence made in clinical consensus (Drake et al., 1990). Notably, the AUS was the 
most accurate single instrument used in their study, which also included a self-report and a 
diagnostic interview (Drake et al., 1990).  Ratings covering 6-month periods have shown good 
inter-rater reliability (range of ICC = .80 to .94 for AUS; range of ICC = .93 to .95 for DUS) and 
retest reliability (ICC = .92) among outpatient samples of persons with schizophrenia and 
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comorbid SUD (Drake et al., 2006; Drake, et al., 1990).         
       
Table 3. Alcohol Use Scale and Drug Use Scale Probes, Ratings, and Anchors 
Rating Scale AUS/ DUS Probesa Rating Anchors 
   
Abstinence:  
 
 
Have you used alcohol/ drugs 
over the past 6-months?  
1 
     
 
 
Client has not used alcohol (AUS)/ 
drugs (DUS) over the past 6 months.  
Use without 
Impairment:  
 
Have you had family problems 
stemming from alcohol/ drug 
use?  
 
Have you encountered physical 
injury stemming from alcohol/ 
drug use?  
 
2 
     
Client has used alcohol (AUS)/ drugs 
(DUS) over the past 6-months, but 
there is no evidence of persistent or 
recurrent problems in social 
functioning, legal status, role 
functioning, psychiatric status, or 
physical problems related to use, and 
no evidence or recurrent dangerous 
use. 
Abuse:  
 
Has recurrent alcohol/ drug use 
led to patterns of disruptive 
behavior and housing problems?  
 
Have serious problems stemming 
from alcohol/ drug use persisted 
for at least 1 month?  
 
 
3 
 
 
Client has used alcohol (AUS)/ drugs 
(DUS) over the past 6-months, and 
there is evidence of persistent 
problems in social functioning, legal 
status, role functioning, psychiatric 
status, or physical problems related to 
use, or evidence of recurrent 
dangerous use.  
Dependence: Has drinking/ drug use caused 
you to stop partaking in non-
drinking/ non-drug related 
social activities?  
 
Have you experienced needing to 
drink/ use a lot more drugs to 
get high (marked tolerance)?  
 
Do you have problems with 
sweating, hands shaking, racing 
heart, agitation (withdrawal 
symptoms)?  
 
Do these problems go away 
when you drink or use drugs? 
4 Client meets criteria for abuse, plus at 
least three of the following: (1) greater 
amounts of use than intended; (2) 
much of time spent obtaining or using 
alcohol (AUS)/ drugs (DUS); (3) 
frequent intoxication or withdrawal 
interferes with other activities; (4) 
important activities given up because 
of alcohol/ drug use; (5) continued use 
despite knowledge of alcohol  (AUS)/ 
(DUS) drug-related problems; marked 
tolerance; (6) withdrawal symptoms; 
(7) or alcohol (AUS)/ drug (DUS) 
taken to relieve or avoid withdrawal 
symptoms.  
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Dependence with 
Institutionalization:  
 
 
Have you been hospitalized or 
incarcerated in the past 6-
months?   
5 
 
 
    
 
 
Client meets criteria for alcohol (AUS)/ 
drug (DUS) dependence, plus related 
problems are so severe that they make 
noninstitutionalized living difficult.   
Note.  AUS = Alcohol Use Scale; DUS = Drug Use Scale. The AUS and DUS are 1-item parallel 5-
point behaviorally anchored scales that correspond to the patient’s most severe use of alcohol or 
drugs over a 6-month period from direct observation of behavior, patients self-report, and collateral 
sources. Drug Use Scale substances include: cannabis, cocaine, amphetamine, hallucinogens, and/or 
phencyclidine. Nicotine/ Tobacco products are not included in the DUS composite rating.  
a To reduce visual clutter and redundant information, only select AUS/ DUS probes are presented.  
 
3. Moderator Variable: Gender 
 To examine gender differences in the cross-sectional relationship between intrinsic 
motivation and substance use severity (Aim #2), and whether gender moderates the longitudinal 
relationship between intrinsic motivation and substance use severity (Aim #3), data on gender 
are garnered from a demographic form that was administered during the screening procedures of 
the CATIE study. This screening form is a questionnaire that queries information about the 
patient’s age, gender, race, ethnicity, illness severity, chart diagnosis, and probable comorbidity 
status (Stroup et al., 2010). The questionnaire consists of 11-items covering the aforementioned 
areas, with the patient’s gender being categorized as male or female by the clinician 
administering the form (Stroup et al., 2010).   
 
D.  PROCEDURES  
 Upon recruitment and study enrollment, the 535 individuals with co-occurring SUDs and 
schizophrenia selected for this research were randomly assigned to receive up to 18-months of 
antipsychotic treatment (Figure 1; Figure2).  Prior to the initiation of treatment, demographic 
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information was initially garnered from these participants, and then such participants were 
assessed using the previously described measure of intrinsic motivation (as assessed via the 
QLS) and substance use severity.  Participants then began the medication to which they were 
randomly assigned in treatment Phase 1, and were assessed every 6-months for up to 18-months 
using the same instruments.  Medication compliance, dosage, and side-effects were closely 
monitored for all participants throughout the course of the study. This research only makes use of 
baseline, 6-month follow-up, and 12-month follow-up data from the CATIE study, as the most 
data are available for the first year of the study.  For this secondary analysis of these data, only 
assessment information on the sample of 535 participants who remained in Phase 1 for the 12-
month duration of the study is reported.  This decision was made to avoid introducing new 
treatment effects (i.e., treatment phase 2 and phase 3), which could considerably affect the 
primary outcomes of this research, as well as to maximize the sample of available participants 
for this study, the largest set of whom came from Phase 1.  All participants provided written, 
informed consent prior to participation in this research, and this study was monitored and 
reviewed annually by local University Institutional Review Boards.   
 
   E.  DATA ANALYSIS 
 The data analysis plan for this research proposes to test the hypotheses delineated within 
the specific aims above to (1) validate the factor structure of the intrinsic motivation measure 
developed by Nakgami and colleagues (2008) when applied to persons with schizophrenia and 
co-occurring SUDs; (2) examine the cross-sectional relationships among intrinsic motivation, 
gender, and substance use severity; and (3) examine the longitudinal relationship between 
changes in intrinsic motivation and changes in substance use severity, and whether gender 
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moderates this relationship.  This section will provide a detailed description of the analyses 
proposed to carry out these aims and associated hypotheses.   
1. Preliminary Analysis 
 Prior to investigating the primary analytic aims of this research, four preliminary analyses 
are conducted to verify internal consistency among study measures, check assumptions 
associated with the statistical tests proposed for this research, and inform subsequent analyses 
about the potential effects of demographic heterogeneity and patient attrition on estimates 
obtained from subsequent analyses.  First, the internal consistency of the neurocognitive 
composite and the PANSS (the PANSS will be used to measure negative symptoms [negative 
symptom subscale] and overall psychopathology [PANSS total score]) will be checked to ensure 
measurement reliability (the internal consistency of the intrinsic motivation measure will be 
examined separately in Aim #1).  Second, the distributions the continuous variables will be 
examined for skewness and transformed using non-linear transformations and outliers will be 
winsorized as appropriate, to meet the assumptions of parametric testing.  
 Third, to examine the effects of patient attrition on longitudinal relationship estimates, 
baseline differences in demographics, illness chronicity, medication (i.e., pre-randomization 
medications and self-reported side-effects), neurocognitive function, overall psychopathology, 
and legal status will be examined between completer (n = 145: patients with complete 
observations across the 12-month study period) and attrited (n = 390: patients with missing 
follow-up data due to attrition) samples using independent t tests or χ2 tests, as appropriate.  Any 
significant differences uncovered between the 145 completers and 390 patients who dropped out 
of the study before 1-year will be noted as potential limitations to the generalizability of the 
sample.  
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 Finally, since previous research has indicated that intrinsic motivation may be related to 
negative symptoms and neurocognition (Nakagami et al., 2010; Yamada et al., 2010; Choi & 
Medalia, 2010; Gard, Fisher, Garrett, Genevsky, & Vinogradov, 2009; Medalia et al., 2002; 
Nakagami et al., 2008), preliminary analyses will be conducted to determine whether such 
variables need to be controlled in subsequent analyses.  In addition, previous research has 
suggested the potential for demographic characteristics such as race and education (Yamada et 
al., 2010), as well as clinical characteristics such as chronicity (schizophrenia), overall 
psychopathology, medication dosage, and self-reported  medication side effects (i.e., whether 
antipsychotic medications produce somnolence effects) to confound the relationship between 
intrinsic motivation and substance use severity (Choi & Medalia, 2010; Yamada et al., 2010; 
Barch, 2004). As such, Pearson, point-biserial, tetrachoric, or polychoric correlation matrices 
will be computed to determine whether these variables need adjusted in the analyses used to 
carry out the analytic aims of this research. Any significant relationships that are detected 
between these demographic and clinical characteristics and two or more of the primary study 
variables will be adjusted using partial correlation and multiple regression in subsequent 
analyses.  Further, this research tested and adjusted for potential variation across the 57 sites 
included in CATIE by treating study site as a covariate in relevant analyses.  
2. Approach to Missing Data 
 The majority of missing data in this research come from those participants who dropped 
out of the study before completing 1-year of treatment (see Table 4).  Recent research suggests 
that when large proportions of attrition are present in longitudinal investigations, the current best 
approach for handling such missing data is to employ an intent-to-study analysis (Georguieva & 
Krystal, 2004; Chakraoty & Gu, 2009; Graham, 2009), using the expectation maximization (EM) 
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algorithm (Shafer & Graham, 2002; Graham, 2009).  EM takes a maximum likelihood approach 
to missing values at the time of analysis (Dempster, Larid, & Rubin, 1997; McCulloch, 1977), 
meaning that the growth curve model parameters in Aim #3 are estimated using all of the data 
gathered on participants over 1-year (i.e., measurement occasions for participants, overall sample 
parameter estimates, and model covariates adjusted in the analysis).  Prior studies have shown 
that intent-to-study growth curve approaches not only provide more powerful tests than other 
analytic options commonly used in longitudinal studies with large proportions of attrition (i.e., 
complete case analysis or last observation carried forward) (Shafer & Graham, 2002; Lachin, 
2002; Chakraborty & Gu, 2009), but can also be safely used with the EM algorithm even when 
missing completely at random assumptions are not met (Graham, 2009).  Since such an approach 
to missing data is the current standard in longitudinal research (Gueorguieva & Krystal, 2004; 
Hamer & Simpson, 2009), the primary longitudinal analyses in Aim #3 of this research are 
conducted on the intent-to-study sample.  However, due to the large proportion of missing data 
observed in the intent-to-study sample over 1-year, complete case (n = 145) sensitivity analyses 
are conducted (presented in Appendix A) to observe variance in the findings between completer 
and intent-to-study (n = 535, at baseline) samples.  As can be seen in Table 4, overall missing 
data in the intent-to-study sample is estimated to be 43% across the study duration, with the 
largest proportion of missing observations at 1-year.  
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Table 4. Participants Lost to Attrition over 1-year 
Sample  Baseline  6-Month  1-Year  Overall 
N - Intent to Study  535  535  535  1605 
    N - Complete  535  219  150  906 
    N - Missing  0  316  385  701 
    % - Missing  0  59  71  43 
Women         
    N - Intent to Study  86  86  86  258 
    N - Complete  86  32  24  142 
    N - Missing  0  54  62  116 
    % - Missing  0  62  72  44 
Men         
    N - Intent to Study  449  449  449  1347 
    N - Complete  449  187  126  762 
    N - Missing  0  262  323  585 
    % - Missing  0  58  71  43 
Note. Baseline = Pre-treatment data. 6-month/1-Year = Phase 1 data.  
 
 The remaining missing data in this research comes from 34 participants who were 
missing neurocognitive data at baseline. These participants are not missing any other data on the 
primary study variables at baseline, and therefore their scores on the neurocognition total scores 
are assumed to be missing at random. Recent research suggests that when data are missing at 
random, the current best approach for handling missing data is to impute using the expectation-
maximization algorithm (Schafer & Graham, 2002), as described previously. Consequently, for 
these 34 cases of missing data, the expectation-maximization approach was used to estimate the 
neurocognition total scores of these participants from available data on the other primary study 
variables, as well as demographic and clinical characteristics.  
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3. Aim #1: Extend Validation of the Intrinsic Motivation Measure developed by Nakagami 
and colleagues (2008) to Co-occurring SUDs and Schizophrenia  
Hypothesis 1a. The 3-items of purpose, motivation, and curiosity form a distinct and 
coherent factor apart from the other 4-items of the intrapsychic deficit subscale.  
 A preliminary examination of the factor structure for this intrinsic motivation measure 
will be conducted using a varimax rotated, exploratory factor analysis on the 7-items from the 
intrapsychic deficit subscale of the QLS (Heinrichs et al., 1984), specifying two fixed factors for 
extraction.  Using this approach, previous research has shown support for the 3-items of purpose, 
motivation, and curiosity loading together on one factor and forming a distinct factor apart from 
the other 4-items of the intrapsychic deficit subscale when applied to community patients with 
schizophrenia (Nakagami et al., 2008).  Consequently, demonstrating the 3-items of purpose, 
motivation, and curiosity from the 7-item intrapsychic deficit subscale of the QLS load together 
on one factor, using exploratory factor analysis of baseline data (n = 535), with varimax rotation, 
and specifying two fixed factors for extraction, would provide preliminary support for the 
validation of this measure of intrinsic motivation when applied to persons with co-occurring 
SUDs and schizophrenia.  Since the QLS items of interest (i.e., purpose, motivation, and 
curiosity) are hypothesized to be correlated, alternative factor-analytic solutions will also be 
explored to examine the best fit to the observed data structure.   
Hypothesis 1b. The 3-item intrinsic motivation measure demonstrates acceptable levels 
of internal consistency (α  ≥ .70) when applied to persons with co-occurring SUDs and 
schizophrenia.   
To evaluate the internal consistency of this intrinsic motivation measure, baseline data on 
participants with co-occurring SUDs and schizophrenia will be used to calculate the Cronbach’s 
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α coefficient for the instrument.  Previous research has shown that this measure of intrinsic 
motivation demonstrated acceptable levels of internal consistency (α = .74) when applied to a 
sample of community patients with schizophrenia.  As such, showing that this measure of 
intrinsic motivation yields estimates of α  ≥ .70, which are considered to be indicative of a 
minimally adequate internally consistent scale (Nunnelly, 1978), would suggest that the 
reliabilities of the instrument are comparable between persons with schizophrenia and persons 
with co-occurring SUDs and schizophrenia.  
Hypothesis 1c. The 3-item measure of intrinsic motivation demonstrates adequate levels 
of retest reliability (r ≥ .40) across study assessment periods.  
 The retest reliability of the intrinsic motivation measure will be evaluated by calculating 
pairwise lagged Pearson correlation coefficients of participants intrinsic motivation scores across 
the study (i.e., baseline to 6-month; 6-month to 12-month).  Results showing that this measure of 
intrinsic motivation meets at least minimally sufficient levels of retest reliability (r  ≥ .40) when 
examined across the 3 assessment observation periods of the study, would provide adequate 
retest reliability support for this measure of intrinsic motivation among persons with co-
occurring schizophrenia and SUDs.   
4. Aim#2: Examine the Cross-sectional Relationships Between Intrinsic Motivation, 
Gender, and Substance Use Severity 
Hypothesis 2a. Intrinsic motivation is significantly, negatively correlated with substance 
use severity at baseline.  
 The zero-order, cross-sectional relationship between intrinsic motivation and substance 
use severity at baseline will be examined by computing Pearson correlation coefficients between 
baseline total intrinsic motivation measure scores and baseline AUS and DUS total scores. The 
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presence of significant, negative relationships between these measures would indicate that 
intrinsic motivation is negatively associated with substance use severity.  
Hypothesis 2b. Intrinsic motivation is significantly, negatively correlated with substance 
use severity at baseline, after adjusting for neurocognition and negative symptoms.  
 The relationship between intrinsic motivation and substance use severity, after adjusting 
for neurocognition and negative symptoms will be investigated by employing a series of 
hierarchical linear regression analyses.  These analyses will predict baseline AUS/ DUS scores 
from intrinsic motivation scores, and adjust for the potentially confounding effects of baseline 
neurocognition composite and negative symptom total scores from the PANSS.  The presence of 
significant increments in variance explained in AUS/ DUS scores by intrinsic motivation scores 
after entering neurocognitive composite and negative symptom scores into the model would 
indicate that intrinsic motivation is significantly associated with substance use severity, 
independent of neurocognitive function and negative symptomatology.  
Hypothesis 2c. Men demonstrate significantly greater degrees of substance use severity 
compared to women at baseline.  
 The bivariate, cross-sectional relationship between men and women and substance use 
severity at baseline will be examined by computing independent sample t-tests (two-tailed) 
between a dichotomously coded gender (male = 1; female = 2) variable and baseline AUS/ DUS 
scores.  The presence of relationships showing that men have significantly higher mean scores on 
the AUS or the DUS than women at baseline, would indicate that men demonstrate significantly 
greater degrees of substance use severity compared to women at baseline.  
Hypothesis 2d. Men exhibit significantly greater deficits in intrinsic motivation compared 
to women at baseline.  
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 The bivariate, cross-sectional relationship between the genders and intrinsic motivation 
deficits at baseline will be investigated by computing independent sample t-tests (two-tailed) 
using a dichotomously coded gender (male = 1; female = 2) variable and baseline intrinsic 
motivation scores.  The presence of relationships showing that men have significantly lower 
intrinsic motivation means than women at baseline, would indicate that men demonstrate 
significantly greater deficits in intrinsic motivation compared to women at baseline.  
5. Aim #3: Investigate the Longitudinal Association Between Changes in Intrinsic 
Motivation and Changes in Substance Use Severity, and then Examine the Impact of 
Gender on these Relationships 
 This analytic aim will be addressed by employing a series of linear growth curve models.  
Growth curve modeling involves examining the way in which individuals change over time and 
whether there are differences in patterns of change (Bliese & Ployhart, 2002).  Such data can be 
analyzed using a structural equation modeling framework (see Bollen & Curran, 2006) or using a 
random coefficient modeling (i.e., hierarchical/mixed model) framework (see Singer & Willet, 
2003; Bliese & Polyhart, 2002; Raudenbush & Bryk, 2009). According to Raudenbush and Bryk 
(2009), investigations that seek to capture systematic change in individual phenomena, such as 
relations between changes in intrinsic motivation and changes in substance use severity, can be 
robustly examined by fitting a two-level random coefficients model to the longitudinal data 
structure. This approach to longitudinal data analysis is a form of hierarchical linear modeling 
for repeated measures data, where multiple measurement occasions are nested within individuals 
(Raudenbush & Bryk, 2009).  Such an approach to longitudinal data analysis will be used to 
carry out this analytic aim and its associated hypotheses.  
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H3a. Participants exhibit, on average, significant improvement in substance use severity 
over the 1-year study period.  
 Analysis will begin by fitting two unconditional linear growth curve models to the 
substance use severity outcomes of interest, where the outcomes of alcohol use severity (AUS 
scores) and drug use severity (DUS scores) will each be predicted from time. The multilevel 
unconditional growth curve model that will be used to fit these data is presented in eq. 1-3.  
 
              Level 1: 
                                    Yti = π0i + π1i(Time)ti + eti                                                     (1)                             
              Level 2: 
            π0i = β00 + r0i                                                       (2)  
            π1i = β10 + r1i                                  (3) 
 
As shown in the unconditional growth curve model above, the level-1 equation (eq. 1) 
represents scores on the substance use severity outcome Y for an individual i at time t as a 
function of his/her intercept, π0i, and rate of change, π1i, plus error, eti.  The subscript i (i = 
1…535) indicates that the model estimates a separate intercept (π0i) and a separate growth rate 
(π1i) for each person in the sample. The set of two level-2 equations (eq. 2 & 3) characterize the 
initial status (π0i) and the rate of change (π1i) for each substance use severity outcome of interest, 
Y, as a function of the average initial status, β00, and the rates of change, β10, for the sample plus 
individual variation in these parameters (that is, r0i and r1i).  For this study, the growth covariate 
(Time) will be coded such that: 0 = baseline, 0.5 = follow-up at 6-months, 1 = follow-up at 12-
months in order to interpret the intercept for each of these unconditional models in terms of each 
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participant’s initial status (study baseline) on outcome Y (AUS/ DUS scores). Since time is coded 
so that initial status = 0/baseline, the between-person variance in the intercept (𝜏00) is interpreted 
as the between-person variability in each participant’s initial status. As such, this parameter, 𝜏00, 
captures how much between-person variability exists in terms of where participants start the 
study.  The variance parameter, 𝜏11, for the time slope captures the variability between 
participants in terms of their linear growth rates, and the covariance parameter, 𝜏01, represents the 
correlation between participant’s initial scores (or intercepts) and their growth rates.  
These unconditional growth curve models are premised on the assumption that the AUS 
and DUS data collected on participants over the 1-year study period display significant non-
independence.  While researchers have cautioned that it is unlikely longitudinal data will be 
independent (Bliese & Ployhart, 2002), it is often valuable to estimate the interclass correlation 
coefficient (ICC) to determine the strength of the non-independence (Raudenbush & Bryk, 2009; 
Hox, 2002).  As such, the ICC for AUS/ DUS unconditional models will be assessed to ascertain 
the magnitude of non-independence in the sample, which represents the proportion of between-
individual variance to the sum of between- and within individual variances [i.e.(𝜏00 / (𝜏00 + 𝜎2 ))].   
In addition, these unconditional growth curve models are premised on the assumption 
that the level-1 within-individual errors are independently and identically distributed with a mean 
of 0 and homogeneous variance 𝜎2 across the sample (Raudenbush & Bryk, 2009). According to 
Campbell and Kenny (1999), the correlation structure of longitudinal data often has proximally 
autocorrelated errors (i.e., adjacent waves of measurement correlate more highly than non-
adjacent waves), and therefore cannot meet these basic error distribution assumptions.  Such a 
problem has been widely acknowledged by methodologists, who have recommended that fitting 
a first-order autoregressive (AR(1)) error structure to the level-1 within-individual covariance 
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matrix often provides the best solution in longitudinal growth curve analysis (Kenny & 
Campbell, 1989; Campbell & Reichardt, 1991; Singer, 1998; Campbell & Kenny, 1999; Singer 
& Willet, 2003).  As such, this research will make use of time-structured data such that 
participant measurement occasions are identically spaced over the 12-month study period (T = 3 
occasions), and an AR(1) error structure will be fit to the level-1 within-individual covariance 
matrix for the unconditional models. The error structures used at level-1 and level-2 for both 
unconditional models are presented in eq. 4-5.  
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While checking the aforementioned assumptions for the AUS and DUS unconditional 
models, competing models in terms of complexity [i.e., models fit with AR(1) versus models fit 
without AR(1)] will be compared using the χ2 of difference test based on the deviance statistic 
(log likelihood ratios) (Lou & Kwok, 2006; Meyers & Beretvas, 2006; Raudenbush & Bryk, 
2009; McCoach & Kaniskan, 2010).  The final AUS/ DUS unconditional models selected will be 
estimated using either full maximum likelihood (FIML) or restricted maximum likelihood 
(REML) estimation methods as appropriate.  For example, current best practice is to use FIML 
estimation by default for hierarchically nested models derived from the same sample (Hox, 2000; 
McCoach & Black, 2008; Raudenbush & Bryk, 2009). However, when two hierarchically nested 
models differ only in terms of their random effects (not fixed-effects), then such models can be 
compared using deviances derived using REML estimation (McCoach & Black, 2008). Finally, 
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the presence of fixed effects showing that participants exhibit, on average, significant reductions 
in their AUS/ DUS scores over 1-year, would signal improvements in substance use severity.    
H3b. Improvement in intrinsic motivation is associated with significant reductions in 
substance use severity over the 1-year study period.  
 Analysis will proceed by expanding the unconditional models to conditional growth 
curve models, where the outcomes of alcohol use severity (AUS scores) and drug use severity 
(DUS scores) will each be predicted from time and a time-varying intrinsic motivation variable. 
The conditional growth curve model that will be used to fit these data is presented in eq. 6-9.  
 
                       Level 1: 
                                 Yti = π0i + π1i(Time)ti + π2i(Intrinsic Motivation)ti + eti                    (6)                                             
                       Level 2: 
                                 π0i = β00 + r0i                                                                                     (7)                                
                                 π1i = β10 + r1i                                                                                     (8) 
                                 π2i = β20                                                                                                    (9) 
 
 As shown in the conditional growth curve model above, the coefficient for the time-
varying intrinsic motivation slope (β20) represents the relationship between changes in intrinsic 
motivation to changes in substance use severity for patients over the 1-year study period. As 
defined, time-varying variables are those whose values change across time. Notably, however, 
the parameter value estimating the effect of the time-varying variable (intrinsic motivation) on 
the dependent variable (AUS/ DUS scores) is assumed to be constant across time (McCoach & 
Kaniskan, 2010). In the context of this study, this means that the rate of improvement in intrinsic 
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motivation may change at each data collection point (i.e., baseline, 6-, 12-month), but the 
estimated relationship between changes in intrinsic motivation to changes in substance use 
severity remains constant over time.  
Since this study includes three time points (i.e., baseline, 6-, 12-months), random effects 
can be estimated for the intercept (β00), the linear trajectory (β10), and for the slope of time-
varying intrinsic motivation (β20).  While allowing time-varying intrinsic motivation’s slope to 
randomly vary (i.e., intrinsic motivation would take on a different value for every patient in the 
sample) across patients may seem preferable to fixing the slope (i.e., every patient would have 
the same average estimate of intrinsic motivation improvements), methodologists have cautioned 
against estimating such slopes as random effects by default to avoid estimation and convergence 
issues in subsequent models (Raudenbush & Bryk, 2009).  Others have indicated that the 
temptation to automatically allow the effects of time-varying predictors to randomly vary at 
level-2 should be avoided unless there is good reason, and sufficient data (i.e., measurement 
occasions) to do so (Lou & Kwok, 2006; Meyers & Beretvas, 2006; Raudenbush & Bryk, 2009; 
McCoach & Kaniskan, 2010). Since there is no consensus on whether to fit the slopes of time-
varying variables as fixed or random (McCoach & Kaniskan, 2010), and only three-measurement 
occasions are utilized in this present study, analysis will proceed by fitting time-varying intrinsic 
motivation’s slope as fixed in the AUS/ DUS conditional growth models.   
The conditional models will then be expanded to include person-level characteristics at 
level-2, which include baseline covariates that may confound the relationship between intrinsic 
motivation and substance use severity.  As such, previously conducted cross-sectional analyses 
will be used to inform whether it is necessary to adjust for study site effects, patient comorbidity 
status, age, race, education, negative symptoms, neurocognition, psychopathology, self-reported 
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medication side-effects, and illness chronicity in this series of growth curve analyses. Any 
potential confounders will be included in these conditional models as time-invariant covariates in 
the level-2 model (eq. 7 & 8), as they may account for differences in the growth parameters on 
the AUS/ DUS outcomes.  In addition, phase1 randomization treatment assignment will be 
adjusted at level-2. After determining potential confounders, the conditional growth curve 
models will be estimated using either FIML or REML as appropriate (see Hox, 2000; McCoach 
& Black; Raudenbush & Bryk, 2009), and an AR(1) error structure that is suitable for 
longitudinal data structures will be employed at level-1 for each  of these models (Singer, 1998).  
The presence of relationships indicating that patients show significant reductions in substance 
use severity as they make gains in intrinsic motivation over 1-year, would demonstrate that 
improvements in intrinsic motivation are associated with reductions in substance use severity.  
H3c. Women demonstrate a stronger association between improvement in intrinsic 
motivation and reductions in substance use severity than men over 1-year.  
To test whether women demonstrate stronger associations between improvements in 
intrinsic motivation and reductions in substance use severity over the study, two gender 
moderated growth curve models will be constructed such that an interaction between intrinsic 
motivation and gender predicts the initial levels and the 1-year rates of change on the outcomes 
of alcohol use severity and drug use severity for the sample.  The gender moderated conditional 
growth curve model that will be used to fit these data is presented in eq. 10-13. 
 
            Level 1: 
                    Yti = π0i + π1i(Time)ti + π2i(Intrinsic Motivation)ti + eti                              (10)                                            
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 Level 2: 
                       π0i = β00 + r0i                                                                                            (11)                                                     
                       π1i = β10 + r1i                                                                                            (12)                     
                       π2i = β20   + β21 (Gender)                                                                              (13)    
                                                       
            As shown in the conditional gender moderated growth curve model in eq. 10-13, a 
dichotomously coded variable representing gender (1= male; 2 = female) is now a predictor of 
both the level-2 intercept (π0i), growth rate/slope (π1i), and time-varying intrinsic motivation 
slope (π2i).  The coefficient for the cross-level interaction Gender × Intrinsic Motivation (time-
varying) slope (β21) represents the impact of gender on the longitudinal association between 
changes in intrinsic motivation and changes in substance use severity (AUS/ DUS scores, 
respectively).  The presence of a significant Gender × Intrinsic Motivation (time-varying) would 
signal a need to further decompose this conditional effect to evaluate the pattern of significance 
reflected in this relationship (Aiken & West, 1991). According to Preacher, Curran, & Bauer 
(2006), a simple slopes test provides a robust method to evaluate the pattern of significant 
interaction effects detected as part of a linear growth curve analysis.  Specifically, simple slopes 
denote the regression of an outcome Y (AUS/ DUS) on the predictor (intrinsic motivation) at a 
specific value of the moderator z (gender). The simple slope equation that will be used to fit 
these data is presented in eq. 14.  
 
                              ?̂?1 = ?̂?20 + ?̂?21 (Gender)                                                                        (14)           
        
 The simple slope (?̂?1) will then be evaluated using the simple slope technique and test of 
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significance. Such a technique indicates that the first step in deriving the significance of ?̂?1 is to 
determine the variance of the simple slope, which can be computed for any conditional value 
(gender coded: 1=male; 2=female) of the moderator (Preacher et al., 2006). The equation that 
will be used to compute the variance of ?̂?1 is shown in eq. 15.  
 
               var(?̂?1|Gender) = var(?̂?20) + 2(Gender)cov(?̂?20,  ?̂?21)  
                                                                      + (Gender)2 var(?̂?21)                                        (15) 
 
 The requisite values for computing the variance of ?̂?1 will be taken from the parameter 
estimates of the gender moderated growth curve models. Then, the square root of the quantity 
derived in eq. 15 will be used to compute the standard error of ?̂?1, 𝑆𝐸?̂?1. This value (𝑆𝐸?̂?1) will 
then be used to form the critical ratio to perform a significance test for determining the difference 
between ?̂?1 and 0. The critical ratio equation is presented in eq. 16.  
 
    t = 
?̂?1
𝑆𝐸?̂?1
                               (16)  
 
 The simple slope significance test can then be computed by taking the t obtained in eq. 16 
to a t distribution at an α = .05 level, using an equation such that (df) = N – p – 1, where N will be 
substituted with the sample size, 535, and p will be substituted with the number of predictors in 
these gender moderated growth curve models. Because methodologists increasingly recommend 
the use of confidence intervals in addition to hypothesis tests whenever possible (Wilkinson, 
1999; Preacher et al., 2006), confidence bands will be computed to supplement the simple slope 
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tests of significance. The general formula for a 100 × (1 – α) % CI for a simple slope (Cohen, 
Cohen, West, & Aiken, 2003) is presented in eq. 17.  
 
  𝐶𝐼?̂?1 =  ?̂?1  ±  𝑡𝑐𝑟𝑖𝑡 𝑆𝐸?̂?1                              (17) 
 
   Such an analysis will conclude by plotting and examining the results of the simple slopes 
analysis and the confidence bands (𝐶𝐼?̂?1).  The presence of a significant Gender × Intrinsic 
Motivation (time-varying) interaction, followed by confirmatory simple slope test results 
reflecting a pattern of significance such that women exhibit a stronger association between 
change in intrinsic motivation and change in substance use severity over the 1-year study than 
men, would provide sufficient support to substantiate this hypothesis.  
6. Power Analysis 
 Statistical power to detect cross-sectional relationships among the constructs discussed 
above is based upon the 535 participants with co-occurring SUDs and schizophrenia who have 
completed baseline assessments. Statistical power to detect longitudinal relationships among the 
constructs above is based upon those participants who were available at baseline (n = 535) 6-
months (n = 219) and 1-year (n = 150) follow-up periods.  All power analyses were conducted a 
priori using G*Power statistical software (Faul, Erdfelder, Lang, & Buchner, 2007).   
 Psychometric analyses proposed in Aim #1 will depend on examining the factor structure 
of the intrinsic motivation measure. Although guidelines for sample sizes required to estimate a 
reliable factor structure remain controversial and dependent on a number of different parameters 
(Fabrigar, Wegener, MacCallum, & Strahan, 1999), more conservative approaches suggest that 
reliable factor structures can be estimated with participant to item ratios of 10:1 (Everitt, 1975; 
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Nunnelly, 1978).  As such, with 535 participants and 8 intrapsychic deficit items, this analytic 
aim will be able to meet these more conservative requirements for examining the factor structure 
of the intrinsic motivation measure developed by Nakagami and colleagues (2008) among this 
sample of persons with co-occurring SUDs and schizophrenia.  
 Investigating the cross-sectional relationship between intrinsic motivation and substance 
use severity in Aim #2 hypothesis 2b, relies on a series of hierarchical linear regression analyses 
with 3 predictors.  As can be seen in Figure 4, using power analytic methods outlined by Cohen 
(1988), with 535 participants, given power = .80, α = .05, and k = 3, adequate power will be 
available to detect medium to large relationship sizes in variance explained in AUS/ DUS scores 
by intrinsic motivation scores, after adjusting for the potentially confounding effects of negative 
symptoms and neurocognition.  Examining the cross-sectional relationship between gender and 
intrinsic motivation and gender and substance use severity in hypothesis 2c and hypothesis 2d 
will rely upon a series of independent sample t-test (two-tailed).  Using power analytic methods 
outlined by Cohen (1988), with n = 86 women and n = 449 men at baseline, power = .80, and α = 
.05, adequate power will be available to detect medium to large relationship sizes (d = .50 and 
greater) between gender and intrinsic motivation and gender and substance use severity. 
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Figure 4. Power as a function of total sample size (n = 535) for the hierarchical regression 
analysis k = 3, alpha = .05, in study Aim #2, hypothesis 2b 
 
 The relationship between longitudinal changes in intrinsic motivation and changes in 
substance use severity examined in Aim #3 hypothesis 3b will rely upon a linear growth curve 
analysis with a single time-varying predictor (intrinsic motivation).  As can be seen in Figure 5, 
using data from the intent-to-treat sample (n = 535 at baseline; n = 219 at 6-months; n = 150 at 1-
year), given power = .80, α = .05, k = 2 (intrinsic motivation and time), measurement occasions = 
3 (every 6-months for 1-year), and 1 group of participants, adequate power will be available to 
detect medium to large relationship sizes between changes in intrinsic motivation and changes in 
substance use severity over the 1-year study period.   
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Figure 5. Power as a function of total sample size (n = 535) for the linear growth curve analysis 
(groups = 1, repeated measurement occasions = 3, k = 2, alpha = .05), in study Aim #3, 
hypothesis 3b. 
 
 The relationship testing the impact of gender on the longitudinal association between 
intrinsic motivation and substance use severity in hypothesis 3b will rely on a gender moderated 
linear growth curve analysis such that an interaction between change in intrinsic motivation and 
gender predicts the outcomes of changes in alcohol use severity and drug use severity for the 
sample.  As can be seen in Figure 6, using data from the n = 449 men and n = 86 women from 
the intent-to-treat sample (n = 535 at baseline; n = 219 at 6-months; n = 150 at 1-year), given 
power = .80, α = .05, k = 3, and 2 participant groups, adequate power will be available to detect 
medium to large relationship sizes with regard to the impact of gender on the relationship 
between intrinsic motivation and substance use severity over the 1-year study. 
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Figure 6. Power as a function of total sample size (n = 535) for the gender moderated growth 
curve analysis (groups = 2 [n = 86 women; n = 449 men], repeated measurement occasions =3, k 
=3, alpha = .05), in study Aim #3, hypothesis 3c 
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IV. RESULTS 
 
 This chapter presents a series of statistical analyses designed to answer the primary 
analytic questions of this research. These analyses were carried out to answer questions focused 
on (1) extending the intrinsic motivation instrument developed by Nakagami and colleagues 
(2008) for schizophrenia to schizophrenia and comorbid SUD, (2) examining the cross-sectional 
relationships between intrinsic motivation, gender, and substance use severity, (3) investigating 
the association between longitudinal changes in intrinsic motivation and changes in substance 
use severity, and (4) examining whether gender moderates the longitudinal association between 
changes in intrinsic motivation and changes in substance use severity. This chapter  begins with a 
presentation of the demographic and clinical characteristics ascertained for this research, and 
then proceeds by presenting the results of a series of preliminary analyses designed to check the 
internal consistency of the study measures, verify that the study data meets criteria for parametric 
statistical testing, examine potential differences between study completers and those lost to 
attrition,  and investigate potential demographic and clinical confounds with primary study 
variables.  Subsequent to these preliminary analyses, the results from the primary study aims are 
presented.  The statistical analyses presented in this chapter will be carried out using R version 
2.14.2 (R Development Core Team, 2014).  
 
A. SAMPLE CHARACTERISTICS 
 A total of 535 persons with comorbid SUD and schizophrenia were included in this 
research, 220 were available at the 6-month follow-up, and 151 completed 1-year follow-up. At 
baseline, most participants were male (83.9%), white (56.4%), and in their late thirties (M = 
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37.98; SD = 10.62).  Few patients were married (8.4%), completed a college degree (including a 
community college or a trade school) (10.3%), and were employed (6.2%).  Further, while most 
patients were taking an antipsychotic medication at baseline (78.1%), such patients had been ill 
(schizophrenia) for 15 years on average (SD = 10.43) and presented for treatment with moderate 
degrees of illness chronicity (M = 4.00; SD = 0.95).  As can be seen in Table 4, many patients 
with schizophrenia and comorbid SUD reported that they had used substances within 90-days of 
enrollment, with alcohol, cannabis and cocaine being among the most frequent recently used 
substances reported.  In addition, 86.0% of patients with schizophrenia and comorbid SUD 
reported using tobacco products within 90-days of enrollment.  Notably, there was a considerable 
degree of overlap in SUD diagnoses (comorbidity status) observed among these schizophrenia 
patients at baseline. For example, 65.8% were diagnosed with any alcohol use disorder, 62.2% 
were diagnosed with any cannabis use disorder, and 41.7% were diagnosed with any cocaine use 
disorder (see Table 5). 
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In order to obtain a greater understanding of the heterogeneity of the sample regarding 
SUD diagnoses, an analysis was conducted to examine demographic characteristics across three 
mutually exclusive groups distinguished by comorbidity status (i.e., comorbid schizophrenia and 
alcohol use disorders [n = 119]; comorbid schizophrenia and SUD other than an alcohol use 
disorder [n = 183], and comorbid schizophrenia and poly disorders [n = 233]).  As can be seen in 
Table 6, overall differences were observed across 5 of the 17 baseline characteristics among 
these mutually exclusive groups.  Planned follow-up pairwise comparisons showed that patients 
with comorbid schizophrenia and alcohol use disorder were significantly older and in more 
chronic stages of schizophrenia illness. Patients with comorbid schizophrenia and alcohol use 
disorders also demonstrated greater neurocognitive deficits than the other groups. A greater 
proportion of patients with alcohol use disorders were white; polysubstance disordered patients 
Table 5. Comorbid Substance Use Disorder Diagnoses and Self-Reported Substance Use 
among Schizophrenia Patients at Baseline 
 
    Variable 
 
 
Substance Usea 
n (%) 
 DSM Diagnosisb 
n (%) 
Alcohol  300 (56.1%)  352 (65.8%) 
Cannabis  197 (36.8%)  333 (62.2%) 
Cocaine  106 (19.8%)  223 (41.7%) 
Amphetamine  27 (5.0%)  62 (11.6%) 
Opiate  15 (2.8%)  34 (6.4%) 
Phencyclidine  3 (0.6%)  19 (3.6%) 
aPatient’s were asked to report their use of any substance (alcohol, cannabis, cocaine, 
amphetamine, opiates, or phencyclidine) within 90-days of baseline. Responses were recorded 
as “yes=1” indicating use or “no=0” indicating no use.  
bPatient’s were assessed at baseline by research project clinicians trained in administering the 
DSM-IV SCID (First et al., 1996) for the presence of a substance use disorder.  
142 
 
were significantly more likely to have encountered the legal system within 30-days of study 
enrollment compared to schizophrenia patients with comorbid alcohol use disorder.  
 
Table 6. Participant Baseline Characteristics 
 
 
A 
(n = 119) 
 D 
(n = 183) 
 A/D 
(n = 233)  
 Analysisa  
           Variable  M SD  M SD  M SD  p Directionb 
Age  43.19 9.21  37.41 10.90  35.76 10.91  <.001 D < A > AD 
Educationc  12.07 2.05  11.92 1.94  11.63 1.92  .108         - 
Chronicityd   17.89 10.98  13.94 10.90  14.30 10.45  .002 D < A > AD 
PANSS Totale  77.80 17.24  75.60 18.16  76.83 16.30  .538         - 
Negativef  20.50 6.09  19.64 6.70  19.53 6.30  .375         - 
Neurocognitiong  -0.16 1.03  0.12 0.89  0.23 0.92  .001 D > A < AD 
CPZh  423.48 10.98  387.23 405.38  297.85 225.85  .090  - - 
  N %  N %  N %  p Direction 
Male  97 81.5  150 82.0  202 86.7  .307         - 
White  87 73.1  95 51.9  120 51.5  <.001 A < D, AD 
Employedi  22 18.5  21 11.5  41 17.6  .177         - 
Married  15 12.6  14 7.7  16 6.9  .307         - 
Legalj  10 8.4  22 12.0  41 17.6  .043 AD > A, D 
Antipsychotic  84 70.6  130 71.0  154 66.1  .815         - 
Antidepressant  40 33.6  51 27.9  75 32.2  .525         - 
Anxiolytic   22 18.5  28 15.3  34 14.6  .752         - 
Antiepileptic   84 70.6  28 15.3  35 15.0  .855         - 
No Medication  97 81.5  12 6.6  13 5.6  .471         - 
SE-1k  32 26.8  63 34.4  55 23.6  .682         - 
SE-2l  69 57.9  124 67.7  104 44.6  .643         - 
Note. A = alcohol use disorder; D = substance use disorder other than an alcohol use disorder  
(i.e., cannabis, cocaine, amphetamine, opiate, or phencyclidine [PCP]); A/D = concurrent alcohol 
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 use disorder and other substance use disorder diagnoses. All SUD diagnoses are combined  
current (present within 30-days), or lifetime (present within 5 years).    
a χ2 test or analysis of variance test, two tailed, for significant differences between mutually  
exclusive A, D, or A/D groups with comorbid SUD and schizophrenia at baseline.   
bp-values of analysis of variance tests are adjusted using Hochberg’s (1988)  correction. 
c Based on years of education.  
d Based on years of treatment for schizophrenia.  
e Positive and Negative Syndrome Scale Total Scores; higher scores indicate more symptoms. 
f Positive and Negative Syndrome Scale Negative subscale scores; higher scores indicate greater 
negative symptoms.  
g Neurocognition composite; higher scores indicate better neurocognitive performance.  
h Chlorpromazine equivalent dose; pre-treatment antipsychotic medications were converted to  
CPZ equivalent dose for all participants. CPZ data are available for 358 participants.  
i Based on any paid employment.  
j Legal is based on any parole, probation, or incarceration within 30 days of enrollment.  
k Based on patient reported somnolence effects of taking antipsychotic medications; response of  
“true” indicated that such medications have zombie-like effects.  
l Based on patient reported somnolence effects of taking antipsychotic medications; response of  
“true” indicated that such medications were associated with tired/sluggish effects.  
 
B. PRELIMINARY ANALYSES  
1. Internal Consistency of the PANSS and Neurocognitive Composite  
 Preliminary analysis of study data began by performing a series of analyses to check the 
internal consistency of the primary baseline covariates (PANSS Total, PANSS Negative sub-
scale, Neurocognition Composite).  The internal consistency of the independent intrinsic 
motivation measure is examined separately in Aim #1; the internal consistency of the dependent 
substance use severity measures are not computed as only 1-item composite scores for AUS/ 
DUS scales are available.  Using baseline data, these analyses provided reliability estimates of 
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the study measures, but did not serve as the sole basis for including and excluding items within 
measures.  Cronbach’s α was utilized as the internal consistency measure for these analyses.  
Estimates of α ≥ .80 were considered indicative of a highly internally consistent scale (Nunnelly, 
1978). Estimates of α ≥ .70 were considered indicative of minimally adequate internally 
consistent scale (Nunnelly, 1978).  Internal consistency estimates for scales with missing data 
were calculated using the EM algorithm, which has been shown to be more accurate than listwise 
or pairwise deletion when computing Cronbach’s α (Enders, 2003).     
 PANSS.  Table 7 presents internal consistency estimates of the total scale and three 
subscales of the PANSS at baseline. This study only considers total scale and negative subscales; 
other subscales were considered insofar that they comprise part of the total scale. The internal 
consistencies of the PANSS total, negative symptomatology, and general psychopathology 
subscales were all within acceptable ranges.  
 
  Table 7. Positive and Negative Symptom Scale Internal Consistency 
                  
                                             Item 
 
Alpha 
Item 
Total 
Alpha 
Without 
Total .86 - - 
Positive .70 - - 
   Delusions (P1)  .57 .61 
   Conceptual Disorganization (P2)  .35 .67 
   Hallucinatory Behavior (P3)  .41 .66 
   Excitement (P4)  .36 .67 
   Grandiosity (P5)  .45 .64 
   Suspiciousness (P6)  .38 .65 
   Hostility (P7)  .29 .68 
Negative .81 - - 
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   Blunted Affect (N1)  .62 .77 
   Emotional Withdrawal (N2)  .63 .77 
   Poor Rapport (N3)  .70 .76 
   Passive/Apathetic Social Withdrawal (N4)  .58 .78 
   Difficulty in Abstract Thinking (N5)  .34 .83 
   Lack of Spontaneity and Flow of Conversation (N6)  .63 .77 
   Stereotyped Thinking (N7)  .39 .81 
General Psychopathology .78 - - 
   Somatic Concerns (G1)  .37 .77 
   Anxiety (G2)  .43 .76 
   Guilt Feelings (G3)  .28 .78 
   Tension (G4)  .45 .76 
   Mannerisms and Posturing (G5)  .38 .77 
   Depression (G6)  .27 .77 
   Motor Retardation (G7)  .40 .76 
   Uncooperativeness (G8)  .41 .76 
   Unusual Thought Content (G9)  .41 .76 
   Disorientation (G10)  .26 .77 
   Poor Attention (G11)  .43 .76 
   Lack of Judgment and Insight (G12)  .32 .77 
   Disturbance of Volition (G13)  .50 .76 
   Poor Impulse Control (G14)  .29 .77 
   Preoccupation (G15)  .51 .76 
   Active Social Avoidance (G16)  .35 .77 
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 Neurocognitive composite.  Table 8 presents internal consistency estimates of the 
neurocognitive composite measure at baseline.  The internal consistency of the neurocognitive 
composite was within acceptable ranges.  Since this study is only focused on accounting for the 
potentially confounding effects of neurocognitive total scores in primary analyses, the internal 
consistency of the neurocognitive subdomains (i.e., processing speed, reasoning/problem 
solving, verbal/working memory, and vigilance) are not reported or discussed herein.  
  
Table 8. Neurocognitive Composite Internal Consistency 
 
                                         Item 
 
Alpha 
Item 
Total 
Alpha 
Without 
Total .88 - - 
  WAIS-R Mazes: 9 timed mazes  .42 .88 
  WCST: Number of categories complete/perseverative errors  .36 .88 
   LNS: Repeat clusters of letters combined with numbers   .66 .86 
  Computerized Test of Visuospatial WM: Variable Inter-stimulus 
interval (no delay, 5 second delay, 15 second delay)  
 .49 .87 
  WAIS-R: Digit-span test  
 
 .72 .86 
  COWAT/category instances: Generate words beginning with F, 
A, and S. Name animals, fruits, vegetables within 60 seconds.  
 
 .56 .87 
  Grooved Pegboard: choice reaction time; dominant hand  
 
 .50 .87 
  CPT 1: Vigilance response to identical 2-digit paired numbers  .63 .87 
  CPT 2: Vigilance response to identical 3-digit paired numbers  .64 .86 
  CPT 3: Vigilance response to identical 4-digit paired numbers   .60 .87 
  HVLT 1: List A; Recall 12 words read aloud by the tester  
 
 .52 .87 
  HVLT 2: List B; Recall 12 words read aloud by the tester  .59 .87 
  HVLT 3: List C; Recall 12 words read aloud by the tester  .59 .87 
Note. Scores are standardized. WAIS-R = Wechsler Adult Intelligence Scale-Revised Mazes; 
WCST = Wisconsin Card Sorting Test; LNS = Letter Number Sequencing Test; WMS-R = 
Wechsler Memory Scale-Revised; COWAT = Controlled Word Association Test; CPT = 
Continuous Performance Test; HVLT = Hopkins Verbal Learning Test. 
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2. Verifying Parametric Assumptions 
After checking the internal consistency of these covariates, a series of analyses was 
conducted to examine the distributions of these measures as well as the independent/dependent 
measures to ensure they met the assumptions of parametric testing. These analyses were 
conducted by visually inspecting Box and Whisker plots for each of these measures to identify 
potential outliers, calculating skewness statistics to quantify skewed data distributions, and 
inspecting histograms of data distributions to identify potentially non-normal distributions.  
Skewness statistics greater than .75 were considered to be indicative of moderately skewed 
distributions (McAweeney & Klockars, 1998), and for those distributions that exceeded this 
threshold, non-linear transformation procedures were used to reduce the skewness. Cases were 
identified as outliers if their score on a single measure was 2 times the interquartile range of the 
distribution of scores in the sample (Hoaglin, Iglewicz, & Tukey, 1986).  Outliers were handled 
by employing a winsorization procedure to bring such cases within 2 times the interquartile 
range of the data distribution, by setting the score value of the outlier to that of the next closest 
number within 2 times the interquartile range (Dixon & Tukey, 1968).  In order to preserve 
comparability between baseline and follow-up measures for the primary study variables (intrinsic 
motivation, and drug/alcohol use severity), baseline, 6-, and, 12-month data were stacked and 
simultaneously transformed across study periods. Further, baseline covariates were only 
transformed at baseline.   
 As can be seen by the descriptive statistics and skewness information for the primary 
study variables and baseline covariates presented in Table 9, slightly over half of these variables 
required a non-linear transformation or winsorization procedure to reduce skewness or remove 
outliers.  Nevertheless, once transformed or winsorized, all study variables demonstrated 
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acceptable ranges of skewness and contained no significant outliers.  The two substance use 
severity dependent variables (AUS/ DUS) demonstrated significant skeweness across study 
periods.  After applying logarithmic transformations to these two dependent measures, skewness 
was substantially reduced.  Only the neurocognitive composite covariate required a winsorization 
procedure to remove outliers and reduce skewness.  All subsequent analyses will make use of 
these transformed and winsorized variables, and any transformation applied to them will not be 
considered or discussed hereafter.  
 
Table 9. Descriptive and Skewness Statistics of Primary Study Variables 
Variable Na N
b M SD Min Max Skew 
(pre) 
Transform Skew 
(post) 
 Baseline Covariates 
PANSS Total 0 535 76.63 17.16 33 140 .26 - - 
Negative 0 535 19.79 6.40 7 41 .29 - - 
Neurocognitive Composite 0 535 0.11 0.94 -2.48 2.51 .05 win(5) .03 
 Stacked Longitudinal Data 
Intrinsic Motivation 609 904 5.02 0.91 0 12 .36 - - 
AUS 609 904 0.97 0.29 0 1.79 1.05 log1p .47 
DUS 609 904 0.95 0.31 0 1.79 1.00 log1p .63 
Note. Skew (pre) refers to skewness before non-linear transformation. Skew (post) refers to skewness 
after non-linear transformation. win(n) = winsorization procedure performed on n outliers.  
aN = missing data at baseline for covariates; N = missing data for stacked longitudinal data.  
bN = baseline sample for covariates; N = combined observations across study periods for stacked 
longitudinal data.  
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3. Examining Potential Attrition Bias 
 Having winsorized outliers and transformed variables to reduce skewness, a series of 
analyses were then conducted to examine the possibility of systematic differences between those 
participants for whom complete observations were available across all study time points (i.e. 
completer sample: n = 145) and those participants who had any missing follow-up data due to 
study attrition (i.e., dropped out—attrited sample: n = 390). These analyses were conducted by 
calculating descriptive statistics for the primary study variables, and demographic and clinical 
characteristics between these two groups at baseline, and then conducting independent t tests or 
χ2 tests to identify significant between-group differences at baseline on these variables.   
 As can be seen in Table 10, the only statistically significant baseline difference between 
completer and attrited samples was with regard to participant comorbidity status. A significantly 
greater proportion of participants with alcohol use disorders completed the study than dropped 
out of the study. However, a significantly greater proportion of participants with substance use 
disorders other than an alcohol use disorder dropped out of the study than completed the study.  
Overall, these results suggest that the completer and attrited samples were generally comparable 
on most of the primary study variables at baseline; however, systematic differences do exist with 
regard to pre-randomization comorbidity status.  
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Table 10. Comparison of Baseline Characteristics of Patints in Completer and Attrited Samples 
 
 
Completer 
(n = 147) 
Dropped Outa 
(n = 390) 
 
 
Variable M (SD) / N (%) M (SD) / N (%) pb 
Age 38.70 (10.54) 37.71 (10.65) .335 
Education (years) 11.91 (1.73) 11.80 (2.04) .533 
Chronicity 14.89 (10.92) 14.99 (10.26) .924 
White 85 (58.6%) 217 (55.6%) .302 
Employed 22 (14.9%) 62 (15.8%) .458 
Married 9 (6.2%) 36 (9.2%) .173 
Legalc 22 (15.2%) 51 (13.1%) .309 
Antipsychotic  110 (75.9%) 258 (66.2%) .064 
Antidepressant 50 (30.1%) 116 (29.7%) .096 
Anxiolytic 27 (18.6%) 57 (14.6%) .080 
Antiepileptic  21 (14.5%) 58 (14.9%) .092 
No Medication 6 (4.1%) 22 (5.6%) .069 
CPZ 302.41 (331.43) 381.34 (498.31) .132 
SE-1d 38 (25.8%) 117 (30.0%) .431 
SE-2e 82 (56.5%) 215 (55.1%) .890 
Study Sitef 128.67 (15.32) 127.82 (15.97) .579 
Comorbidity Status    
   Alcohol/SZ 42 (29.0%) 77 (19.7%) <.001 
   Drug/SZ 39 (26.9%) 144 (36.9%) <.001 
   Poly/SZ 64 (44.1%) 169 (43.3%) .945 
PANSS Total  74.99 (17.26) 77.24 (17.10) .178 
Negative 20.18 (6.49) 19.64 (6.36) .385 
Neurocognition 0.09 (0.86) 0.11 (0.97) .728 
Intrinsic Motivation 4.98 (2.75) 4.86 (2.72) .658 
Male 123 (84.8%) 326 (83.6%) .420 
AUS (log) 0.99 (0.29) 0.99 (0.29) .990 
DUS (log) 0.94 (0.28) 0.99 (0.32) .087 
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Note. PANSS = Positive and Negative Syndrome Scale; Negative = Negative Symptom subscale 
of the PANSS; CPZ = Chlorpromazine equivalent dose. Comorbidity Status = mutually 
exclusive groups based on DSM-IV SCID diagnoses [SZ = schizophrenia; Alcohol = alcohol use 
disorder; drug = disorder other than an alcohol use disorder; Poly = alcohol and drug use 
disorder]. AUS = Alcohol Use Scale; DUS = Drug Use Scale.  
a Dropped out = attrited sample. 
b χ2 or independent t-test, two-tailed, for differences between completer and attrited samples.  
c Legal is based on any parole, probation, or incarceration within 30 days of enrollment. 
d Patient reported somnolence effects of taking antipsychotic medications; response of  
“true” indicated that such medications have zombie-like effects.  
e Patient reported somnolence effects of taking antipsychotic medications; response of  
“true” indicated that such medications were associated with tired/sluggish effects. 
f Study Site = 57 study sites included in the CATIE trial.  
 
4. Identifying Potential Demographic and Clinical Confounds with Study Variables  
 After examining potential systematic differences between participants with complete 
observations across the study time points, and those participants with missing follow-up data due 
to study attrition, a series of correlation analyses was conducted to examine the associations 
between the primary study variables (i.e. drug/alcohol use severity, intrinsic motivation, gender), 
and potential clinical and demographic confounders at baseline. Based on previous research, 
these potential confounders included the demographic characteristics of age, education, and race, 
as well as the clinical characteristics of illness chronicity, medication dosage, self-reported 
medication side effects (i.e., somnolence effects), neurocognition, negative symptoms, and 
overall psychopathology.   
 As can be seen by the correlation matrix presented in Table 11, age, race, illness 
chronicity, and overall psychopathology showed significant and moderate associations with a 
number of the primary study variables. In particular, age, illness chronicity, and overall 
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psychopathology exhibited significant and moderate associations with components of both 
intrinsic motivation and one of the substance use severity dependent variables (DUS, log), 
suggesting their potential confounding influence on estimates between these constructs.  As a 
consequence, subsequent cross-sectional and longitudinal analyses examining the relations 
among intrinsic motivation and substance use severity adjusted for age, illness chronicity, and 
overall psychopathology. In addition to adjusting for these variables, subsequent cross-sectional 
analyses (Section 4.D.2) examining such relations adjusted for study site effects, comorbidity 
status, neurocognition, and negative symptoms; longitudinal analyses (Section 4.E.2.) examining 
such relations adjusted for phase 1 randomization, comorbidity status, neurocognition, and 
negative symptoms.   
 
Table 11. Association Between Primary Study Variables and Potential Confounders at Baseline 
   Variable Age Racea EDb ICc CPZd P-tote  P-negf Neurog SE-1h SE-2i 
IMj -.13** -.05 .08 -.13** -.05 -.33** -.34** .28** -.09* -.05 
Genderk .01 .16** .04 -.04 -.04 -.03 -.07 .06 .07 .18** 
AUS (log)l .01 -.07 .01 .02 -.02 .05 -.01 .04 -.02 .01 
DUS (log)m -.16** .10** .02 -.10* -.07 .13** .04 .05 -.01 -.01 
Note. Pearson, point-biserial, polychoric, or tetrachoric correlations between primary study 
variables and potential confounders at baseline (n = 535). IM = Intrinsic Motivation; ED = Years of 
Education. IC= Illness Chronicity; P-tot = Positive and Negative Syndrome Scale. P-neg = 
Negative Symptom Subscale of the Positive and Negative Symptom Scale; Neuro = 
Neurocognition; SE-1 = Patient reported somnolence effects of taking antipsychotic medications 
(response of “true” indicate such medications have zombie-like effects); SE-2 = Patient reported 
somnolence effects of taking antipsychotic medications (response of “true” suggests such 
medications are associated with tired/sluggish effects); AUS = Alcohol Use Scale; DUS = Drug 
Use Scale.  
a1 = White; 2 = Non-White.  
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b Higher values indicate more years of education. 
c Higher values indicate more years of schizophrenia treatment. 
d Chlorpromazine equivalent dose; higher numbers indicate higher medication dosages.  
e Higher scores indicate greater degrees of psychopathology. 
f Higher scores indicate greater degrees of negative symptomatology. 
g Higher scores indicate better neurocognitive performance.  
h1= True; 0 = False 
i1 = True; 0 = False 
j Higher scores indicate greater degrees of intrinsic motivation.  
k1 = Men; 2 = Women. 
l Higher scores indicate greater alcohol use severity. 
mHigher scores indicate greater drug use severity.  
 
**p < .01, *p < .05, 2-tailed. 
 
C. AIM #1 EXTEND VALIDATION OF NAKAGAMI AND COLLEAGUES INTRINSIC 
MOTIVATION MEASURE TO COMORBID SUD AND SCHIZOPHRENIA 
1. Factor Structure 
 Analysis proceeded by conducting the first ever examination of the intrinsic motivation 
measure’s factor structure among patients with schizophrenia and comorbid SUD.  As such, a 
series of exploratory factor analyses were conducted, and began using principal axis factoring 
with varimax rotation, on a correlation matrix of the QLS’s 7 intrapsychic deficit subscale scores 
among (n = 535) the baseline  sample (see Table 12).  Support for taking this initial approach 
was garnered from a recent investigation by Nakagami and colleagues (2008), which showed that 
the 3 items of purpose, motivation, and curiosity form a distinct intrinsic motivation factor in 
schizophrenia, when two fixed factors are specified for extraction using varimax rotation.  While 
similar results were hypothesized in this study (Aim #1; Chapter 3, Section E.3), it is important 
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to mention that exploratory techniques are critical for examining alternative solutions that may 
better represent the construct in schizophrenia and comorbid SUD, which could be overlooked 
using confirmatory models (Kelloway, 1995; Hurley et al., 1997; Tomarken & Waller, 2003).  In 
addition, methodologists caution against using confirmatory models in the early stages of scale 
validation and development, as such factor-analytic methods do not show how well items load on 
non-hypothesized factors (Kelloway, 1995).  Given the fact that Nakagami and colleagues (2008) 
intrinsic motivation scale has yet to be validated in schizophrenia and comorbid SUD, an 
exploratory approach was taken in this research to avoid prematurely settling on a model that 
may only adequately describe the construct among this population.  
 
  
As can be seen in Figure 7, the scree plot of the intrapsychic deficit subscale components 
suggested a 2-factor solution. Nonetheless, a 3-factor solution was also examined from principal 
axis analyses, in addition to a 2-factor solution, to explore the degree to which intrapsychic 
Table 12. Correlations Among Quality of Life Scale Intrapsychic Deficit Subscale Items 
          Item 1 2 3 4 5 6 7 
1. Purpose -       
2. Motivation .60** -      
3. Curiosity .40** .48** -     
4. Anhedonia .40** .52** .45** -    
5. Time Utilization .40** .55** .40** .50** -   
6. Empathy .34** .37** .42** .45** .31** -  
7. Engagement .38** .43** .43** .49** .36** .57** - 
Note. Analyses were conducted on the baseline sample (n = 535).  
 
**p < .01, 2-tailed. 
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deficit subscale items fit intrinsic motivation factor solutions (curiosity, purpose, and motivation) 
previously identified in schizophrenia patients (see Nakagami et al., 2008).    
 
 
Figure 7. Screeplot of Eigen Values for the QLS Intrapsychic Deficit Subscale Components 
  
As can be seen in Table 13, both 2 and 3-factor solutions with varimax rotation produced 
numerous split loadings and generally indefinite factor solutions that raised serious concern 
about prematurely settling on an intrinsic motivation factor without exploring alternative 
solutions.  Therefore, this series of exploratory analyses proceeded by investigating other 
solutions that may better fit the data structure.
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Given the high degree of significant correlations among QLS intrapsychic deficit 
subscale items (see Table 12), subsequent exploratory analyses proceeded using principal axis 
factoring, with oblique oblimin rotation instead of the orthogonal varimax rotation used by 
Nakagami and colleagues (2008) (see Table 13).  As methodologists have cautioned (Fabrigar, 
MacCallum, Wegener, & Strahan, 1999; Preacher, Zhang, Kim, & Mels, 2013), solely relying on 
an orthogonal rotation (varimax) forfeits any knowledge of the existing correlations among 
factors, which signals the importance of exploring whether using an oblique rotation improves 
the degree to which intrinsic deficit subscale items fit the intrinsic motivation factor solutions 
previously identified in schizophrenia (see Nakagami et al., 2008). An oblique solution is also 
more appropriate and likely given that the items identifying different factors come from the same 
subscale, and thus are factors hypothesized to be correlated.  As can be seen in Table 14, both 2 
Table 13. Factor Structure of the Intrapsychic Deficit Subscale with Varimax Rotation 
 2-Factor  
Solutiona 
 3-Factor  
Solutionb 
Variable Factor 1 Factor 2  Factor 1 Factor 2 Factor 3 
 Standardized Loadings 
Purpose .60 .27  .21 .26 .64 
Motivation .84 .24  .45 .23 .69 
Curiosity .46 .43  .34 .40 .34 
Anhedonia .51 .48  .56 .43 .25 
Time Utilization .60 .43  .59 .20 .35 
Empathy .21 .72  .18 .71 .19 
Engagement .31 .70  .24 .68 .24 
Note. Factor loadings greater than .40 appear in boldface.  
a χ2(8, n = 535) = 19.75, p =.011 
b χ2(3, n = 535) = 0.27, p =.966 
157 
 
and 3-factor solutions with oblique oblimin rotation provided a good fit to the observed data, 
with a 3-factor solution providing a better fit than the 2-factor solution. 
 
 
Although a 3-factor oblique solution appeared to best represent the observed data, the 
pattern of results obtained was not congruent with the 2-factor orthogonal solution previously 
found among community patients with schizophrenia by Nakagami and colleagues (2008). As 
such, the hypothesis (Hypothesis 1a) that a 2-factor orthogonal solution would yield an intrinsic 
Table 14. Factor Structure of the Intrapsychic Deficit Subscale with Oblique Oblimin Rotation 
 2-Factor  
Solutiona 
 3-Factor  
Solutionb 
Variable Factor 1 Factor 2  Factor 1 Factor 2 Factor 3 
 Standardized Loadings 
Purpose .60 .07  .75 .07 -.12 
Motivation .91 -.06  .75 -.03 .16 
Curiosity .37 .33  .24 .32 .17 
Anhedonia .40 .37  .04 .33 .49 
Time Utilization .60 .08  .24 .01 .52 
Empathy -.50 .78  -.02 .78 -.02 
Engagement .05 .73  .05 .71 .04 
                                     Factor Correlations 
                            Factor     1 2 3 
3-Factor Solution    
Factor 1 -   
Factor 2 .60 -  
Factor 3 .68 .53 - 
Note. Factor loadings greater than .40 appear in boldface.  
a χ2(8, n = 535) = 19.75, p =.011 
b χ2(3, n = 535) = 0.27, p =.966 
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motivation factor consisting of the QLS’s intrapsychic deficit items of purpose, motivation, and 
curiosity was not supported.  This current research found that the items of purpose and 
motivation load together on the same factor; as expected; however, the curiosity item did not 
load with these items or on any other factor in any of the solutions examined. Consequently, 1 of 
the 3 items (curiosity) will not be retained as part of the intrinsic motivation factor, as this 
exploratory investigation suggests that curiosity does not strongly represent part of the intrinsic 
motivation construct in comorbid SUD and schizophrenia.  Subsequent analyses proceeded using 
this empirically-derived 2-item scale, which consists of the QLS items of purpose and 
motivation, to measure intrinsic motivation deficits in comorbid schizophrenia and SUD.   
2. Internal Consistency of the Intrinsic Motivation Measure  
 Having found preliminary evidence of an intrinsic motivation factor that consists of 2-
items (purpose and motivation) from the QLS in comorbid SUD and schizophrenia, the internal 
consistency of this scale was then examined.  This 2-item measure showed surprisingly strong 
levels of internal consistency, given the small number of items (see Table 15). These results 
support the hypothesis (Hypothesis 1b) that the intrinsic motivation measure would demonstrate 
at least adequate levels of internal consistency (α  ≥ .70) in comorbid SUD and schizophrenia.  
Table 15. Intrinsic Motivation Measure Internal Consistency 
 
                                         Item 
 
Alpha 
Item 
Total 
Alpha 
Without 
Total .75 - - 
Purpose  .59 - 
Motivation  .59 - 
Note. Analyses were conducted on the baseline sample (n = 535). 
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3.  Re-test Reliability of the Intrinsic Motivation Measure  
 After demonstrating that the 2-item intrinsic motivation measure possesses at least 
adequate levels of internal consistency among persons with comorbid SUD and schizophrenia, 
the re-test reliability of this intrinsic motivation measure was evaluated.  As can be seen in Table 
16, this intrinsic motivation measure satisfied re-test reliability criteria of 0.40 or greater across 
study assessment periods (baseline to 6-month; 6-month to 12-month).  As such, the hypothesis 
(Hypothesis 1c) that the intrinsic motivation measure would demonstrate at least minimally 
sufficient levels of re-test reliability (r  ≥ .40) when examined across the 3 multi-month 
assessment observation periods of the study was supported. 
  
 In summary, factor-analytic findings provided strong support for a 3-factor oblique 
solution with an intrinsic motivation factor consisting of the QLS items purpose and motivation; 
as expected; however, the curiosity item did not load with these items or on any other factor in 
any of the solutions examined.  Psychometric analyses provided robust support for the reliability 
of this 2-item intrinsic motivation measure and its re-test reliability in this sample of individuals 
Table 16. Correlations Among Participant Intrinsic Motivation Scores Across Study Periods 
             Period 0 6 12 
0   - Intrinsic Motivation -   
6   - Intrinsic Motivation .50** -  
12 - Intrinsic Motivation .50**   .60** - 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150). 0 = Baseline; 6 = 6-month; 12 = 12-month are presented in boldface  
 
**p < .01, 2-tailed. 
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with schizophrenia and comorbid SUD. Taken together, such results were persuasive enough to 
use this 2-item intrinsic motivation measure for informing the subsequent analytic approaches 
employed for examining the cross-sectional and longitudinal relationships between intrinsic 
motivation and substance use severity, and whether such relations vary across genders.  
 
D. AIM#2 EXAMINE THE CROSS-SECTIONAL RELATIONSHIPS BETWEEN 
INTRINSIC MOTIVATION, GENDER, AND SUBSTANCE USE SEVERITY 
1.  Bivariate Relationship between Intrinsic Motivation and Substance Use Severity 
After validating an intrinsic motivation measure consisting of 2-items (purpose and 
motivation) taken from the QLS in comorbid SUD and schizophrenia, the first step was taken in 
elucidating the relations between intrinsic motivation and substance use severity by examining 
the bivariate, cross-sectional relationship between intrinsic motivation and AUS (log)/ DUS (log) 
scores at baseline.  As can be seen in Table 17, small but significant or trend-level relationships 
were observed between intrinsic motivation scores and AUS (log)/ DUS (log) scores at baseline.  
Relationship estimates were the largest and only statistically significant for the relationship 
between intrinsic motivation scores and AUS (log) scores, although a trend toward significance 
was observed for the association between intrinsic motivation and DUS (log) scores.  The 
direction of these relationships indicated the hypothesis (Hypothesis 2a) that statistically 
significant negative relations would exist between intrinsic motivation and substance use severity 
in a bivariate context at baseline was partially supported.  
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2.  Multivariable Relationship between Intrinsic Motivation and Substance Use Severity, 
Adjusting for Demographic and Clinical Confounds, Neurocognition and Negative 
Symptoms 
Having found partial support for significant negative relations between intrinsic 
motivation and substance use severity in a bivariate context, such relationships were further 
examined in a multivariable context, after adjusting for age, illness chronicity, and total 
psychopathology.  Table 18 presents the results of partial correlation analyses investigating the 
relations between intrinsic motivation scores and AUS (log)/ DUS (log) scores at baseline, after 
adjusting for the effects of these potential demographic and clinical confounds.  As can be seen 
in this table, only small and statistically non-significant relations were observed between 
intrinsic motivation scores and AUS (log)/ DUS (log) scores in this multivariable context, 
adjusting for age, illness chronicity, and overall psychopathology.  Such findings surprisingly 
suggest no cross-sectional relationship between intrinsic motivation and substance use severity 
Table 17. Bivariate Associations Between Intrinsic Motivation and Substance Use Severity at 
Baseline 
 
                                         Variable 
 
AUS (log)a 
 
DUS (log)b 
Intrinsic Motivationc -.09*  -.07†  
Note. Zero-order correlation analyses were conducted on the baseline sample (n = 535). AUS 
= Alcohol Use Scale; DUS = Drug Use Scale.  
a Higher scores indicate greater alcohol use severity. 
b Higher scores indicate greater drug use severity. 
c Higher scores indicate greater degrees of intrinsic motivation.  
 
†p < .15, *p < .05, two-tailed. 
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among persons with comorbid SUD and schizophrenia after adjusting for these clinical and 
demographic and clinical confounds.  
 
 
Upon finding little to no support for significant cross-sectional relations between intrinsic 
motivation and substance use severity after controlling for age, illness chronicity, and overall 
psychopathology, such relations were further investigated using hierarchical regression analyses. 
This approach examines the relationship between intrinsic motivation scores and AUS (log)/ 
DUS (log) scores, adjusting for these demographic and clinical confounds, neurocognition and 
negative symptoms. While this series of analyses may seem excessive, given the null results 
garnered from the partial correlation analyses, such an approach affords benefits beyond the 
previous analyses.  For example, the potential for a suppression effect of negative symptoms and 
neurocognition should not be overlooked, given that the aspects of intrinsic motivation that are 
most strongly associated with substance use severity may only be those that are independent of 
negative symptoms and neurocognition (see Paulhus, Robins, Trzesniewski, & Tracy, 2004, for 
Table 18. Multivariable Associations Between Intrinsic Motivation and Substance Use 
Severity at Baseline 
 
                                         Variable 
 
AUS (log)a 
 
DUS (log)b 
Intrinsic Motivationc -.06 -.05 
Note. Partial correlation analyses adjusting for age, illness chronicity, and psychopathology 
were conducted on the baseline sample (n = 535). AUS = Alcohol Use Scale; DUS = Drug 
Use Scale.  
a Higher scores indicate greater alcohol use severity. 
b Higher scores indicate greater drug use severity. 
c Higher scores indicate greater degrees of intrinsic motivation.  
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review). In addition, this approach allows for the examination of the effects of study site 
variability and participant comorbidity status on the relationship between intrinsic motivation 
and substance use severity. 
 Table 19 presents the results of a series of hierarchical linear regression models 
examining the relationship between intrinsic motivation scores and AUS (log)/ DUS (log) scores 
at baseline, after adjusting for demographic and clinical confounds, negative symptoms and 
neurocognition.  As can be seen in this table, a significant negative prediction of AUS (log) 
scores was observed by intrinsic motivation scores, after adjusting for the effects of demographic 
and clinical confounds, negative symptoms and neurocognition, B = -0.03, t(457) = -2.02, p = 
.043.  In addition, a significant prediction of DUS (log) scores was observed by intrinsic 
motivation scores, after adjusting for these potential confounds, B = -0.03, t(457) = -2.36, p = 
.018.  Further, patient comorbidity status and total psychopathology scores were also found to 
significantly predict DUS scores (all p < .001).  No other clinical or demographic confounders 
were observed to significantly predict AUS (log) or DUS (log) scores (all p > .415).   
Overall, results garnered from such hierarchical regression analyses showed significant 
negative relations exist between intrinsic motivation scores and AUS (log)/ DUS (log) scores at 
baseline, after adjusting for demographic and clinical confounds, neurocognition and negative 
symptoms.  While such results are inconsistent with those observed in the partial correlation 
analyses (see Table 18), methodologists have indicated that this paradoxical pattern occurs when 
variables (i.e., neurocognition and negative symptoms) improve the prediction of the criterion 
independent variable (i.e., intrinsic motivation) by suppressing criterion irrelevant variance (see 
Paulhus et al., 2004, for review).  Consequently, results of this series of multivariable analyses 
appear to suggest a suppression effect of neurocognition and negative symptoms on relations 
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between intrinsic motivation and substance use severity at baseline.  
In summary, results garnered from the hierarchical regression analyses support the 
hypothesis (Hypothesis 2b) that significant negative relations would exist between intrinsic 
motivation scores and substance use severity scores in a multivariable context, adjusting for 
demographic and clinical confounds, negative symptoms and neurocognition. 
 
Table 19. Associations Between Intrinsic Motivation and Substance Use Severity after Adjusting 
for Neurocognition and Negative Symptoms 
  AUS (log)a  DUS (log)b 
               Variable/Step  B SE p  B SE p 
Step 1  Demographic and Clinical Characteristics 
       Age  0.00 0.01 .732  0.00 0.02 .824 
       Comorbidity Statusc  0.00 0.02 .923  0.20 0.02 <.001 
       Study Sited  0.11 0.13 .403  0.03 0.13 .818 
       Illness Chronicitye  0.01 0.02 .744  -0.00 0.02 .869 
       PANSS Totalf  0.00 0.02 .762  0.04 0.15 <.001 
  Negative Symptoms and Neurocognition 
Step 2  ∆R2 = .00  ∆R2 = .00 
       PANSS Negativeg  -0.01 0.02 .565  -0.03 0.02 .300 
       Neurocognition Totalh  0.01 0.16 .742  -0.00 0.01 .704 
  Intrinsic Motivation 
Step 3  ∆R2 = .01  ∆R2 = .01 
       Intrinsic Motivationi  -0.03 0.01 .043  -0.03 0.01 .018 
Note. Analyses were conducted on the baseline sample (n = 535). AUS = Alcohol Use Scale; 
DUS = Drug Use Scale; PANSS = Positive and Negative Syndrome Scale. Step 1 and Step 2 are 
only presented once to reduce visual clutter and to avoid redundancy.  
a Higher scores indicate greater alcohol use severity. 
b Higher scores indicate greater drug use severity. 
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3.  Bivariate Relationship between Gender and Substance Use Severity  
 Having found that intrinsic motivation scores were statistically related to AUS (log)/ 
DUS (log) scores after adjusting for demographic and clinical confounds, neurocognition and 
negative symptoms, the relations between gender and substance use severity were investigated.  
Comparable degrees of substance use severity were observed for men and women with comorbid 
SUD and schizophrenia at baseline (see Table 20).  Such findings suggest no cross-sectional 
relations between gender and substance use severity among persons with comorbid SUD and 
schizophrenia.  The hypothesis that men would demonstrate significantly higher mean scores on 
the AUS (log) or the DUS (log) than women at baseline (Hypothesis 2c) was not supported.  
c Comorbidity Status = 3 mutually exclusive groups based on DSM-IV SCID diagnoses. B 
represents the average effect of participant comorbidity status.  
d Study Site = 57 study sites for the CATIE trial. B represents the average effect of study site.  
e Higher values indicate greater years of schizophrenia treatment.  
f Higher scores indicate greater psychopathology.  
g Higher scores indicate greater degrees of negative symptomatology  
h Higher scores indicate better neurocognitive function.  
i Higher scores indicate greater degrees of intrinsic motivation. 
Table 20. Comparisons of Substance Use Severity Between Men and Women at Baseline 
 Men 
n = 449 
Women 
n = 86 
 
Analysisa 
                          Variable M (SD) M (SD) t p 
AUS (log)b 1.00 (0.29) 0.93 (0.28) 1.25 .210 
DUS (log)c 0.31 (0.14) 0.35 (0.04) 0.17 .865 
Note. Analyses were conducted on the baseline sample (n = 535). AUS = Alcohol Use Scale; 
DUS = Drug Use Scale.  
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4. Bivariate Relationship between Gender and Intrinsic Motivation  
 After observing comparable degrees of substance use severity between the genders at 
baseline, the cross-sectional relationship between men and women and intrinsic motivation was 
investigated.  Women demonstrated significantly higher intrinsic motivation scores than men at 
baseline (Table 21). This finding supports the hypothesis (Hypothesis 2d) that men would 
demonstrate significantly greater deficits in intrinsic motivation compared to women at baseline.  
 
 
E. AIM#3 EXAMINE THE LONGITUDINAL CONTRIBUTION OF CHANGES IN 
INTRINSIC MOTIVATION TO CHANGES IN SUBSTANCE USE SEVERITY, AND 
THEN INVESTIGATE THE IMPACT OF GENDER ON THESE RELATIONSHIPS  
1. Longitudinal Change in Substance Use Severity   
To begin examining the longitudinal contribution of changes in intrinsic motivation to 
changes in substance use severity, and the impact of gender on such relations, the 1-year rates of 
a Independent sample t-test (two-tailed).  
b Higher mean scores indicate greater alcohol use severity. 
c Higher mean scores indicate greater drug use severity. 
Table 21. Comparisons of Intrinsic Motivation Between Men and Women at Baseline 
 Men 
n = 449 
Women 
n = 86 
 
Analysisa 
                                Variable M (SD) M (SD) t p 
Intrinsic Motivationb 4.71 (2.66) 5.84 (2.89) 3.53 <.001 
Note. Analyses were conducted on the baseline sample (n = 535).  
a Independent sample t-test (two-tailed).  
b Higher mean scores indicate greater degrees of intrinsic motivation. 
167 
 
change in AUS (log)/ DUS (log) scores were investigated.  This was accomplished by fitting two 
linear unconditional growth curve models to the longitudinal data structure, where AUS (log) 
and DUS (log) scores were each predicted from time (0 = baseline, 0.5 = follow-up at 6-months, 
and 1 = follow-up at 1-year). Such an approach provides useful empirical evidence for 
determining a proper specification of individual growth over time (i.e., 1-year rates of change in 
AUS [log]/ DUS [log] scores) and baseline statistics (i.e., initial status in AUS [log]/ DUS [log] 
scores) for expanding to subsequent conditional models.  Consistent with guidelines for the 
appropriateness of using linear growth curve models to capture systematic change in individual 
substance use severity phenomena over time, sufficient between-patient dependence was 
achieved  for both AUS (log) (ICC = 0.56) and  DUS (log) (ICC = 0.59) unconditional models 
(Hox, 2000; Raudenbush & Bryk, 2009).  As can be seen in Table 22, the χ2 of difference test 
favored the AUS (log)/ DUS (log) unconditional models fit with level-1 AR(1) error covariance 
structures.  Consequently, final AUS (log)/ DUS (log) unconditional models were fit with level-1 
AR(1) error covariance structures and were estimated using REML methods (Bliese & Ployhart, 
2002; Raudenbush & Bryk, 2009).  
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Table 23 presents the results for the AUS (log) and DUS (log) unconditional growth 
curve models.  As can be seen in this table, the estimated average AUS (log) score at baseline 
was 1.00 (log), with patients showing significant reductions in alcohol use severity by -0.07 (log) 
every six months over 1-year, t(367) = -3.72, p < .001. The estimated average DUS (log) score at 
baseline was 0.98 (log), with patients exhibiting significant reductions in drug use severity by     
-0.09 (log) every six months over 1-year, t(367) = -4.22, p < .001. In addition, significant 
variability was observed among patients in terms of their mean baseline AUS scores, [τ01 = 0.04 
(95% CI = 0.18 to 0.24)]; and with regard to the mean rates of reduction in alcohol use severity 
Table 22. Comparisons of Deviance Statistics Across Alternative Models (Unconditional Models) 
    AUS (log) Model Summary  Deviance df  
            1- Unrestricted Model   -80.91 6  
            2- AR(1)   -124.84 7  
    AUS (log) Model Comparison   Deviance Difference χ2a p 
            Model 1 vs. Model 2   43.93 87.86 <.001 
     
    DUS (log) Model Summary   Deviance df  
           1- Unrestricted Model   -142.31 6  
           2- AR(1)   -174.07 7  
    DUS (log) Model Comparison   Deviance Difference χ2b p 
         Model 1 vs. Model 2   31.76 63.51 <.001 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150). AUS = Alcohol Use Scale; DUS = Drug Use Scale. AR(1) = first order 
autoregressive error structure. FIML estimation was used for comparing model1 with model2.  
a χ2 of difference test based on the deviance statistic indicated that adding an AR(1) error 
covariance structure to the unrestricted model improved the AUS unconditional model fit. 
b χ2 of difference test based on the deviance statistic indicated that adding an AR(1) error 
covariance structure to the unrestricted model improved the DUS unconditional model fit. 
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observed over 1-year, [τ11 = 0.01 (95% CI = 0.01 to 1.64)].  Patients also demonstrated 
significant variability with regard to their mean baseline DUS scores, [τ01 = 0.05 (95% CI = 0.18 
to 0.26)], but not in terms of the mean rates of reduction in drug use severity observed over 1-
year, [τ11 = 0.04 (95% CI = 0.14 to -0.20)].  While significant variability was not observed in 
terms of the mean rates of reduction in drug use severity observed over 1-year, subgroups may 
exist for whom there are differences in such longitudinal trajectories (i.e., women, patients with 
low intrinsic motivation), and thus the moderators of these slopes are still tested in subsequent 
conditional growth models (Hoffman, 1997). Taken together, results garnered from these 
unconditional models support the hypothesis (Hypothesis H3a) that patients would demonstrate, 
on average, significant reductions in AUS (log) and DUS (log) scores over 1-year, suggesting 
significant longitudinal improvement in substance use severity. 
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2. Longitudinal Relationship between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity  
 After finding that patients demonstrated significant reductions in substance use severity 
over the 1-year study, the longitudinal contribution of changes in intrinsic motivation to changes 
Table 23. 1-Year Trajectories of Substance Use Severity (Unconditional Models) 
                                Parameter  AUS (log) Unconditional Modela  
 Fixed Effect  Coefficient SE t p 
        Mean Initial Status, 𝛽00  1.00 0.01 80.15 <.001 
        Mean Growth Rate, 𝛽10  -0.07 0.02 -3.72 <.001 
Random Effect  Variance Component 95% CI 
       Initial Status, Var(r0i) = τ01  0.04 0.18 to 0.24 
       Growth Rate, Var(r1i) = τ11  0.01 0.01 to 1.64 
       Level-1 error, Var(e1i) = σ2  0.04 - 
                                Parameter  DUS (log) Unconditional Modelb  
Fixed Effect  Coefficient SE t p 
        Mean Initial Status, 𝛽00  0.98 0.01 69.98 <.001 
        Mean Growth Rate, 𝛽10  -0.09 0.02 -4.22 <.001 
Random Effect  Variance Component 95% CI 
       Initial Status, Var(r0i) = τ01  0.05 0.18 to 0.26 
       Growth Rate, Var(r1i) = τ11  0.04 0.14 to -0.20 
       Level-1 error, Var(e1i) = σ2  0.05 - 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150).  AUS = Alcohol Use Scale; DUS = Drug Use Scale.  
a Only the final AUS unconditional model is presented to reduce visual clutter, which was fit 
using AR(1) and REML estimation.  
b Only the final DUS unconditional model is presented to reduce visual clutter, which was fit 
using AR(1) and REML estimation.  
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in substance use severity was investigated.  This was accomplished by expanding the previously 
fit unconditional models to conditional models such that AUS (log)/ DUS (log) scores were each 
predicted from time and a time-varying intrinsic motivation variable.  Notably, there is no 
consensus on whether to fit the slopes of time-varying variables as fixed or random (McCoach & 
Kaniskan, 2010), and methodologists have cautioned against fitting such slopes as randomly 
varying by default particularly when individual phenomena are observed over few measurement 
occasions (i.e., < 5)  (Lou & Kwok, 2006; Meyers & Beretvas, 2006; Raudenbush & Bryk, 2009; 
McCoach & Kaniskan, 2010).  As such, given that only three measurement occasions (baseline, 
6-months, and 1-year) were used to test this hypothesis, time-varying intrinsic motivation’s slope 
was fit as a fixed effect only in the final AUS (log)/ DUS (log) conditional growth models, which 
provides estimates of the average relationship between changes in intrinsic motivation and 
changes in substance use severity for patients in the overall sample.  
    Table 24 presents the results of the final conditional growth curve models where AUS 
(log)/ DUS (log) scores were each predicted from time and time-varying intrinsic motivation.  As 
can be seen in this table, the average effect of intrinsic motivation on AUS (log) scores was 
highly statistically significant (𝛽20 = -0.01, p < .001). Such results indicate that average 
improvements in intrinsic motivation were associated with significant reductions in patient’s 
alcohol use severity over the 1-year study.  In addition, the average effect of intrinsic motivation 
on DUS (log) scores was also statistically different from 0 (𝛽20 = -0.01, p = .024).  These 
findings indicate that average improvements in intrinsic motivation were associated with 
significant reductions in patient’s drug use severity over 1-year.  Consequently, it appears that 
the results garnered from these conditional growth curve analyses lend support to the Hypothesis 
(Hypothesis 3b) that patients would exhibit significant reductions in substance use severity as 
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they make improvements in intrinsic motivation over the 1-year study period.  
 
 
 Previous preliminary (Section 4.B.4) and cross-sectional (Section 4.D.2) analyses 
signaled age, illness chronicity, overall psychopathology, and comorbidity status as potential 
confounds to the relationship between intrinsic motivation and substance use severity. As such, 
analysis proceeded by including these potential confounds as time-invariant covariates at level-2, 
as they may account for differences in estimating the longitudinal relationships between changes 
in intrinsic motivation and changes in substance use severity.  In addition, AUS (log)/ DUS (log) 
Table 24. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity (Conditional Growth Models) 
                                Parameter  AUS (log) Conditional Modela  
 Fixed Effect  Coefficient     SE t p 
        Mean Initial Status, 𝛽00  1.06 0.02 50.45 <.001 
        Mean Growth Rate, 𝛽10  -0.08 0.02 -4.11 <.001 
       Time-Varying IM, 𝛽20  -0.01 0.01 -3.79 <.001 
                                Parameter  DUS (log) Conditional Modelb  
Fixed Effect  Coefficient SE t p 
        Mean Initial Status, 𝛽00  1.02 0.02 45.07 <.001 
        Mean Growth Rate, 𝛽10  -0.09 0.02 -4.15 <.001 
        Time-Varying IM, 𝛽20  -0.01 0.01 -2.25   .024 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150).  AUS = Alcohol Use Scale; DUS = Drug Use Scale; IM = Intrinsic 
Motivation.  
a Only the final AUS conditional model is presented to reduce visual clutter, which was fit with 
AR(1) and accounted for heteroscedasticity of level-1 errors. REML estimation was used. 
b Only the final DUS conditional model is presented to reduce visual clutter, which was fit 
using AR(1) and REML estimation. 
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conditional models adjusted for phase1 randomization medication effects at level-2.  
Table 25 presents the results of the AUS (log) conditional growth curve model where 
such scores were predicted from time and time-varying intrinsic motivation, adjusting for age, 
illness chronicity, overall psychopathology, comorbidity status, and phase1 randomization.  As 
can be seen in this table, the average effect of intrinsic motivation on AUS (log) scores was 
statistically different from 0 (𝛽20 = -0.01, p < .001).  Therefore, after adjusting for these potential 
demographic and clinical confounds, the results continued to suggest that average improvements 
in intrinsic motivation were associated with significant reductions in patient’s alcohol use 
severity over 1-year. Consequently, these findings indicate that intrinsic motivation change is an 
important incremental predictor of reductions in patient’s alcohol use severity above and beyond 
the effects of age, illness chronicity, overall psychopathology, comorbidity status, and phase1 
randomization.  
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Table 25. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Alcohol Use Severity, Adjusting for Demographic and Clinical Confounds 
Fixed Effect                          Parameter  Coefficient SE t p 
 Initial Status 𝛽00  1.06 0.04 24.03 <.001 
        AUD/ SUDa 𝛽01  0.05 0.03 1.69 .090 
        SUDa 𝛽02  -0.68 0.03 -1.96 .049 
        AUDb 𝛽03  0.06 0.03 1.96 .050 
        Quetiapinec 𝛽04  -0.01 0.04 -0.41 .681 
        Perphenazinec 𝛽05  -0.01 0.04 -0.25 .801 
        Ziprasidonec 𝛽06  -0.01 0.05 -0.28 .778 
        Risperidonec 𝛽07  -0.01 0.04 -0.15 .876 
        Olanzapined 𝛽08  0.01 0.04 0.41 .681 
        Age 𝛽09  -0.00 0.00 -0.07 .940 
        Chronicity 𝛽010  0.00 0.00 0.17 .863 
        PANSS Total 𝛽011  0.00 0.01 0.13 .893 
Growth Rate 𝛽10  -0.07 0.05 -1.26 .205 
        Time x AUD/ SUDa 𝛽11  0.01 0.05 -0.23 .813 
        Time x SUDa 𝛽12  -0.02 0.06 0.29 .765 
        Time x AUDb 𝛽13  0.01 0.05 0.29 .770 
        Time x Quetiapinec 𝛽14  -0.05 0.06 -0.82 .412 
        Time x Perphenazinec 𝛽15  0.03 0.06 0.65 .513 
        Time x Ziprasidonec 𝛽16  0.03 0.07 0.45 .652 
        Time x Risperidonec 𝛽17  0.02 0.05 0.43 .666 
        Time x Olanzapined 𝛽18  0.05 0.06 0.82 .412 
        Time x Age 𝛽19  -0.00 0.00 -1.45 .147 
        Time x Chronicity 𝛽120  0.00 0.00 0.96 .333 
        Time x PANSS Total 𝛽121  0.00 0.00 0.24 .805 
Time-Varying IM 𝛽20  -0.01 0.01 -3.61 <.001 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150).  IM = Intrinsic Motivation. AUD/ SUD = alcohol use disorder and other 
substance use disorder; SUD = substance use disorder other than alcohol use disorder; AUD = 
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Table 26 presents the results of the DUS (log) conditional growth curve model where 
such scores were predicted from time and time-varying intrinsic motivation, adjusting for age, 
illness chronicity, overall psychopathology, comorbidity status, and phase1 randomization. As 
can be seen in this table, the average effect of intrinsic motivation on DUS (log) scores was 
statistically significant (𝛽20 = -0.01, p = .039).  Therefore, after adjusting for such confounds, the 
findings continued to suggest that average improvements in intrinsic motivation were associated 
with significant reductions in patient’s drug use severity over 1-year. These findings also signal 
that intrinsic motivation change is a key incremental predictor to reductions in patient’s drug use 
severity above and beyond the effects of age, illness chronicity, overall psychopathology, 
comorbidity status, and phase1 randomization.  
 
 
 
 
 
 
alcohol use disorder; PANSS = Positive and Negative Syndrome Scale. Only the final AUS 
(log) model is presented to reduce visual clutter, which was fit using AR(1) and accounted for 
heteroscedasticity of level-1 errors. REML estimation was used. Age, Chronicity, and PANSS 
Total were grand mean centered.  
aReference category is AUD.  
bReference category is SUD. 
cReference category is Olanzapine. 
dReference category is Quetiapine.  
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Table 26. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in Drug 
Use Severity, Adjusting for Demographic and Clinical Confounds 
Fixed Effect                          Parameter  Coefficient SE t p 
 Initial Status 𝛽00  0.85 0.04 17.98 <.001 
        AUD/ SUDa 𝛽01  0.29 0.03 8.31 <.001 
        SUDa 𝛽02  0.27 0.03 7.36 <.001 
        AUDb 𝛽03  0.06 0.03 1.96 .050 
        Quetiapinec 𝛽04  -0.06 0.04 -1.29 .196 
        Perphenazinec 𝛽05  -0.05 0.05 -1.14 .252 
        Ziprasidonec 𝛽06  -0.09 0.04 -1.99 .046 
        Risperidonec 𝛽07  -0.07 0.04 -1.72 .085 
        Olanzapined 𝛽08  0.01 0.04 0.41 .681 
        Age 𝛽09  -0.00 0.00 -0.09 .927 
        Chronicity 𝛽010  -0.00 0.00 -0.92 357 
        PANSS Total 𝛽011  0.00 0.00 2.70 .007 
Growth Rate 𝛽10  -0.07 0.06 -1.20 .229 
        Time x AUD/ SUDa 𝛽11  -0.12 0.06 -2.11 .035 
        Time x SUDa 𝛽12  -0.11 0.06 -1.82 .068 
        Time x AUDb 𝛽13  0.01 0.05 0.29 .770 
        Time x Quetiapinec 𝛽14  0.74 0.07 0.97 .332 
        Time x Perphenazinec 𝛽15  0.09 0.07 1.29 .197 
        Time x Ziprasidonec 𝛽16  0.22 0.08 2.60 .009 
        Time x Risperidonec 𝛽17  0.10 0.06 1.51 .131 
        Time x Olanzapined 𝛽18  0.05 0.06 0.82 .412 
        Time x Age 𝛽19  0.00 0.00 0.50 .612 
        Time x Chronicity 𝛽120  0.00 0.00 0.08 .932 
        Time x PANSS Total 𝛽121  -0.00 0.00 -0.27 .783 
Time-Varying IM 𝛽20  -0.01 0.00 -2.06 .039 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150).  IM = Intrinsic Motivation. AUD/ SUD = alcohol use disorder and other 
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 Having found evidence that intrinsic motivation change is an important incremental 
predictor of reductions in patient’s alcohol/ drug use severity above and beyond the effects of 
several key demographic and clinical confounders, the consistency of these findings were further 
examined, adjusting for neurocognition and negative symptoms.  Even after adjusting for key 
demographic and clinical confounds, neurocognition and negative symptoms, the findings 
continued to suggest that average improvements in intrinsic motivation were associated with 
significant reductions in patient’s substance use severity over 1-year (see Table 26).  
Taken together, results garnered from the AUS (log)/ DUS (log) conditional models 
highlight the importance of longitudinal changes in intrinsic motivation to changes in substance 
use severity among individuals with schizophrenia and comorbid substance use disorders. This 
series of conditional growth curve analyses support the study hypothesis (Hypothesis 3b) that 
improvements in intrinsic motivation would be associated with significant reductions in 
substance use severity over the 1-year study. 
substance use disorder; SUD = substance use disorder other than alcohol use disorder; AUD = 
alcohol use disorder. PANSS = Positive and Negative Syndrome Scale. Only the final DUS 
(log) model is presented to reduce visual clutter, which was fit using AR(1) and REML 
estimation. Age, Chronicity, and PANSS Total were grand mean centered.  
aReference category is AUD.  
bReference category is SUD. 
cReference category is Olanzapine. 
dReference category is Quetiapine. 
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Table 27. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity, Adjusting for Demographic and Clinical Confounds, Neurocognition 
and Negative Symptoms 
Fixed Effect                          Parameter  Coefficient SE t p 
 AUS (log) Conditional Growth Modela 
 Initial Status 𝛽00  1.07 0.04 24.20 <.001 
        PANSS Negative 𝛽012  -0.01 0.00 -1.48 .137 
        Neurocognition  𝛽013  -0.01 0.02 -0.03 .979 
Growth Rate 𝛽10  -0.08 0.05 -1.50 .134 
        Time x PANSS Negative 𝛽122  0.01 0.00 1.64 .101 
        Time x Neurocognition 𝛽123  -0.00 0.02 -0.02 .279 
Time-Varying IM 𝛽20  -0.01 0.01 -3.95 <.001 
 DUS (log) Conditional Growth Modelb 
 Initial Status 𝛽00  0.87 0.04 19.20 <.001 
        PANSS Negative 𝛽012  -0.01 0.00 -2.08 .037 
        Neurocognition  𝛽013  -0.01 0.01 -0.01 .984 
Growth Rate 𝛽10  -0.07 0.06 -1.16 .244 
        Time x PANSS Negative 𝛽122  0.01 0.00 0.45 .652 
        Time x Neurocognition 𝛽123  0.02 0.02 0.93 .352 
Time-Varying IM 𝛽20  -0.01 0.01 -2.69 .007 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150).   AUS = Alcohol Use Scale; DUS = Drug Use Scale; IM = Intrinsic 
Motivation. PANSS = Positive and Negative Syndrome Scale.  
a Only the final AUS conditional growth model with effects of interest are presented to reduce 
visual clutter. Age, chronicity, overall psychopathology, comorbidity status, phase1 
randomization, negative symptoms, and neurocognition were adjusted at level-2. Age, 
Chronicity, PANSS Total, PANSS Negative, and neurocognition were grand mean centered.  
This model was fit using AR(1) and accounted for heteroscedasticity of level-1 errors. REML 
estimation was used. 
b Only the final DUS conditional growth model with effects of interest are presented to reduce 
visual clutter. Age, chronicity, overall psychopathology, comorbidity status, phase1 
179 
 
 
Finally, to understand the magnitude of the aforementioned results from a threshold 
perspective, raw metric conversions were computed from log transformations to discern expected 
reductions in AUS (raw)/ DUS (raw) scores for one, two, and three unit increases in intrinsic 
motivation. As can be seen in Table 28, patients AUS (raw)/ DUS (raw) scores reduced by 
approximately 1 point for a 1 unit increase in IM scores every 6-months over the 1-year study 
period.  
 
 
randomization, negative symptoms, and neurocognition were adjusted at level-2. Age, 
Chronicity, PANSS Total, PANSS Negative, and neurocognition were grand mean centered. 
This model was fit using AR(1) and REML estimation.  
 
Table 28. Raw metric and threshold conversions for expected increases in AUS/ DUS scores for 
one, two, and three unit increases in intrinsic motivation 
 1x (raw) 2x (raw) 3x (raw) 
AUS Conditional Model Coefficient     SE Coefficient     SE Coefficient     SE 
   Time-Varying IM, 𝛽20 0.99 1.01 1.98 2.02 2.97 3.03 
 1x (raw) 2x (raw) 3x (raw) 
DUS Conditional Model Coefficient  SE Coefficient SE Coefficient SE 
  Time-Varying IM, 𝛽20 0.99 1.01 1.98 2.02 2.97 3.03 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 219; 
1-year, n = 150).  AUS = Alcohol Use Scale; DUS = Drug Use Scale; IM = Intrinsic Motivation. 1x 
= expected decrease in AUS/ DUS for 1 unit increase in IM; 2x = expected decrease in AUS/ DUS 
for a 2 unit increase in IM; 3x = expected decrease in AUS/ DUS for a 3 unit increase in IM.  
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3. Moderating Effect of Gender on the Longitudinal Association between Changes in 
Intrinsic Motivation and Changes in Substance Use Severity  
Having demonstrated average longitudinal improvements in intrinsic motivation were 
associated with significant reductions in substance use severity, the impact of gender on these 
relationships estimates was investigated through the use of gender moderated conditional growth 
curve models.  As can be seen in Table 29, no significant gender interactions were found for 
estimates of the relationship between changes in intrinsic motivation and changes in alcohol or 
drug use severity.  Consequently, such findings do not support the study hypothesis (Hypothesis 
3c) that women would demonstrate a stronger association between improvements in intrinsic 
motivation and reductions in substance use severity than men over the 1-year study. 
Table 29. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity (Gender Moderated Conditional Growth Models) 
Fixed Effect                          Parameter  Coefficient SE T p 
 AUS (log) Gender Moderated Conditional Growth Modela 
 Initial Status 𝛽00  1.07 0.07 14.53 <.001 
 Male 𝛽01  -0.04 0.06 0.72 .469 
Growth Rate 𝛽10  -0.04 0.06 -0.78 .433 
Time-Varying IM 𝛽20  -0.02 0.01 -2.61 .009 
Time-Varying IM x Male 𝛽21  0.01 0.01 1.19 .232 
 DUS (log) Gender Moderated Conditional Growth Modelb 
Initial Status 𝛽00  0.86 0.07 11.40 <.001 
Male 𝛽01  0.02 0.06 0.37 .708 
Growth Rate 𝛽10  -0.09 0.06 -1.46 .144 
Time-Varying IM 𝛽20  -0.01 0.01 -0.50 .613 
Time-Varying IM x Male 𝛽21  -0.01 0.01 -0.61 .536 
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After finding no significant gender interactions, follow-up analyses were computed 
within subsamples of men and women using conditional growth models for estimates of the 
relations between changes in intrinsic motivation and changes in substance use severity.  As can 
be seen in Table 30, average improvements in intrinsic motivation was associated with 
significant reductions in drug/ alcohol use severity within the subsample of men.  Within the 
subsample of women, average improvements in intrinsic motivation was only associated with a 
non-significant trend in alcohol use severity reductions, and no significant or marginal 
associations were observed with regard to the relationship between intrinsic motivation and drug 
use severity over 1-year (Table 30). Such findings were unexpected and seemingly contradict the 
study hypothesis (Hypothesis 3c) that women would show stronger associations between 
improvements in intrinsic motivation and greater reductions in substance use severity than men 
over 1-year.    
 
Note. Analyses were conducted on the intent-to-study sample (baseline, n = 535; 6-month, n = 
219; 1-year, n = 150).  AUS = Alcohol Use Scale; DUS = Drug Use Scale; IM = Intrinsic 
Motivation.  
a Only the final AUS gender moderated conditional growth model with effects of interest are 
presented to reduce visual clutter. Age, chronicity, psychopathology, comorbidity status, 
phase1 randomization, and race were adjusted at level-2. Age, Chronicity, and PANSS Total 
were grand mean centered. This model was fit using AR(1) and accounted for 
heteroscedasticity of level-1 errors. REML estimation was used.  
b Only the final DUS gender moderated conditional growth model with effects of interest are 
presented to reduce visual clutter. Age, chronicity, psychopathology, comorbidity status, 
phase1 randomization, and race were adjusted at level-2. Age, Chronicity, and PANSS Total 
were grand mean centered. This model was fit using AR(1) and accounted for 
heteroscedasticity of level-1 errors. REML estimation was used.  
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Table 30. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity (Subsamples of Men and Women) 
Fixed Effect                          Parameter  Coefficient SE t p 
Mena AUS (log) Conditional Growth Model 
     Initial Status 𝛽00  1.04 0.05 19.47 <.001 
     Growth Rate 𝛽10  -0.04 0.07 -0.63 .528 
     Time-Varying IM 𝛽20  -0.01 0.00 -2.69 .007 
Womenb   
     Initial Status 𝛽00  0.98 0.10 9.03 <.001 
     Growth Rate 𝛽10  -0.06 0.08 -0.71 .478 
     Time-Varying IM 𝛽20  -0.01 0.01 -1.97 .054 
Mena DUS (log) Conditional Growth Model 
     Initial Status 𝛽00  0.89 0.05 16.77 <.001 
     Growth Rate 𝛽10  -0.05 0.07 -0.67 .497 
     Time-Varying IM 𝛽20  -0.01 0.00 -2.73 .006 
Womenb  
     Initial Status 𝛽00  0.77 0.13 5.73 <.001 
     Growth Rate 𝛽10  -0.24 0.17 -1.35 .183 
     Time-Varying IM 𝛽20  0.01 0.01 0.10 .914 
Note. AUS = Alcohol Use Scale; DUS = Drug Use Scale; IM = Intrinsic Motivation. Only 
final AUS/ DUS conditional growth models with effects of interest are presented to reduce 
visual clutter. Models adjusted for the effects of age, chronicity, psychopathology, comorbidity 
status, phase1 randomization, and race at level-2. Age, Chronicity, and PANSS Total were 
grand mean centered. Models were fit using AR(1) and accounted for heteroscedasticity of 
level-1 errors. REML estimation was used.  
a Analyses were conducted on the subsample of Men (baseline, n = 449; 6-month, n = 187; 12-
month, n = 126). 
b Analyses were conducted on the subsample of Women (baseline, n = 86; 6-month, n = 32; 
12-month, n = 24).  
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 Having found that investigating gender differences in the relationship between intrinsic 
motivation and substance use severity yielded results that were weaker and somewhat contrary to 
expectations, a series of analyses were conducted to explore subsamples for which substance use 
and SUD diagnosis may have a greater impact on the relationship between intrinsic motivation 
and substance use severity. For example, variations in smoking, drinking, and other substance 
use behavior patterns are frequently associated with different clinical outcomes and potentials for 
achieving remission and recovery among individuals with schizophrenia and comorbid SUD 
(i.e.,Volkow, 2009). Consequently, it stands to reason that the relationship between intrinsic 
motivation and substance use severity may differ in strength depending on the patient’s use of 
substances (i.e., reported within 90-days of enrollment) and/or specific SUD diagnosis (i.e., 
SCID DSM-IV [First et al., 1996] diagnosis determined by a project clinician at study baseline). 
As such, a series of post-hoc exploratory moderator models were carried out to examine the 
longitudinal association between intrinsic motivation and substance use severity by the 
substances patient’s most frequently reported using within 90-days of enrollment (i.e., tobacco, 
alcohol, cannabis, and cocaine), as well as the most commonly diagnosed SUDs (i.e., alcohol use 
disorder, cannabis use disorder, and cocaine use disorder) represented among the sample.  
 Results revealed no significant interactions between intrinsic motivation and tobacco use 
(𝛽21 = 0.01, p = .590), alcohol use (𝛽21 = 0.01, p = .524), cannabis use (𝛽21 = -0.00, p = .968), or 
cocaine use (𝛽21 = -0.01, p = .330) on alcohol use severity. Given this pattern of results, perhaps 
it is not surprising that no significant interactions were found between intrinsic motivation and 
tobacco use (𝛽21 = -0.00, p = .831), alcohol use (𝛽21 = -0.01, p = .418), cannabis use (𝛽21 = 0.01, 
p = .191), or cocaine use (𝛽21 = 0.01, p = .425) on drug use severity either. Having found 
patient’s use of substances within 90-days of enrollment did not moderate the relationship 
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between intrinsic motivation and substance use severity, potential variations in such relations 
were then examined by patient’s SUD diagnosis. Such results revealed no significant interactions 
between intrinsic motivation and any of the most commonly diagnosed SUDs (i.e., alcohol use 
disorder, cannabis use disorder, and cocaine use disorder) on alcohol use severity (all p > .095) 
or on drug use severity (all p > .426).  Such results do not suggest that subsamples of substance 
users or patients with specific SUD diagnoses exist for which intrinsic motivation has a greater 
impact on the relationship between intrinsic motivation and substance use severity among 
individuals with schizophrenia and comorbid SUD.  Consequently, such findings lend support to 
the previously garnered results suggesting that average improvement changes in intrinsic 
motivation lead to broad and significant reductions in substance use severity among those who 
suffer from schizophrenia and comorbid SUD.  
 
 
 
 
 
 
 
 
 
 
 
185 
 
V. DISCUSSION 
 
 Persistent and pervasive patterns of substance use severity are highly problematic 
features of SUD pathology that often plague the lives of those who suffer from schizophrenia 
and comorbid SUD. Despite the introduction of novel rehabilitation programs designed to offset 
the destabilizing patterns of substance use severity observed among this population, individuals 
with schizophrenia and SUD remain difficult to engage, demonstrate low motivation to change 
their substance use behaviors, make slow progress, and drop out of such programs at high rates 
(see Drake et al., 2008; Horsfall et al., 2009; Hunt et al., 2013, for reviews). Consequently, this 
comorbidity continues to be associated with less favorable long-term outcomes in schizophrenia 
and represents a major, unsolved challenge for the clinical management and outcome of this 
population (Mueser et al., 1990; Green et al., 1999; Green, 2005).  Research has increasingly 
pointed to the importance of intrinsic motivation deficits, particularly those stemming from the 
negative symptoms of amotivation and anticipatory anhedonia (Heerey & Gold, 2007; Foussias 
& Remington, 2010; Harvey & Strassnig, 2012), as potential overlooked or unexamined 
contributors to substance use severity in comorbid schizophrenia and SUD and novel areas for 
therapeutic intervention (Martino et al., 2002; Graber et al., 2003; Kavanagh et al., 2004a; James 
et al., 2004; Edwards et al., 2006; Baker et al., 2006), with evidence suggesting that women may 
demonstrate lower deficits in intrinsic motivation than men (Drapalski et al., 2011). Recently, 
exciting research on the presence of deficits in intrinsic motivation, or the ability to carry out 
goal directed behaviors (i.e. reducing substance use severity) in the absence of extrinsic reward 
(i.e., money or praise) (Deci & Ryan, 2007) has documented pervasive deficits in this domain 
among individuals with schizophrenia (Nakagami et al., 2008; Yamada et al., 2010; Nakagami et 
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al., 2010), and linked such deficits to prospective change in psychosocial functioning in a 1-year 
study of community patients with the disorder (Nakagami et al., 2010). Notably, however, the 
study of intrinsic motivation in comorbid schizophrenia and SUD and its contribution to 
substance use severity has been profoundly limited by measures that do not estimate the way 
such deficits may impede this population’s ability to carry out goals, particularly in the areas of 
interest and drive. As such, the longitudinal role of naturalistic change in intrinsic motivation to 
change in substance use severity among individuals with schizophrenia and comorbid SUD and 
the degree to which such relations vary across genders has largely remained unexamined.  
 This research sought to begin to elucidate the role of prospective naturalistic changes in 
intrinsic motivation to changes in substance use severity among persons with schizophrenia and 
comorbid SUD, and the degree to which such relations varied across genders. Secondary data 
were garnered from 535 community patients with schizophrenia and comorbid SUD who were 
randomized (first or second generation antipsychotic medication) to phase1 of the CATIE (see 
Liberman et al., 2005) study and were treated for up to 1-year to (1) extend validation of a 
promising  measure of intrinsic motivation to persons with schizophrenia and comorbid SUD; (2) 
examine the cross-sectional relationships between intrinsic motivation, gender, and substance use 
severity; and (3) investigate the longitudinal contribution of changes in intrinsic motivation to 
changes in substance use severity, and whether gender moderates this relationship.  This chapter 
provides a summary of the results of this research designed to address these aims, as well as a 
discussion of the study limitations and implications for future research and social work practice.  
 
 A. SUMMARY OF FINDINGS 
This investigation provided three important advances to substance use comorbidity in 
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schizophrenia research. First, psychometric examination of a promising measure of intrinsic 
motivation deficits in schizophrenia developed by Nakagami et al. (2008), has now been 
extended to individuals with comorbid SUD and schizophrenia. Of particular importance, results 
garnered from a series of exploratory factor analyses revealed compelling reasons to question the 
prevailing 2-factor orthogonal solution of the intrinsic motivation measure in this population, 
which is considered to be a significant contribution of this research. The resulting 3-factor 
oblique solution found in this research showed an intrinsic motivation factor consisting of the 
QLS items purpose and motivation. This solution is inconsistent with the 2-factor orthogonal 
solution previously found in community schizophrenia samples by Nakagami et al. (2008), 
which showed an intrinsic motivation factor consisting of QLS items purpose, motivation, and 
curiosity. Nevertheless, such results were persuasive enough to inform the subsequent analytic 
approaches used for examining the cross-sectional and longitudinal relations between intrinsic 
motivation and substance use severity in this sample of patients with schizophrenia and 
comorbid SUD.  Psychometric analyses also provided robust support for the reliability of the 
intrinsic motivation measure and its re-test reliability among this population.  
 The second major contribution of this research comes from parsing the relations between 
intrinsic motivation and substance use severity in schizophrenia and comorbid SUD.  Cross-
sectional bivariate relationship estimates were significant for the relationship between intrinsic 
motivation and alcohol use severity, and marginal support was found regarding the association 
between intrinsic motivation and drug use severity.  In addition, cross-sectional multivariate 
relationship estimates revealed a significant negative prediction of alcohol/ drug use severity by 
intrinsic motivation, after adjusting for demographic and clinical confounds, neurocognition and 
negative symptoms. Results of the longitudinal analyses with intrinsic motivation strengthened 
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the findings garnered in the cross-sectional analyses.  Evidence was found suggesting that 
longitudinal intrinsic motivation improvement is a salient incremental predictor of reductions in 
patient’s alcohol/ drug use severity, above and beyond the effects of age, illness chronicity, 
overall psychopathology, comorbidity status, and phase 1 randomization medication effects. 
Such results suggest that changes in intrinsic motivation may be uniquely associated with 
changes in substance use severity in schizophrenia and comorbid SUD. While future research 
will need to replicate these findings, it seems promising that interventions seeking to target 
change in intrinsic motivation deficits as a method of reducing substance use severity in this 
population, may help offset the long-term disability exacted by chronic and pervasive use.  
 The third contribution of this study comes from the elucidation of relations between 
intrinsic motivation, substance use severity, and gender, which were contrary to hypotheses. 
Analyses of relationships with gender indicated little to no cross-sectional associations between 
intrinsic motivation and substance use severity, and gender did not moderate the longitudinal 
association between changes in intrinsic motivation and changes in substance use severity. 
Specifically, while cross-sectional analyses with gender showed that women had significantly 
less intrinsic motivation deficits than men at baseline, these women did not maintain a stronger 
association with intrinsic motivation improvements leading to faster reductions in substance use 
severity than men over 1-year.  Exploratory longitudinal analyses within the subsamples of men 
and women supported average improvements in intrinsic motivation to significant reductions in 
substance use severity within the subsample of men, which was unexpected and contrary to 
expectations.  In addition, average improvements in intrinsic motivation were associated with 
trend-level reductions in alcohol use severity within the subsample of women. Consequently, 
while gender may play some important role in the relationship between intrinsic motivation and 
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substance use severity among those with schizophrenia and comorbid SUD, the outcomes of this 
research suggest that future investigations of these relationships will be needed before deriving 
firm conclusions.   
 The broader implications of the three major contributions of this research will be 
discussed below in detail within the study context in which they were conducted. In addition, a 
number of important study limitations will also be addressed, which require replication of these 
results before confirmatory conclusions can be made regarding the factor structure of the 2-item 
intrinsic motivation instrument and its relations to substance use severity in individuals with 
schizophrenia and comorbid SUD.  First, however, a detailed discussion of the findings of this 
investigation are provided.  
1. Psychometric Properties of the Intrinsic Motivation Measure 
One of the major aims of this research, beyond investigating the relationship between 
intrinsic motivation deficits and substance use severity in schizophrenia and comorbid SUD, was 
to first extend validation of a promising measure of intrinsic motivation deficits in schizophrenia 
to schizophrenia and comorbid SUD.  This research sought to measure intrinsic motivation by 
employing a novel cross-situational technique developed by Nakagami et al. (2008), which 
gauges intrinsic motivation by taking the sum of theoretically pertinent intrapsychic deficit items 
from the QLS (Heinrichs et al., 1984), probing purpose, motivation, and curiosity (Nakagami et 
al., 2008). The psychometric findings of this dissertation study signaled a number of strengths 
and limitations with regard to using the intrinsic motivation measure as developed by Nakagami 
et al. (2008) to assess intrinsic motivation deficits among individuals with schizophrenia and 
comorbid SUD.  Most notably, a series of exploratory factor analyses provided compelling 
reasons to challenge the validity of Nakagami and colleague’s (2008) 2-factor 3-item (purpose, 
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motivation, curiosity) orthogonal solution to their intrinsic motivation instrument when applied 
to individuals with schizophrenia and comorbid SUD.  Rather, this current research found clear 
evidence supporting an alternative factor structure in schizophrenia and comorbid SUD to the 2-
factor orthogonal solution previously found in community patients with schizophrenia.   
Quite surprisingly, factor analytic results of both 2 and 3-factor solutions with orthogonal 
rotation were generally uninterpretable due to numerous split loadings and indefinite solutions. 
Since this series of analyses were being conducted via an exploratory framework, the degree to 
which oblique rotated solutions improved the model fit were investigated. Of note, no evidence 
was found from the screeplots of eigenvalues for additional factors extending beyond a 3-factor 
solution. While factor-analytic results using oblique rotation pointed to the possibility of a 2-
factor solution, a moderately correlated 3-factor solution provided a significantly better fit to the 
observed data. The resulting 3-factor solution found in this research demonstrated an intrinsic 
motivation factor consisting of the QLS items purpose and motivation; the item of curiosity did 
not load to together with these items or on any other factor. Consequently, the curiosity item was 
not retained as part of the intrinsic motivation factor, as the item does not seemingly represent 
part of the construct in schizophrenia and comorbid SUD. While this factor-analytic solution is at 
variance with the 2-factor orthogonal solution previously reported in community patients with 
schizophrenia (Nakagami et al., 2008), it does make some conceptual sense as purpose (i.e., 
degree to which the person posits realistic, integrated goals for his/her life) and motivation (i.e., 
extent to which a person is able to initiate or sustain goal directed activity due to adequate drive) 
both largely rely upon intrinsic processes related to interest and drive, whereas curiosity (i.e., 
degree to which the person is interested in his/her surroundings) in this sample may be linked 
with novelty seeking behaviors associated with procuring substances of abuse and less relevant 
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to intrapsychic deficits (Dervaux et al., 2001).   
That previous factor-analytic studies of the intrinsic motivation instrument developed by 
Nakagami et al. (2008) have yet to demonstrate the 3-factor solution derived in this research may 
indicate a true difference in the construct among individuals with schizophrenia and comorbid 
SUD, compared to those with schizophrenia. Another likely alternative, is that the intrinsic 
motivation construct in schizophrenia and comorbid SUD extends well beyond this 2-item scale, 
which is of course limited in this study to theoretically relevant items derived from the QLS.  It 
is important to highlight the fact that while deficits in intrinsic motivation are thought to emerge 
from negative symptoms such as anhedonia and avolition (Barch, 2004; Nakagami et al., 2010), 
the QLS’s anhedonia item was not hypothesized to comprise part of the intrinsic motivation 
construct in schizophrenia and comorbid SUD.  Such a decision was largely influenced by the 
fact that the QLS’s anhedonia item does not measure anticipatory anhedonia or deficits in an 
individual’s ability to formulate goals that are premised on anticipating pleasurable/ desirable 
outcomes (i.e., such as achieving remission or recovery from substance use severity), but rather 
estimates a person’s present ability to experience pleasure or consummatory anhedonia (Harvey 
& Strassnig, 2012), which has not been previously identified or linked with intrinsic motivational 
processes in schizophrenia (Nakagami et al., 2010; Harvey & Strassnig, 2012).  Consequently, it 
remains unclear whether the factor structure found for the intrinsic motivation measure in this 
research fully represents such deficits in schizophrenia and comorbid SUD, as the QLS does not 
estimate anticipatory anhedonia, which may comprise part of the intrinsic motivation construct 
among this population. Nevertheless, it is important to note that this is the first factor analytic 
study that sought to extend validation of Nakagami and colleagues (2008) intrinsic motivation 
instrument for schizophrenia to individuals with schizophrenia and comorbid SUD.  As such, all 
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subsequent analyses of the relationship between intrinsic motivation and substance use severity 
were conducted based upon the 3-factor solution demonstrating an intrinsic motivation factor 
with purpose and motivation, as this solution provided the best fit to the sample.  
While psychometric results pointed to an alternative factor-analytic solution for the intrinsic 
motivation measure developed by Nakagami et al. (2008) among persons with schizophrenia and 
comorbid SUD, analyses of the internal consistency and re-test reliability provided strong 
evidence regarding the reliability and validity of the instrument in this population. Estimates of 
internal consistency for the intrinsic motivation measure were found to be indicative of at least a 
minimally adequate internally consistent scale (i.e., α ≥ .70) as hypothesized (Nunnelly, 1978), 
and satisfied re-test reliability criteria of 0.40 or greater across all study assessment periods 
(baseline to 6-month; 6-month to 12-month). Reliability estimates mirrored that of Nakagami 
and colleagues (2008), who found that the internal consistency of their intrinsic motivation 
measure was α = .74 among community patients with schizophrenia.  
2. Relationship between Intrinsic Motivation and Substance Use Severity 
The first aim of this investigation guided subsequent aims toward an appropriate factor-
analytic solution for this sample of individuals with schizophrenia and comorbid SUD, and 
provided some confidence in the reliable and valid use of such an intrinsic motivation measure’s 
use in substance use comorbidity in schizophrenia research. While garnering such psychometric 
evidence is critical to employing this intrinsic motivation measure among individuals with 
schizophrenia and comorbid SUD, the primary focus of this study was on parsing the relations 
between intrinsic motivation and substance use severity among this population.  The critical 
findings from the analyses of these relations in the second and third aims of this research pointed 
to a host of interesting cross-sectional and longitudinal relationships between intrinsic motivation 
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and substance use severity. The bivariate analyses conducted on relations between intrinsic 
motivation and substance use severity were nonetheless mixed, where such results were only 
statistically significant for the relationship between intrinsic motivation scores and AUS (log) 
scores, though a trend was observed indicating an association between intrinsic motivation and 
DUS (log) scores. As such, some support was found for Hypothesis 2a, indicating intrinsic 
motivation was significantly and negatively correlated with alcohol use severity at baseline. 
These results signaled the need to examine the consistency of such results in a multivariable 
context, adjusting for the confounding effects of age, illness chronicity, and psychopathology.  
The patterns of significant and marginal findings observed in the bivariate relationship 
between intrinsic motivation and substance use severity were not maintained in a multivariable 
context, after adjusting for age, illness chronicity, and overall psychopathology. While such 
results seemed to suggest the potential for no cross-sectional relations to exist between intrinsic 
motivation and substance use severity among the sample, that these effects were null indicates 
the fact that potential suppression effects of negative symptoms and neurocognition on such 
relationship estimates should not be overlooked, and a series of hierarchical linear regression 
analyses were then employed to test Hypothesis 2b. Results of the hierarchical linear regression 
models revealed a significant negative prediction of AUS (log) scores and DUS (log) scores by 
intrinsic motivation scores after adjusting for demographic and clinical confounds, negative 
symptoms and neurocognition. Given these results were at variance with the previous findings 
conducted in a multivariable context, and such relations were not significant until neurocognition 
and negative symptoms were entered into the model, a suppression effect of neurocognition and 
negative symptoms on the relationship between intrinsic motivation and substance use severity 
seems to explain such phenomena.  While there is not an exact statistical test for suppression 
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effects, this interesting, yet paradoxical pattern of results can occur when variables, such as 
neurocognition and negative symptoms, improve the prediction of the criterion independent 
variable (intrinsic motivation) after they are added to the regression model, by suppressing 
criterion-irrelevant variance (see Paulhaus et al., 2004, for review). Such an explanation is 
plausible given this pattern of results, and supports Hypothesis 2b, that significant negative 
relations exist between intrinsic motivation and substance use severity in a multivariable context, 
adjusting for demographic and clinical confounds, negative symptoms and neurocognition. 
Consequently, cross-sectional findings suggesting a significant negative relationship between 
intrinsic motivation and substance use severity laid the foundation for the possibility of such 
effects to persist over time in this sample of individuals with schizophrenia and comorbid SUD.  
Over the course of the 1-year study, patients with schizophrenia and comorbid SUD 
demonstrated significant average reductions in substance use severity (Hypothesis 3a). Results 
garnered from the conditional models suggested that intrinsic motivation may accelerate the rate 
of reduction from substance use severity among patients with schizophrenia and comorbid SUD 
over 1-year. Longitudinal analyses with intrinsic motivation not only significantly accelerated 
the rate of reduction from substance use severity recovery for the sample over 1-year, but also 
strengthened the findings observed with intrinsic motivation in the cross-sectional analyses. For 
example, evidence was found indicating intrinsic motivation change is an important incremental 
predictor of reduction in patient’s substance use severity above and beyond the effects of age, 
illness chronicity, overall psychopathology, comorbidity status, and phase1 randomization. 
Consequently, sufficient support was found for Hypothesis 3b, that improvement in intrinsic 
motivation would be significantly associated with reductions in substance use severity over 1-
year.  Further, the consistency of such findings were confirmed for the relationship between 
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intrinsic motivation and alcohol use severity using a complete case sensitivity analysis (see 
Appendix A), and trend-level support was observed for the relationship between intrinsic 
motivation and drug use severity (see Appendix A).  While this relatively high degree of 
consistency observed between primary intent-to-study and completer findings suggests that the 
statistical conclusions derived from this research are accurate, the high proportion of attrition 
observed over 1-year signals a need for replication studies.  Nevertheless, longitudinal analyses 
with intrinsic motivation signal promising support for interventions seeking to target change in 
intrinsic motivation deficits as a method of reducing substance use severity among individuals 
with schizophrenia and comorbid SUD. These efforts are desperately needed, and could 
considerably help offset the long-term disability that is exacted by the chronic and pervasive 
patterns of substance use severity observed among this population.  
3. Gender Differences in the Relationship between Intrinsic Motivation and Substance Use 
Severity 
The second aim of this research elucidated the cross-sectional and longitudinal 
relationships between intrinsic motivation and substance use severity among individuals with 
comorbid SUD and schizophrenia, and informed subsequent analyses to examine whether such 
relations varied across genders among this population. First, cross-sectional evidence garnered 
from this sample of patients with schizophrenia and comorbid SUD suggested that men and 
women demonstrated comparable degrees of substance use severity. While such results did not 
support Hypothesis 2c that women would demonstrate lower mean substance use severity scores 
compared to men, the literature in this area is mixed, with some studies suggesting comparable 
degrees of substance use severity across genders (Køster et al., 2008; Brunette & Drake, 1997), 
and others suggesting men exhibit higher mean substance use severity scores compared to 
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women (Brunette & Drake, 1998).  Consistent with one study that examined and found evidence 
indicating that women in this population demonstrate less intrinsic motivation deficits than men 
(Drapalski et al., 2011), the cross-sectional evidence garnered from this sample revealed that 
women exhibited significantly less intrinsic motivation deficits than men at baseline (Hypothesis 
2d).  While these cross-sectional results seem to suggest the potential for women to continue to 
improve such deficits in intrinsic motivation at faster rates over 1-year than men, particularly 
because such women demonstrate better long-term outcomes on several domains (Angermeyer, 
Kuhn, & Goldstein, 1990; Leung & Chue, 2000), intrinsic motivation was not associated with 
faster reductions in substance use severity for women in this sample (Hypothesis 3c). Such 
unexpected findings led to an exploratory investigation of the longitudinal relationship between 
intrinsic motivation and substance use severity within subsamples of men and women. These 
analyses led to further unexpected results, as evidence was found supporting improvements in 
intrinsic motivation to significant reductions in substance use severity within the subsample of 
men. However, within the subsample of women, improvements in intrinsic motivation were 
associated with trend-level reductions in alcohol use severity over 1-year. Taken together, such 
results signal the potential for important differences to exist between men and women regarding 
the relationship between intrinsic motivation and substance use severity. However, the null and 
otherwise unexpected outcomes of this research call for replication before firm conclusions can 
be derived toward initiating gender-based models of care among this population.  
 
B. LIMITATIONS 
 Prior to addressing the implications of this research, it is critical to discuss a number of 
limitations, which should both highlight the need for future research in this area as well as serve 
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to temper substantive interpretations of this work and its implications for research and social 
work practice.  While specific hypotheses were developed based on previous evidence, this 
research, which is the first to examine the use of the intrinsic motivation measure developed by 
Nakagami et al. (2008) among individuals with schizophrenia and comorbid SUD, was largely 
exploratory in nature. Hypotheses proposed a general relationship between intrinsic motivation 
and substance use severity, but the degree to which differences in these relations may vary across 
genders and substances of abuse remained largely unknown. Given the somewhat exploratory 
nature of this research and the considerable proportion of study attrition observed over 1-year, a 
robust analytic approach (i.e., intent-to-study) was adopted favoring power to detect significant 
relations among the primary study variables of interest (i.e., Chakraborty & Gu, 2009). Such an 
approach is suitable for exploratory work, and is the current field standard to use in longitudinal 
studies with large proportions of attrition (i.e., Georguieva & Krystal, 2004; Hamer & Simpson, 
2009). Given the increased likelihood of deriving false positive results from the biased parameter 
estimates that can result from high proportions of attrition (Chakraborty & Gu, 2009, Graham, 
2009), this study conducted a series of complete case sensitivity analyses (see Appendix A) to 
maximize the potential for deriving accurate statistical conclusions (Chakraborty & Gu, 2009).  
In fact, the consistency of significant results garnered from the primary intent-to-treat analyses 
were maintained for AUS (log) models under complete case analyses, and marginal support was 
largely observed for the DUS (log) models. While this relatively high degree of consistency 
between intent-to-study and completer findings suggests that the statistical conclusions derived 
from this research are accurate, the considerable proportion of attrition observed over 1-year 
signals a need for replication studies.  Further, while the attrition observed over 1-year in this 
research was considerable, it is similar to that reported in comparable studies (see Bellack et al., 
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2006; Mueser et al., 2013). In summary, although the key longitudinal analyses (i.e., intent-to-
treat) of this research largely revealed statistically significant relations between changes in 
intrinsic motivation and changes in substance use severity, the attrition observed in this research 
renders such results tentative  until confirmatory evidence is available from future studies.  
 Another limitation of study attrition is the potential bias stemming from the baseline 
heterogeneity observed between patients who dropped out of the study before 1-year (n = 390, 
attrited sample) and the patients who completed the study (n = 145, completer sample). Cross-
sectional analyses were conducted across 24 study variables between these groups (see Chapter 
4, Section B.3., Table 9); a greater proportion of completers were diagnosed with alcohol use 
disorder compared to those patients who dropped out of the study. Further, a greater proportion 
of those who dropped out of the study were diagnosed with other substance use disorders (i.e., 
cannabis or cocaine use disorder) compared to those who completed the study.  Recall that of the 
535 patients with schizophrenia and comorbid SUD, the majority were diagnosed with poly-
disorders (43.5%), followed by other substance use disorders (34.3%), and alcohol use disorders 
(22.2%).  While other substance use disordered patients did not comprise the majority of the 
sample, the presence of systematic differences between completer and attrited samples with 
regard to comorbidity status signal some concern about the generalizability of the significant 
relations found between intrinsic motivation and substance use severity.  Regardless of this 
limitation, however, the overall results of these analyses suggested that completer and attrited 
samples were largely comparable across all other study variables observed at baseline.  
 In addition to problems of study attrition, this research is limited by its unbalanced 
sample of men and women. This limitation could have precluded the detection of significant 
gender differences in the longitudinal relationship between changes in intrinsic motivation and 
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changes in substance use severity.  While adequate power was seemingly available in this 
research to detect medium to large-sized estimates between these constructs, others have 
cautioned that it is difficult to obtain specific guidelines on sample size requirements for 
hierarchical linear models (Bassiri, 1988; VanDerLeeden & Busing, 1994), and many commonly 
used software packages may underestimate sample estimates needed for detecting significant 
cross-level interactions (Hoffman, 1997).  With regard to specific numbers, at least two studies 
have indicated that to have adequate power (i.e., .80) to detect cross-level interactions, a sample 
of 30 groups with 30 individuals is necessary (Bassiri, 1988; VanDerLeeden & Busing, 1994), 
although unbalanced designs require more individuals per group to obtain sufficient power 
(Hoffman, 1997).  Given such challenges, estimates of whether gender moderated the 
longitudinal association between changes in intrinsic motivation and changes in substance use 
severity, which were largely null, could have been undetected due to power limitations from the 
unbalanced sample (Hypothesis 3c).  Currently, because of the unbalanced sample of men and 
women employed in this research coupled with the challenges of estimating power for cross-
level interactions, it is difficult to draw firm conclusions from such results.  Although some 
unexpected significant relations were found supporting average improvements in intrinsic 
motivation to reductions in substance use severity within the subsample of men, more pervasive 
moderator effects could also exist indicating that such relations vary across genders but were 
overlooked due to sample size limitations resulting from the unbalanced sample.  
Another limitation of this research stems from the nature of the sample employed, in that 
such study participants were not enrolled in a motivational rehabilitation program targeting 
reductions in substance use severity, but were rather selected from a randomized controlled trial 
of antipsychotic medications.  This may potentially explain the low base rates (initial status) of 
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alcohol use severity (M = 2.71; SE =1.01, AUS raw score) and drug use severity (M = 2.66; SE = 
1.01; DUS raw score) observed among the sample.  While such scores suggest that this sample of 
patients with schizophrenia and comorbid SUD started the study at sub-threshold levels of drug/ 
alcohol abuse, it is important to mention that severity levels are generally low in community 
samples of patients with these conditions (see Drake et al., 2006).  This is usually the case as 
community patients with schizophrenia and comorbid SUD often become destabilized and 
hospitalized at moderate/ high severity levels (Drake et al., 2006). Indeed, participants in this 
current research demonstrated low/moderate substance use severity at baseline, and while 
subsequent findings did signal intrinsic motivation change is a key incremental predictor to 
naturalistic reductions in substance use severity beyond demographic and clinical confounds, 
these effects may be more modest than that observed in motivational rehabilitation programs.  
Further, this research is also limited to some degree by the cross-situational nature of 
Nakagami and colleague’s (2008) intrinsic motivation measure. This cross-sectional approach 
signaled compelling reason to question the prevailing 2-factor orthogonal solution of the intrinsic 
motivation measure in schizophrenia and comorbid SUD (i.e., Nakagami et al., 2008), while at 
the same yielded notable and unexpected limitations to its implementation. Such limitations are 
plausible given prior evidence suggests high levels of sensation seeking and curiosity-driven 
behaviors are associated with substance use in schizophrenia and comorbid SUD (i.e., Dervaux 
et al., 2001), which may explain the reason for why the QLS curiosity item did not load with 
purpose and motivation as hypothesized.  As such, while this study presented strong evidence to 
question the application of Nakagami and colleague’s (2008) 2-factor solution in this population, 
results based on the intrinsic motivation measure used in this research must be made with caution 
until confirmatory evidence is available from future studies.  
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 Finally, this research is limited by its modest 1-year follow-up of participants. While the 
longitudinal nature of this research is a considerable strength, the longitudinal design employed 
is also limited in terms of answering some critical questions regarding the relationship between 
changes in intrinsic motivation and changes in substance use severity. Improvements in intrinsic 
motivation did lead to significant reductions in substance use severity over 1-year (Hypothesis 
3b), yet the observed duration was not sufficient to determine whether this sample of patients 
actually achieved sustained remission. Consequently, the negative linear trajectory found in this 
research only suggests that improvements in intrinsic motivation were associated with significant 
reductions in substance use severity for the duration of 1-year. Unfortunately, what this research 
is unable to answer with a 1-year follow-up is whether such improvements in intrinsic motivation 
are significantly associated with sustained remission among this population. As such, additional 
studies will be needed to examine whether the impact of intrinsic motivation on individuals with 
schizophrenia and comorbid SUD leads to sustained remission among this population when such 
relations are observed over longer periods of time.   
 
C. IMPLICATIONS 
 The results of this investigation have a number of notable implications for new research 
and social work practice, despite the existing limitations of this study.  Consistent with the dual 
diagnosis treatment literature and hypotheses of this investigation, the deficits assessed by the 2-
item intrinsic motivation measure were, for the most part, highly significant with substance use 
severity.  Intrinsic motivation held the strongest relations to alcohol use severity; evidenced by 
the number of significant relations that were observed both cross-sectionally and longitudinally. 
In addition, the primary longitudinal analyses (i.e., intent-to-study) examining the relationship 
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between changes in intrinsic motivation and changes in alcohol use severity were maintained 
under complete case analysis (see Appendix A). In addition, a number of significant relations 
were also observed between intrinsic motivation and drug use severity; however, such findings 
were more robust in the longitudinal analyses, and the consistency of such results maintained 
trend-level thresholds of statistical significance under complete case analysis (see Appendix A). 
Further, few significant cross-sectional relations were observed between intrinsic motivation, 
gender, and substance use severity, and gender appeared to have no significant impact on the 
longitudinal relations observed between changes in intrinsic motivation and changes in substance 
use severity.  While the limitations discussed above may account for the discrepancies noted 
between intent-to-study and completer analyses as well as the sparse gender differences found, it 
also seems clear from the results of this research that there is a need to further examine the 
intrinsic motivation construct among this population.  
 To date, schizophrenia researchers have shown individuals with the disorder exhibit 
profound deficits in intrinsic motivation (i.e., Nakagami et al., 2008; Barch et al., 2008; Yamada 
et al., 2010; Nakagami et al., 2010), however a consensus has yet to be achieved with regard to 
how to best measure such deficits among this population. Furthermore, this issue has become 
compounded by disagreement with regard to whether intrinsic motivation is a negative symptom 
dimension, or emerges from existing negative symptoms (i.e., amotivation and anticipatory 
anhedonia) in schizophrenia (i.e., Blanchard & Cohen, 2006; Nakagami et al., 2010).  While 
some evidence suggests that such deficits may stem from the negative symptoms of anticipatory 
anhedonia (i.e., deficits in the ability to perceive pleasure, which preclude the formation of goal 
directed activities) and amotivation (i.e., decreases in goal directed activity and goal-directed 
cognition) (Heerey & Gold, 2007; Harvey & Strassnig, 2012), the relation of such deficits to 
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intrinsic motivation in schizophrenia and comorbid SUD have yet to be fully examined in this 
population. Consequently, given the limited scope of the 2-item intrinsic motivation measure 
used in this research, there is an urgent need to further examine, and potentially further develop 
the construct in schizophrenia and comorbid SUD. This should be done by carefully constructing 
and validating additional instruments that may capture the fundamental role of the key intrinsic 
motivational deficits in this population.  Recently, discrete negative symptom subdomains have 
been investigated in individuals with schizophrenia and comorbid SUD, with findings showing a 
central role of motivational deficits in anticipatory pleasure (Foussias & Remington, 2010, for 
review). Consequently, future research may profitably focus measurement development efforts 
on incorporating deficits in anticipatory anhedonia as a step in further examining the intrinsic 
motivation construct in this population.    
  In addition to this research signaling the need to further examine the intrinsic motivation 
construct among this population in future studies, the results of this investigation pertaining to 
intrinsic motivation also call for additional studies of this probable negative symptom dimension 
among individuals with schizophrenia and comorbid SUD.  While not all hypotheses in this 
research were supported, some cross-sectional and all primary (i.e., intent-to-study) longitudinal 
analyses did show significant relations between intrinsic motivation and substance use severity, 
signaling the potential importance of the tested construct to substance use severity among this 
sample of individuals with schizophrenia and comorbid SUD.  Considerable study attrition, the 
unbalanced sample of men and women, and the somewhat exploratory nature of this research 
preclude drawing firm conclusions from this investigation, but these findings may provide some 
encouraging leads for future studies.  
 First, it will be important for subsequent studies to replicate the factor analytic findings of 
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this investigation, to examine whether these results might actually point to an alternative factor 
structure for Nakagami and colleague’s (2008) intrinsic motivation measure among individuals 
with schizophrenia and comorbid SUD.  This will be important for future studies employing this 
measure that seek to make valid cross-group comparisons between those with schizophrenia and 
those with schizophrenia and comorbid SUD.  Such comparisons will only yield meaningful 
results if there is a consistent latent factor structure to intrinsic motivation observed across these 
groups, and the findings of this dissertation study call this point into question.  As such, whether 
individuals with schizophrenia and comorbid SUD exhibit intrinsic motivation deficits by this 2-
item measure will remain uncertain until future investigations resolve these factor-analytic 
questions.  Consequently, studies of Nakagami and colleague’s (2008) measure in individuals 
with schizophrenia and matched samples of individuals with schizophrenia and comorbid SUD 
are particularly important avenues for future research, given the findings of this investigation.  
 Second, future research will also need to replicate the findings examining potential 
gender differences in the longitudinal relationship between intrinsic motivation and substance 
use severity. While largely no significant relations were found in this regard, it is possible that 
relations did exist that were beyond the statistical power of this study to detect (Hoffman, 1997). 
Cross-sectional findings of this research showed that women did exhibit less intrinsic motivation 
deficits than men at baseline, yet such women did not continue to show stronger associations 
with intrinsic motivation leading to faster reductions in substance use severity than men over 1-
year.  This may suggest a limit to the prospective gains such women can make with regard to 
intrinsic motivation, yet another plausible explanation is that such findings stem from estimating 
growth parameters for the cross-level interaction using an unbalanced sample of men and women 
(Hoffman, 1997).  Consequently, these limitations render such findings tentative, and clearly 
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indicate a need for future studies using adequately powered and balanced samples of men and 
women among this population.  
Further, given the somewhat exploratory nature of this work, even the largely significant 
longitudinal findings of the relationship between changes in intrinsic motivation and changes in 
substance use severity need to be interpreted with caution and call for replication.  As mentioned, 
the attrition observed in this research was considerable, such that missing data in the intent-to-
study sample was estimated to be 43% across the study duration, with the largest proportion of 
missing observations at 1-year.  This undoubtedly raises the possibility that some of the findings 
garnered from the primary intent-to-study sample reflected false positive results stemming from 
biased parameter estimates.  In fact, such an issue may even explain the reason for which the 
significant relations observed between intrinsic motivation and drug use severity in the intent-to-
study primary analyses were not maintained under complete case analysis in this research.  As 
such, the outcomes of this dissertation study should be seen as providing a foundation for future 
investigations, rather than supplying definitive answers to the longitudinal relations between 
changes in intrinsic motivation and changes in substance use severity among individuals with 
schizophrenia and comorbid SUD.  Based on the results on this investigation, studies focusing on 
intrinsic motivation deficits, alcohol use severity, and the severity of various other psychoactive 
substances of abuse are needed to replicate these findings among this population.      
In addition, if the longitudinal relationships observed between changes in intrinsic 
motivation and changes in substance use severity demonstrated in this research are with merit, 
and improvement in intrinsic motivation deficits do in fact lead to reductions in substance use 
severity, subsequent studies might consider providing clarification to the long-term nature of this 
relationship. Similar to previous studies (i.e., Drake et al., 2006), evidence was found in this 
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research demonstrating low/ moderate substance use severity in this sample of patients with 
schizophrenia and comorbid SUD. As mentioned above, while improvements in intrinsic 
motivation did lead to significant reductions in substance use severity over the 1-year study 
period, the modest duration observed was not sufficient to determine whether this sample of 
patients actually achieved sustained remission. Given that substance use severity levels can 
either increase or decrease over time as a consequence of SUD pathology (Drake et al., 2006),  
long-term prospective studies with multiple follow-up periods will be needed to determine the 
nature and extent to which intrinsic motivation in schizophrenia and comorbid SUD may be 
associated with sustained remission and recovery in this population.  
Notably, some critical implications of this research for social work practice are apparent 
from the findings of this investigation. Perhaps the most directly related to the primary focus of 
this research is the implication that intrinsic motivation deficits are salient factors by which 
substance use severity can be reduced among individuals with schizophrenia and comorbid SUD. 
Not only does this research confirm evidence garnered from long-term longitudinal studies that 
individuals with schizophrenia and comorbid SUD show prospective reductions in substance use 
severity (i.e., Drake et al., 2006), but it suggests that improvements in intrinsic motivation in this 
population are among the salient factors driving this effect. The limitations of this research 
notwithstanding, evidence provided by this investigation suggest that intrinsic motivation deficits 
may serve as one salient factor for which psychosocial interventions could target to produce 
faster reductions in substance use severity.  Evidence garnered from this study also provides 
critical support for targeting intrinsic motivation deficits using diverse treatment approaches, 
particularly given the known challenges of conducting intervention studies in schizophrenia and 
comorbid SUD—as such individuals are difficult to engage in treatment and are especially 
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difficult to retain in treatment (Horsfall et al., 2009).  If substance use severity can indeed be 
reduced by improving intrinsic motivation deficits, this could provide social work practitioners 
and treatment developers with critical insights into how to best help people with this comorbidity 
recover from the long-term disability exacted by persistent and pervasive use.  To date, salient 
factors that contribute to the persistent patterns of substance use severity in schizophrenia and 
comorbid SUD have remained largely elusive, and refractory to psychosocial and medication 
treatment (Westermeyer, 2006). The elucidation of such relations provides a solid foundation for 
initiating future treatment development that could have a substantial impact on social work 
practice with this population, and ultimately serve to improve the lives of the many individuals 
with schizophrenia and comorbid SUD.  That intrinsic motivation deficits indeed appear to be 
one salient factor by which substance use severity can be reduced suggest that interventions 
focusing on targeting such deficits could be effective for this population.  Consequently, social 
work practitioners and researchers will need to collaborate to begin applying these findings in 
order to identify the utility and feasibility of initiating intrinsic motivation treatment approaches 
for schizophrenia and comorbid SUD.  
 Finally, not only does this research have broad treatment implications directly for those 
with schizophrenia and comorbid SUD, but these results provide some early support for initiating 
gender-based models of care within this population.  To date, despite the growing interest in the 
study of substance use comorbidity in schizophrenia, little attention has been paid to subgroups 
of men and women with these conditions as potentially demonstrating different substance use 
severity patterns, which may necessitate unique treatment needs (Drapalski et al., 2011).  Given 
the cross-sectional evidence garnered from this research suggested that men showed significantly 
greater deficits in intrinsic motivation compared to women at baseline, interventions initiated 
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within subsamples of men may benefit from using extrinsic rewards to boost (initially) low base-
rates. Silverstein (2010) recently showed that extrinsic rewards (i.e., tokens/ money) increased 
the low base-rates of intrinsic motivation in schizophrenia patients upon treatment enrollment, 
which set the foundation for continued intrinsic motivation improvement in treatment.  Recall 
that exploratory longitudinal evidence from this study showed that men exhibited significant 
reductions in substance use severity as they made improvements in intrinsic motivation over 1-
year. While it is promising that exploratory results showed that men did exhibit improvement in 
intrinsic motivation leading to significant reduction in substance use severity, the fact that men 
had significantly lower levels of intrinsic motivation compared to women at baseline should not 
be overlooked. These results provide preliminary support for extending brief extrinsic reward-
based interventions to improve the low base-rates of intrinsic motivation observed in men with 
schizophrenia and SUD. This could provide social workers with a critical understanding on how 
to initiate and continue to sustain the performance of intrinsically motivated behaviors (i.e., 
reductions in substance use severity) within subsamples of men, and ultimately serve to initiate 
gender-based models of care within this population.  As such, the findings of this research have 
some important implications and applications for potentially leading the field toward developing 
gender-based models of care for individuals with schizophrenia and comorbid SUD.  
In summary, the findings of this study provide a number of promising directions for 
future research and social work practice. Such directions include: (1) further developing the 
intrinsic motivation construct in schizophrenia and comorbid SUD; (2) replication of prospective 
longitudinal associations between intrinsic motivation and substance use severity in carefully 
conducted studies; (3) replication of findings examining the impact of gender on the longitudinal 
association between intrinsic motivation and substance use severity with balanced samples of 
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men and women; (4) develop and disseminate evidence-based multi-systemic interventions that 
address intrinsic motivation deficits in schizophrenia and comorbid SUD to accelerate the rate of 
substance use severity reduction; (5) explore the feasibility of using extrinsic rewards to improve 
the low-base rates of intrinsic motivation in subsamples of men with schizophrenia and comorbid 
SUD. With such research, it is anticipated that studies will lead to a better understanding of the 
longitudinal impact of intrinsic motivation on substance use severity among this population and 
its patters in men and women, and begin to inform promising targets for future treatment 
development efforts.  
 
 D. CONCLUSIONS 
 This dissertation study sought to extend validation of a promising intrinsic motivation 
measure developed by Nakagami et al. (2008) for schizophrenia to schizophrenia and comorbid 
SUD, examine the unique contribution of change in intrinsic motivation to change in substance 
use severity, and then investigate the degree to which such relations vary across genders in a 
large heterogeneous sample of patients with schizophrenia and comorbid SUD.  Psychometric 
findings revealed a potential shift in the latent factor structure of Nakagami and colleague’s 
(2008) intrinsic motivation instrument when applied to schizophrenia and comorbid SUD, but at 
the same time pointed to the reliability and re-test reliability of the instrument. Evidence was 
found suggesting longitudinal intrinsic motivation change is a salient incremental predictor of 
reductions in patient’s alcohol and drug use severity, above and beyond the effects of age, illness 
chronicity, psychopathology, comorbidity status, and phase 1 randomization medication effects. 
Given that the overall proportion of attrition in this research was considerable, the potential for 
deriving false positive results due to biased parameter estimates could not be ruled out. Future 
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research will need to replicate these findings with less attrition, while focusing on intervention 
efforts that seek to target the intrinsic motivation deficits of schizophrenia and comorbid SUD, 
which may help offset the destabilizing effects exacted by severe and persistent use.  Relations 
with gender indicated little to no cross-sectional associations between intrinsic motivation and 
substance use severity, and gender did not moderate the longitudinal association between change 
in intrinsic motivation and change in substance use severity. Consequently, future research will 
need to replicate these findings with balanced samples of men and women, as little evidence can 
be garnered from this research to support developing and disseminating gender-based models of 
care among this population.  The results of this investigation make three important contributions 
to the field by providing empirically-based information on the strengths and limitations of 
Nakagami and colleague’s (2008) intrinsic motivation measure and its factor structure as applied 
to schizophrenia and comorbid SUD, parsing relatively robust relationship estimates between 
intrinsic motivation and substance use severity, and elucidating much more limited relationship 
estimates among gender, intrinsic motivation, and substance use severity.  By identifying these 
strengths and limitations of Nakagami and colleague’s (2008) intrinsic motivation measure and 
relations between intrinsic motivation and substance use severity, it is hoped that progress will 
be made by social workers and practitioners to identify additional salient contributors to the 
pervasive patterns of substance use severity among this population, and ultimately develop 
effective psychosocial treatments to improve the lives of those who suffer from this comorbidity.  
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APPENDIX A -   RESULTS WITH COMPLETER SAMPLE (N = 145)  
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Primary longitudinal analyses (Aim #1, Hypothesis 1c; Aim #3) in this research were 
conducted by taking an intent-to-study approach to missing data, which used all relevant 
observations collected on participants over the 1-year study, regardless of whether the participant 
completed the study (see Shafter & Graham, 2002; Graham, 2009). This approach to handling 
missing data is the current field standard (see Georguieva & Krystal, 2004; Hamer & Simpson, 
2009), as it provides more powerful tests than other analytic options used in longitudinal studies 
with attrition (Shafter & Graham, 2002; Lachin, 2002; Chakraborty & Gu, 2009), and can be 
safely employed with the EM algorithm even when missing completely at random assumptions 
are not met (Graham, 2009). Given the increased likelihood to obtain false positive results due to 
biased parameter estimates in longitudinal studies with high proportions of attrition, it is usually 
recommended that additional approaches be used and compared (Chakraborty & Gu, 2009). This 
appendix presents an examination of the key longitudinal analyses of this research (Aim #1, 
Hypothesis 1c; Aim #3) under complete case analysis.  Results using the completer sample (n = 
145) are compared to the primary analyses using the intent-to-study sample (n = 535).  Findings 
are presented in identical tables to those that appear in the primary longitudinal analyses, and a 
Change Note is provided in each table outlining the differences between the results in the 
completer sample and those in the primary intent-to-study analyses.  
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A. AIM #1 EXTEND VALIDATION OF NAKAGAMI AND COLLEAGUES’ INTRINSIC 
MOTIVATION MEASURE TO COMORBID SUD AND SCHIZOPHRENIA 
1. Re-test Reliability of the Intrinsic Motivation Measure 
 As can be seen in Table A1.1, the intrinsic motivation measure satisfied re-test reliability 
criteria of 0.40 or greater across study assessment periods) baseline to 6-month; 6-month to 12-
month). Similar to that observed in the intent-to-study sample, the hypothesis (Hypothesis 1c) 
that the intrinsic motivation measure would demonstrate at least minimally sufficient levels of 
re-test reliability (r ≥ .40) when examined across the 3 multi-month assessment observation 
periods was also supported in the completer sample.   
 
Table A1.1. Correlations Among Participant Intrinsic Motivation Scores Across Study Periods  
             Period 0 6 12 
0   - Intrinsic Motivation -   
6   - Intrinsic Motivation .47** -  
12 - Intrinsic Motivation .48** .61** - 
Note. Analyses were conducted on the completer sample (n = 145). 0 = Baseline; 6 = 6-month; 
12= 12-month are presented in boldface.  
Change Note. No significant changes.   
 
**p < .01, 2-tailed. 
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B. AIM#3 EXAMINE THE LONGITUDINAL CONTRIBUTION OF CHANGES IN 
INTRINSIC MOTIVATION TO CHANGES IN SUBSTANCE USE SEVERITY, AND 
THEN INVESTIGATE THE IMPACT OF GENDER ON THESE RELATIONSHIPS.  
1. Longitudinal Change in Substance Use Severity   
 Growth curve analyses in the completer sample began by computing the ICC for both 
AUS (log) and DUS (log) unconditional models. Consistent with guidelines for the 
appropriateness of using growth curve models to capture systematic change in individual 
substance use severity phenomena over time, sufficient between-patient dependence was 
achieved  for both AUS (log) (ICC = 0.54) and  DUS (log) (ICC = 0.52) unconditional models in 
the completer sample (Hox, 2000; Raudenbush & Bryk, 2009).   
Table A1.2 presents the results for the AUS (log) and DUS (log) unconditional growth 
curve models in the completer sample. Similar to that observed in the intent-to-study sample, 
those patients with complete observations demonstrated, on average, significant reductions in 
alcohol and drug use severity over the 1-year study period.  Also similar to that observed in the 
intent-to-study sample, patients with complete observations exhibited variability in terms of their 
mean baseline AUS (log)/ DUS (log) scores, and similar variability was observed with regard to 
the reduction of substance use severity observed over 1-year. Consequently, the study hypothesis 
(Hypothesis H3a) that patients would demonstrate, on average, significant reductions in AUS 
(log) / DUS (log) scores over 1-year, was also supported in the completer sample.   
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Table A1.2. 1-Year Trajectories of Substance Use Severity (Unconditional Growth Models) 
                                Parameter  AUS (log) Unconditional Modela  
 Fixed Effect  Coefficient SE t p 
        Mean Initial Status, 𝛽00  1.00 0.02 37.76 <.001 
        Mean Growth Rate, 𝛽10  -0.08 0.02 -3.32 <.001 
Random Effect  Variance Component 95% CI 
       Initial Status, Var(r0i) = τ01  0.02 0.07 to 0.27 
       Growth Rate, Var(r1i) = τ11  0.03 0.10 to 0.25 
       Level-1 error, Var(e1i) = σ2  0.06 - 
                                Parameter  DUS (log) Unconditional Modelb  
Fixed Effect  Coefficient SE t p 
        Mean Initial Status, 𝛽00  0.95 0.02 36.09 <.001 
        Mean Growth Rate, 𝛽10  -0.07 0.02 -2.55 .011 
Random Effect  Variance Component 95% CI 
       Initial Status, Var(r0i) = τ01  0.02 0.11 to 0.26 
       Growth Rate, Var(r1i) = τ11  0.03 0.12 to 0.28 
       Level-1 error, Var(e1i) = σ2  0.05 - 
Note. Analyses were conducted on the completer (n = 145). AUS = Alcohol Use Scale; DUS = 
Drug Use Scale.  
a Only the final AUS unconditional model is presented here to reduce visual clutter, which was 
fit using AR(1) and REML estimation.  
b Only the final DUS unconditional model is presented here to reduce visual clutter, which was 
fit using AR(1) and REML estimation.  
Change Note. No significant changes.  
 
2. Longitudinal Relationship between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity  
 Upon determining that patients showed significant reductions in substance use severity 
over 1-year in the completer sample, a series of conditional linear growth curve models were 
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then computed to examine the longitudinal contribution of changes in intrinsic motivation to 
changes in substance use severity.  As can be seen in Table A1.3, the average effect of intrinsic 
motivation continued to be associated with significant reductions in patient’s alcohol use severity 
over 1-year in the completer sample. Such initial analyses also seemingly suggested that the 
average effect of intrinsic motivation on DUS scores was not statistically different from 0 in the 
completer sample.   
 
  
 
Table A1.3. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity (Conditional Growth Models) 
                                Parameter  AUS (log) Conditional Modela  
 Fixed Effect  Coefficient     SE t p 
        Mean Initial Status, 𝛽00  1.08 0.03 30.12 <.001 
        Mean Growth Rate, 𝛽10  -0.08 0.02 -3.31 <.001 
       Time-Varying IM, 𝛽20  -0.01 0.01 -3.49 <.001 
                                Parameter  DUS (log) Conditional Modelb  
Fixed Effect  Coefficient SE t p 
        Mean Initial Status, 𝛽00  0.98 0.03 27.10 <.001 
        Mean Growth Rate, 𝛽10  -0.09 0.02 -4.15   .012 
        Time-Varying IM, 𝛽20  -0.01 0.01 -1.27   .204 
Note. Analyses were conducted on the completer sample (n = 145). AUS = Alcohol Use Scale; 
DUS = Drug Use Scale; IM = Intrinsic Motivation.  
a Only the final AUS conditional model is presented here to reduce visual clutter, which was fit 
using AR(1) and REML estimation.  
b Only the final DUS conditional model is presented here to reduce visual clutter, which was fit 
using AR(1) and REML estimation. 
Change Note. The effect of intrinsic motivation on DUS scores was not statistically different 
from 0 in the completer sample.   
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Completer sample analyses proceeded by expanding the AUS (log) / DUS (log) 
conditional models with such scores being predicted from time and time-varying intrinsic 
motivation, adjusting for age, illness chronicity, overall psychopathology, comorbidity status, 
and phase1 randomization.  Such analyses continued to suggest that the average effect of 
intrinsic motivation was associated with significant reductions in patient’s alcohol use severity 
over 1-year in the completer sample, after adjusting for age, chronicity, overall psychopathology, 
comorbidity status, and phase 1 randomization (Table A1.4).  The findings of such analyses also 
continued to suggest that the average effect of intrinsic motivation on patient’s DUS scores were 
not statistically different from 0 in the completer sample, after adjusting for these demographic 
and clinical confounds (Table A1.5).    
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Table A1.4. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Alcohol Use Severity, Adjusting for Demographic and Clinical Confounds 
Fixed Effect                          Parameter  Coefficient SE t p 
 Initial Status 𝛽00  1.09 0.06 16.47 <.001 
        AUD/ SUDa 𝛽01  -0.03 0.06 -0.58 .558 
        SUDa 𝛽02  -0.09 0.07 -1.38 .167 
        AUDb 𝛽03  0.09 0.07 1.38 .167 
        Quetiapinec 𝛽04  0.06 0.07 0.82 .413 
        Perphenazinec 𝛽05  -0.01 0.06 -0.13 .893 
        Ziprasidonec 𝛽06  0.01 0.09 0.13 .889 
        Risperidonec 𝛽07  -0.01 0.06 -0.18 .852 
        Olanzapined 𝛽08  -0.06 0.07 -0.82 .413 
        Age 𝛽09  0.00 0.00 0.24 .809 
        Chronicity 𝛽010  -0.00 0.00 -0.29 .771 
        PANSS Total 𝛽011  -0.00 0.01 -0.20 .840 
Growth Rate 𝛽10  -0.09 0.06 -1.49 .137 
        Time x AUD/ SUDa 𝛽11  0.01 0.05 1.14 .252 
        Time x SUDa 𝛽12  0.02 0.07 0.31 .750 
        Time x AUDb 𝛽13  -0.02 0.07 -0.31 .750 
        Time x Quetiapinec 𝛽14  -0.09 0.07 -1.20 .227 
        Time x Perphenazinec 𝛽15  0.04 0.06 0.60 .542 
        Time x Ziprasidonec 𝛽16  0.01 0.09 0.08 .933 
        Time x Risperidonec 𝛽17  -0.00 0.06 -0.05 .959 
        Time x Olanzapined 𝛽18  0.09 0.07 1.20 .227 
        Time x Age 𝛽19  -0.00 0.00 -1.22 .220 
        Time x Chronicity 𝛽120  0.00 0.01 1.11 .264 
        Time x PANSS Total 𝛽121  0.00 0.00 0.59 .553 
Time-Varying IM 𝛽20  -0.01 0.01 -3.05 <.001 
Note. Analyses were conducted on the completer sample (n = 145). IM = Intrinsic Motivation. 
AUD/SUD = alcohol use disorder and other substance use disorder; SUD = substance use 
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disorder other than alcohol use disorder; AUD = alcohol use disorder; PANSS = Positive and 
Negative Syndrome Scale. Only the final AUS (log) model is presented to reduce visual 
clutter, which was fit using AR(1) and accounted for heteroscedasticity of level-1 errors. 
REML estimation was used. Age, Chronicity, and PANSS Total were grand mean centered.  
aReference category is AUD.  
bReference category is SUD. 
cReference category is Olanzapine. 
dReference category is Quetiapine.  
Change Note. No significant changes. 
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Table A1.5. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Drug Use Severity, Adjusting for Demographic and Clinical Confounds 
Fixed Effect                          Parameter  Coefficient SE t p 
 Initial Status 𝛽00  0.88 0.07 12.36 <.001 
        AUD/ SUDa 𝛽01  0.17 0.06 2.77 .006 
        SUDa 𝛽02  0.23 0.07 3.14 .002 
        AUDb 𝛽03  -0.23 0.07 -3.14 .002 
        Quetiapinec 𝛽04  -0.06 0.08 -0.82 .410 
        Perphenazinec 𝛽05  -0.03 0.07 -0.42 .671 
        Ziprasidonec 𝛽06  -0.06 0.10 -0.64 .519 
        Risperidonec 𝛽07  -0.09 0.07 -1.27 .206 
        Olanzapined 𝛽08  0.06 0.08 0.82 .410 
        Age 𝛽09  -0.00 0.00 -0.55 .578 
        Chronicity 𝛽010  -0.00 0.00 -0.29 .771 
        PANSS Total 𝛽011  0.00 0.00 1.02 .305 
Growth Rate 𝛽10  -0.09 0.06 -1.49 .137 
        Time x AUD/ SUDa 𝛽11  -0.04 0.07 -0.56 .574 
        Time x SUDa 𝛽12  -0.10 0.08 -1.27 .205 
        Time x AUDb 𝛽13  0.10 0.08 1.27 .205 
        Time x Quetiapinec 𝛽14  0.07 0.09 0.84 .398 
        Time x Perphenazinec 𝛽15  0.08 0.08 0.99 .323 
        Time x Ziprasidonec 𝛽16  0.31 0.11 2.74 .006 
        Time x Risperidonec 𝛽17  0.13 0.08 1.65 .099 
        Time x Olanzapined 𝛽18  -0.07 0.09 -0.84 .398 
        Time x Age 𝛽19  -0.00 0.00 -1.22 .220 
        Time x Chronicity 𝛽120  0.00 0.01 0.27 .786 
        Time x PANSS Total 𝛽121  0.00 0.00 0.84 .399 
Time-Varying IM 𝛽20  -0.01 0.01 -1.10 .271 
Note. Analyses were conducted on the completer sample (n = 145). IM = Intrinsic Motivation. 
AUD/SUD = alcohol use disorder and other substance use disorder; SUD = substance use 
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disorder other than alcohol use disorder; AUD = alcohol use disorder; PANSS = Positive and 
Negative Syndrome Scale. Only the final DUS (log) model is presented to reduce visual 
clutter, which was fit using AR(1) and REML estimation. Age, Chronicity, and PANSS Total 
were grand mean centered.  
aReference category is AUD.  
bReference category is SUD. 
cReference category is Olanzapine. 
dReference category is Quetiapine.  
Change Note. The effect of intrinsic motivation on DUS scores was not statistically different 
from 0 in the completer sample, adjusting for demographic and clinical confounds. 
 
Finally, this series of conditional growth curve models in the completer sample examined 
longitudinal relations between intrinsic motivation and substance use severity, after adjusting for 
demographic and clinical confounds, negative symptoms and neurocognition.  Such analyses 
continued to suggest the average effect of intrinsic motivation was associated with significant 
reductions in patient’s alcohol use severity over 1-year in the completer sample, after adjusting 
for age, illness chronicity, overall psychology, phase 1 randomization, neurocognition, and 
negative symptoms (Table A1.6).  Notably, improvements in patient’s intrinsic motivation were 
associated with trend-level reductions in patient’s drug use severity over 1-year, after adjusting 
for these demographic and clinical confounds, neurocognition and negative symptoms.  
The hypothesis (Hypothesis 3b) that improvements in intrinsic motivation would be 
associated with significant reductions over 1-year was only partially supported in the completer 
sample. However, the trend observed between intrinsic motivation and drug use severity, after 
adjusting for demographic and clinical confounds, neurocognition and negative symptoms in the 
completer sample increases the potential that primary intent-to-study results are derived from 
accurate statistical conclusions rather than false positives (Chakraborty & Gu, 2009).  
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Table A1.6. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity, Adjusting for Demographic and Clinical Confounds, Neurocognition 
and Negative Symptoms 
Fixed Effect                          Parameter  Coefficient SE t p 
 AUS (log) Conditional Growth Modela 
 Initial Status 𝛽00  1.17 0.07 14.87 <.001 
        PANSS Negative 𝛽012  -0.00 0.01 -0.61 .536 
        Neurocognition  𝛽013  0.01 0.03 0.46 .536 
Growth Rate 𝛽10  -0.16 0.07 -2.36 .018 
        Time x PANSS Negative 𝛽122  0.00 0.01 0.48 .626 
        Time x Neurocognition 𝛽123  -0.01 0.03 -0.55 .580 
Time-Varying IM 𝛽20  -0.01 0.00 -3.08 .002 
 DUS (log) Conditional Growth Modela 
 Initial Status 𝛽00  0.91 0.06 14.07 <.001 
        PANSS Negative 𝛽012  -0.01 0.00 -0.50 .615 
        Neurocognition  𝛽013  0.04 0.02 1.68 .093 
Growth Rate 𝛽10  -0.09 0.07 -1.29 .194 
        Time x PANSS Negative 𝛽122  -0.00 0.00 -0.27 .652 
        Time x Neurocognition 𝛽123  0.02 0.02 -0.03 .972 
Time-Varying IM 𝛽20  -0.01 0.01 -1.89 .059 
Note. Analyses were conducted on the completer sample (n = 145).   AUS = Alcohol Use 
Scale; DUS = Drug Use Scale; IM = Intrinsic Motivation. PANSS = Positive and Negative 
Syndrome Scale.  
a Only the final AUS conditional growth model with effects of interest are presented to reduce 
visual clutter. Age, chronicity, overall psychopathology, comorbidity status, phase1 
randomization, negative symptoms, and neurocognition were adjusted at level-2. Age, 
chronicity, PANSS Total, PANSS Negative, and neurocognition were grand mean centered.  
This model was fit using AR(1) and REML estimation.  
b Only the final DUS conditional growth model with effects of interest are presented to reduce 
visual clutter. Age, chronicity, overall psychopathology, comorbidity status, phase1 
randomization, negative symptoms, and neurocognition were adjusted at level-2. Age, 
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3. Moderating Effect of Gender on the Longitudinal Association between Changes in 
Intrinsic Motivation and Changes in Substance Use Severity  
 Completer sample analyses proceeded by examining the impact of gender on relationship 
estimates between changes in intrinsic motivation and changes in substance use severity through 
the use of gender moderated growth curve models.  Similar to that observed in the intent-to-study 
sample, no significant interactions were found regarding estimates of the relationship between 
changes in intrinsic motivation and changes in alcohol or drug use severity in the completer 
sample (Table A1.7).  
 
 
 
 
 
 
 
 
 
 
chronicity, PANSS Total, PANSS Negative, and neurocognition were grand mean centered.  
This model was fit using AR(1) and accounted for heteroscedasticity of level-1 errors. REML 
estimation was used.  
Change Note. A non-significant trend was observed for the relationship between intrinsic 
motivation and DUS scores, adjusting for demographic and clinical confounds, neurocognition 
and negative symptoms.  
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Table A1.7. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity (Gender Moderated Conditional Growth Models) 
Fixed Effect                          Parameter  Coefficient SE t p 
 AUS (log) Gender Moderated Conditional Growth Modela 
 Initial Status 𝛽00  1.21 0.12 9.66 <.001 
 Male 𝛽01  -0.11 0.10 -1.03 .302 
Growth Rate 𝛽10  -0.12 0.07 -1.56 .119 
Time-Varying IM 𝛽20  -0.02 0.01 -2.20 .028 
Time-Varying IM x Male 𝛽21  0.01 0.01 1.02 .307 
 DUS (log) Gender Moderated Conditional Growth Modelb 
Initial Status 𝛽00  0.85 0.10 7.89 <.001 
Male 𝛽01  0.06 0.09 0.64 .517 
Growth Rate 𝛽10  -0.13 0.07 -1.70 .089 
Time-Varying IM 𝛽20  -0.01 0.01 -0.50 .613 
Time-Varying IM x Male 𝛽21  -0.01 0.01 -0.32 .742 
Note. Analyses were conducted on the completer sample (n = 145). AUS = Alcohol Use Scale; 
DUS = Drug Use Scale; IM = Intrinsic Motivation.  
a Only the final AUS gender moderated conditional growth model with effects of interest are 
presented to reduce visual clutter. Age, chronicity, psychopathology, comorbidity status, 
phase1 randomization, and race were adjusted at level-2. Age, Chronicity, and PANSS Total 
were grand mean centered. This model was fit using AR(1). REML estimation was used.  
b Only the final DUS gender moderated conditional growth model with effects of interest are 
presented to reduce visual clutter. Age, chronicity, psychopathology, comorbidity status, 
phase1 randomization, and race were adjusted at level-2. Age, Chronicity, and PANSS Total 
were grand mean centered. This model was fit using AR(1) and accounted for 
heteroscedasticity of level-1 errors. REML estimation was used.  
Change Note. No significant changes.  
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 Upon finding no significant gender interactions in the completer sample, follow-up 
analyses were computed within completer subsamples of men and women using conditional 
growth models for estimates of relations between changes in intrinsic motivation and changes in 
substance use severity. Within the completer subsample of men, the average effect of intrinsic 
motivation was associated with significant reductions in alcohol use severity over 1-year, but no 
significant associations were observed for the relationship between intrinsic motivation and drug 
use severity (Table A1.8). Within the completer subsample of women, average improvements in 
intrinsic motivation were only associated with a non-significant trend in alcohol use severity 
reductions; no significant or marginal associations were observed with regard to the relationship 
between intrinsic motivation and drug use severity over 1-year.  
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Table A1.8. 1-Year Relationship Between Changes in Intrinsic Motivation and Changes in 
Substance Use Severity (Subsamples of Men and Women) 
Fixed Effect                          Parameter  Coefficient SE t p 
Mena AUS (log) Conditional Growth Model 
     Initial Status 𝛽00  1.06 0.08 12.99 <.001 
     Growth Rate 𝛽10  -0.08 0.08 -0.98 .323 
     Time-Varying IM 𝛽20  -0.01 0.00 -2.13 .033 
Womenb   
     Initial Status 𝛽00  0.88 0.19 4.63 <.001 
     Growth Rate 𝛽10  -0.06 0.06 -0.95 .347 
     Time-Varying IM 𝛽20  -0.01 0.01 -1.95 .059 
Mena DUS (log) Conditional Growth Model 
     Initial Status 𝛽00  0.95 0.07 12.30 <.001 
     Growth Rate 𝛽10  -0.12 0.08 -1.40 .160 
     Time-Varying IM 𝛽20  -0.00 0.00 -1.41 .157 
Womenb  
     Initial Status 𝛽00  0.54 0.13 4.04 <.001 
     Growth Rate 𝛽10  -0.08 0.18 -0.45 .651 
     Time-Varying IM 𝛽20  0.01 0.01 0.71 .479 
Note. AUS = Alcohol Use Scale; DUS = Drug Use Scale; IM = Intrinsic Motivation. Only 
final AUS/ DUS conditional growth models with effects of interest are presented to reduce 
visual clutter. Models adjusted for the effects of age, chronicity, psychopathology, comorbidity 
status, phase1 randomization, and race at level-2. Age, Chronicity, and PANSS Total were 
grand mean centered. Subsample of men was fit using AR(1) and REML estimation was used. 
Subsample of women was fit using AR(1) and accounted for heteroscedasticity of level-1 
errors. REML estimation was used.  
a Analyses were conducted on the subsample of Men (n = 123). 
b Analyses were conducted on the subsample of Women (n = 22).  
Change note. The effect of intrinsic motivation on DUS scores was not statistically different 
from 0 within the subsample of men. No other significant changes were observed.   
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